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Abstract 
Is melanoma associated leucoderma (MAL) a distinct entity compared to classial 
vitiligo? 
Marwa Ahmed Tharwat Abdel-aziz ELSAYED  
Keywords:  H2O2, ONOO
-
, p53, p21, p76, MDM4, MDM4phospho, SPARC, TGF- β1, 
VEGF-A 
Patients with classical vitiligo lose partially their protecting inherited pigment. The 
cause of the disease is still unknown. Despite massive epidermal oxidative / nitrative 
stress and signs for DNA-damage in the skin and in the plasma, these patients have no 
higher prevalence for sun induced non-melanoma skin cancer and increased photo-
damage. Protection and DNA-repair have been attributed to a functioning up-regulated 
wild type p53 / p21 cascade in association with up-regulated p76 
MDM2
. As some 
patients with cutaneous melanoma develop depigmentations away from their primary 
tumour site post surgical excision, it became of our interest, whether this melanoma 
associated leucoderma (MAL) is the same as classical vitiligo. The purpose of this 
thesis was two-fold.  In part I, we wanted to further substantiate the reasons behind the 
constantly up-regulated wild-type functioning p53 / p21 cascade in classical vitiligo 
utilising a panel of proteins with direct and / or indirect action on p53 regulation, 
including p21, p76
MDM2
, MDM4/MDM4phospho, SPARC, VEGF-A and TGF-β1. In 
part II, we wanted to characterize MAL and compare this peculiar leucoderma with 
classical vitiligo using the same protein panel and methodologies. To achieve our goals, 
we used in vivo FT-Raman spectroscopy, in vitro cell cultures, in vitro and in situ 
immuno-fluorescence labelling, Western blot, dot blot and computer modelling 
techniques. Our data showed distinct differences between classical vitiligo and MAL.  
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Our results in MAL exhibited a concentration dependent protein expression gradient 
between the basal / suprabasl layers and the upper layers of the epidermal compartment 
using  catalase, ONOO
-
, p53, p21, MDM4, p76
MDM2
, TGF-β1 and VEGF-A expression 
gradient. Moreover, we document for the first time the presence of a nitrated non-
fuctional SPARC protein in classical vitiligo which is absent in MAL. Although we 
show in vivo considerable ROS / RNS- mediated stress in MAL and classical vitiligo 
documented by FT-Raman spectroscopy, Western blot and in situ immuno-fluorescence, 
our results prove that MAL and classical vitiligo are two distinct entities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
Acknowledgements 
First and foremost, I would like to express my deepest sense of gratitude to my incredible 
supervisor Professor K U Schallreuter. Without her commitment, precious guidance, 
encouragement, supervision as well as the grateful support from KUS Dermatology GmbH and 
Institute for Pigmentary Disorders in association with Ernst Moritz Arndt University Greifswald, 
Germany, none of the work presented in this thesis would have been possible. I would also like 
to acknowledge the input of Dr M. Thornton, who provided me with lab space and the 
organisation, where needed throughout my project. 
My heartfelt thanks is going to my husband Dr Mohamed Salem, who did not hesitate to give 
me his valuable trusted advice in addition to his patience and constant encouragement. 
Moreover, I would like to thank our lovely daughter, Hanin (the kindest daughter ever) who is 
so curious about my work and asking all the time about the meaning of different scientific 
names involved in my work, despite she is only 9 years old. Although our son Ahmed is only 5 
years old, he was so caring for his mum, that she will do a successful “thesis”. In addition to his 
endless love with many hugs and kisses. I am very grateful to my mum Dr E. Abdelghany, my 
brother Dr M. A. Tharwat and my lovely sisters Dr A. A. Tharwat and Dr E. A. Tharwat for 
their support and their constant prayers for me throughout the entire time. It was difficult to 
survive this long period abroad with just few returns to Egypt, the most beautiful country in my 
eyes.  
All work presented in this thesis is dedicated to the spirit of my best friend and my best tutor, 
my late father, Chemist, Mr Ahmed Tharwat Elsayed. I believe that he would be proud of what I 
have achieved.  I am very proud being his daughter until the end of my life. 
 
 
 
5 
 
TABLE OF CONTENTS 
                 PAGE 
Abstract ......................................................................................................................2 
Acknowledgement.................................................................................................3                                                                                            
List of Figures........................................................................................................16 
List of Tables..........................................................................................................21 
List of abbreviations .........................................................................................22 
Part I: Studies on the p53 / p76
MDM2
/ MDM4 / SPARC/ 
VEGF-A and TGFβ 1 cascade in vitiligo..............................................27 
1.  Introduction (part I)...................................................................................28 
1.1 Human Epidermis.............................................................................................28 
1.1.1    Structure and function of the skin................................................................28 
1.1.1.1  Subcutis and Dermis...................................................................................28 
1.1.1.2  The basement membrane zone (BMZ).......................................................30 
1.1.1.3  The epidermis..............................................................................................31 
1.1.1.3.1  keratinocytes.............................................................................................32 
1.1.1.3.2  Langerhans cells and Merkel cells...........................................................33 
1.1.1.3.3  Melanocytes..............................................................................................33 
1.1.1.3.3.1 Origin, migration and differentiation of melanocytes............................34 
1.1.1.3.3.2  Melanogenesis.......................................................................................35 
6 
 
1.1.1.3.3.2.1 Melanosome biogenesis and transportation........................................35 
1.1.1.3.3.2.2 Regulation of melanogenesis..............................................................39 
1.2 Vitiligo ..................................................................................................................43 
1.2.1 Definition and epidemiology of vitiligo.........................................................43 
1.2.2 Diagnosis and clinical classification of vitiligo..............................................44 
1.2.2.1 Localized vitiligo.........................................................................................44 
1.2.2.1.1 Segmental vitiligo (dermatomal and/or Blasckolinear)............................44 
1.2.2.1.2 Focal vitiligo.............................................................................................45 
1.2.2.2  Generalized vitiligo.....................................................................................45 
1.2.2.2.1  Acrofacial vitiligo....................................................................................45 
1.2.2.2.2  Vitiligo vulgaris.......................................................................................46 
1.2.2.3   Vitiligo with unusual patterns....................................................................46 
1.2.2.3.1 Vitiligo ponctuè (guttate vitiligo)..............................................................46 
1.2.2.3.2  Trichrome and quadrichrome vitiligo......................................................46 
1.2.2.3.3  Blue vitiligo (pentachrome vitiligo).........................................................47 
1.2.2.3.4  Inflammatory vitiligo................................................................................47 
1.2.2.3.5  Blaschko-linear vitiligo............................................................................47 
1.2.3 Etiology of vitiligo..........................................................................................48 
1.2.3.1 Autoimmune hypothesis...............................................................................48 
1.2.3.2 Neural hypothesis.........................................................................................48 
1.2.3.3  Autocytotoxic hypothesis............................................................................49 
1.2.3.4  Genetic hypothesis......................................................................................50 
7 
 
1.2.3.5  Viral hypothesis..........................................................................................51 
1.2.3.6  Oxidative stress hypothesis.........................................................................51 
1.3  Vitiligo and skin cancer........................................................................................57 
 1.4 Regulation of p53 by SPARC, TGF-β and the possible involvement of 
the entire MDM2 family......................................................................................61 
1.4.1 p53 – as the “guardian of the genome”........................................................61 
 1.4.2   p76
MDM2
 and MDM4 interaction in the regulation of p53...........................66 
 
                                                                                           
 
 1.4.3    SPARC (Secreted protein acidic and rich in cysteine)……........................73 
 1.4.4   Transforming growth factor- β1 (TGF- β1).................................................77  
2. Aim of the study (part I).................................................................................79  
3. Materials and methods (part I)..................................................................81 
3.1 Cell culture................................................................................................................81 
3.1.1 Establishment and maintenance of cell cultures..............................................81 
3.1.2 Thawing of frozen cell culture........................................................................82 
3.1.3. Passaging of cell cultures...............................................................................83 
3.1.4. Freezing of cell cultures.................................................................................83 
 3.2 Immunocytochemical Methods........................................................................83 
3.2.1. Cell culture chamber slide preparation...........................................................83 
3.2.2. In vitro immuno-fluorescence labeling......................................................... 84 
 3.3 Immunohistochemical Methods……………................................................86 
3.3.1. Cryosection preparation.................................................................................86 
3.3.2. In situ immuno-fluorescence labelling...........................................................86 
8 
 
3.3.3 Quantification of fluorescence intensity .........................................................89 
3.4 SDS-PAGE and Western Blot.......................................................................89 
3.4.1 Protein extraction from cells ..........................................................................89 
3.4.2 Protein extraction from tissue..........................................................................90 
3.4.3 Quantification of protein content in cells and tissue extracts (Bradford 
 Protein Assay)...............................................................................................90 
3.4.4 SDS-PAGE of protein samples.......................................................................91 
3.4.4 Western blot....................................................................................................92 
3.5   Dot blot for SPARC.......................................................................................95 
3.6   Fourier Transform (FT) -Raman spectroscopy...................................96 
3. 6   Computer modelling of native and oxidised SPARC........................97 
 
4.  Results (part I)................................................................................................98 
4.1 Confirmation of low epidermal catalase expression, up-regulated 
p53, p21 in association with up-regulated p76
MDM2
 in vitiligo
 
as 
prerequisite for further investigation.........................................................98  
4.1.1 Significantly decreased in situ catalase levels in the entire pidermis of  
patients with vitiligo in comparison to healthy controls................................98 
4.1.2 Confirmation of low catalase levels in vitiligo by Western blot...................101 
4.1.3 Catalase is present in epidermal melanocytes...............................................103 
4.1.4  In vivo FT-Raman spectroscopy confirms the presence of 10
-3
M H2O2  
levels in the epidermis of patients with vitiligo...........................................106 
4.1.5 The role of p53 in vitiligo.............................................................................107 
9 
 
4.1.5.1 Significantly increased epidermal expression of p53 in the entire 
 epidermis of patients with vitiligo.............................................................107 
4.1.5.2 p53 expression in vitiliginous melanocytes................................................111 
4.1.5.3 Significantly up-regulated in situ expression of p21 in both lesional 
 and non-lesional skin of vitiligo compared to healthy control skin...........112                                                                         
4.1.5.4 Increased in situ p21 expression in melanocytes in vitiligo.......................116 
4.1.6 The effect of the MDM2 family on epidermal p53 levels, activity and 
 stability in skin of patients with vitiligo....................................................118 
4.1.6.1 A view at p53 regulatory factors, including, p76
MDM2
 and MDM4...........118
 
 4.1.6.1.1 Up-regulated epidermal p76
MDM2
 expression in vitiligo…………........119 
4.1.6.1.2 Confirmation of elevated epidermal p76 
MDM2
 in vitiligo by Western  
Blot.............................................................................................................122 
4.1.6.1.3 In situ MDM4 and MDM4phospho expression in vitiligo......................124 
4.1.6.1.3.1 Significantly increased MDM4 expression in the entire epidermal 
compartment of patients with vitiligo.........................................................124 
4.1.6.1.3.2 Confirmation of up-regulated MDM4 expression in lesional skin of 
patients with vitiligo by Western blot.........................................................127 
4.1.6.1.3.3 Up-regulated in situ MDM4 expression in non-lesional 
melanocytes................................................................................................129  
4.1.6.1.3.4 Significantly increased MDM4phospho expression in the entire 
epidermis of patients with vitiligo……………..…....................................132 
4.1.6.1.3.5 MDM4phospho expression levels differ between patients with 
vitiligo.........................................................................................................134  
4.1.6.1.3.6 MDM4phospho is highly expressed in non-lesional melanocytes in 
vitiligo.........................................................................................................137 
10 
 
4.2 Investigation of the SPARC- p53 axis in vitiligo..................................141 
4.2.1 Significantly up-regulated SPARC-expression in the entire epidermis of 
patients with vitiligo - a novel observation..............................................141 
4.2.2 More support for high epidermal SPARC protein levels in vitiligo..............144 
4.2.3 H2O2 does not affect the antibody binding site of SPARC...........................146 
4.2.4 SPARC expression is increased in no-lesional melanocytes.........................147 
4.2.5 Does elevated nitric oxide (NO) affect epidermal SPARC in vitiligo?
............
151 
4.2.5.1 High expression of 5-nitro-tyrosine in the epidermis of patients with  
vitiligo confirms the presence of ONOO
-
................................................151 
4.2.5.2 In vitiligo SPARC is nitrated throughout the entire epidermis..................152 
4.2.5.3 Weak SPARC in vitro nitration in normal epidermal melanocytes............155 
4.2.5.4 Computer modelling supports deactivation of SPARC-functionality by 
H2O2-mediated oxidation and ONOO
-
- mediated nitration......................156 
 
4.2.5.4.1 H2O2-mediated oxidation and ONOO
-
-mediated
 
nitration alter calcium 
binding of native SPARC.........................................................................157 
4.3 VEGF-A expression in vitiligo....................................................................162 
4.3.1 Significantly up-regulated expression of VEGF-A as SPARC regulator 
 in the epidermal compartment of patients with vitiligo....................................162 
4.3.2 More evidence for increased VEGF-A level in vitiligo ...........................164 
4.3.3 Presence of VEGF-A in epidermal melanocytes......................................166 
4.4. TGF-β1 expression in skin of patients with vitiligo............................170 
4.4.1. Increased expression of TGF-β1 in the epidermal basal / suprabasal 
 layers of vitiliginous skin..................................................................................170 
11 
 
4.4.2. TGF-β1 in epidermal melanocytes...........................................................173 
4.4.3 Epidermal TGF-β1 is nitrated in vitiligo..................................................176 
 
5. Discussion..........................................................................................................178 
Low epidermal catalase levels and high 5-nitro-tyrosine expression support  
the oxidative stress theory in vitiligo................................................................181 
 
Confirmation of up-regulated epidermal functioning wild type p53 
 together with up-regulated p21 expression throughout the entire epidermis 
 in vitiligo...........................................................................................................182 
 
In vitiligo epidermal cells induce p76
MDM2
 expression, hindering in turn 
 p53 degradation................................................................................................183 
 
Up-regulated MDM4 / MDM4phospho levels support up-regulated  
functioning p53 expression in vitiligo – a novel result....................................185 
  
Up-regulated epidermal SPARC expression – a radical scavenger in  
vitiligo skin? A novel result..............................................................................188 
 
Computer simulation supports loss of functional SPARC in vitiligo 
 via oxidative and nitrative stress suggesting SPARC up-regulation as 
 ROS scavenger.................................................................................................189 
 
Is up-regulated VEGF expression enhancing SPARC expression 
 In vitiligo?........................................................................................................191 
Evidence for H2O2 - and ONOO
- 
- mediated deactivtion of TGF-β1 in 
 vitiligo supports p53 dependent p21 induction...............................................193 
 
 
 
12 
 
Part II: Is melanoma associated leucoderma (MAL) a  
 distinct entity compared to classical.....................................................195                                                                                         
 
6. Introduction.....................................................................................................196 
6.1. Malignant Melanoma (MM) in association with “vitiligo-like” 
leucoderma..................................................................................................196 
6.2. Vitiligo and malignant melanoma- Is there a true connection?..................200 
 
6.3. MAL in association with malignant melanoma – Is it a good prognostic 
factor?.........................................................................................................201 
6.4. p53 and malignant melanoma.....................................................................202 
6.5. p53 / MDM4 interaction in malignant melanoma.......................................203 
6.6. p53 / SPARC interaction in malignant melanoma………………………..204 
6.7.  SPARC / TGF-β1/ VEGF-A cascade in malignant melanoma..................205 
 
7. Aim of the study (part II)........................................................................206 
 
8. Materials and methods (part II).........................................................208 
8.1. Patient history and characteristics..............................................................208 
8.2. In vivo Fourier Transform (FT) - Raman spectroscopy………..................209 
8.3. Full skin biopsies from lesional and non-lesional skin...............................209 
8.4. Preparation of cryosections ……………………………………................209 
8.5. In situ immuno-fluorescence labelling.......................................................210 
8.6. Double immuno-fluorescence labelling......................................................211 
8.7. Quantification of fluorescence intensity.....................................................211 
8.8. Western blot................................................................................................213 
8.9. Statistical analysis for Western blot............................................................215 
13 
 
9. Results (part II).............................................................................................216 
 
9.1. In vivo FT - Raman analysis identifies the presence of H2O2 
mediated oxidation in lesional and non – lesional MAL....................216 
 
9.2. Evaluation of epidermal catalase, p53 and p21 in MAL...................217 
 
9.2.1. Catalase expression follows a gradient from the basal layer to the upper 
layers and is lower in lesional and non-lesional skin of MAL compared 
 to control skin..........................................................................................217 
9.2.2. Catalase expression is absent in epidermal melanocytes of MAL…..….219 
9.2.3. Evaluation of p53 and p21 expression in lesional and non-lesional skin 
 of MAL……………………………………………………....................221 
9.2.3.1. Lower basal/suprabasal p53 expression is accompanied with high 
  basal / suprabasal p21 expression in MAL.............................................221 
 
9.2.3.2. Weak p53 in situ expression in epidermal melanocytes in MAL and 
healthy controls...........................................................................................224 
9.2.3.3. Western blot confirms significantly up-regulated p53 in MAL............225 
9.2.3.4. Significantly increased epidermal p21 expression in basal/suprabasal 
layers of MAL............................................................................................227 
9.2.3.5. Western blot analysis confirms significantly increased epidermal p21 
protein expression in MAL.........................................................................230 
9.2.3.6. In situ p21 expression in epidermal melanocytes of MAL and control 
skin..............................................................................................................232 
9.3. MDM2 and p53 regulation in MAL.........................................................233 
9.3.1 High p76
MDM2
 expression in the basal/suprabasal layer of   lesional 
MAL.........................................................................................................234 
9.3.2. Western blot analysis supports up-regulated p76
MDM2
 ...........................236 
14 
 
9.3.3. Significantly increased epidermal MDM4 expression in MAL shows a 
gradient from the basal/suprabasal layer to the upper layer...................238 
9.3.4. Melanocytes of non-lesional skin present MDM4 expression..................241 
9.3.5. Evidence for phosphorylation of MDM4 in MAL...................................242 
9.3.6. Melanocytes of non-lesional skin do not show MDM4phospho 
expression............................................................................................245 
9.4. Expression of SPARC in lesional and non-lesional skin of 
MAL...................................................................................................................246 
9.4.1. Significant up-regulation in SPARC levels.............................................246 
9.4.2. Western blot analysis confirms increased SPARC expression in 
MAL.........................................................................................................248 
 9.4.3. SPARC expression in epidermal melanocytes of MAL.........................250 
9.4.4. SPARC nitration in lesional and non-lesional skin of MAL....................251 
9.4.4.1. 5-nitro-tyrosine expression in lesional and non-lesional skin...............251 
9.4.4.2. ONOO
-
 does not affect SPARC in MAL..............................................254 
9.5. VEGF-A expression in MAL......................................................................256 
9.5.1. Increased VEGF-A expression in skin of MAL......................................256 
9.5.2. Confirmation of VEGF-A up-regulation in MAL by Western blot 
analysis.....................................................................................................259 
9.5.3. In situ VEGF-A expression in epidermal melanocytes ...........................261 
9.5.4. VEGF-A nitration in MAL......................................................................262 
9.6. Evaluation of epidermal TGF-β1 expression in MAL.......................263 
9.6.1. TGF-β1 expression corresponds to p21 expression in MAL...................263 
9.6.2. TGF-β1 is not expressed in epidermal melanocytes of MAL..................266 
15 
 
9.6.3. Western blot confirms significantly increased TGF-β1 expression in  
both lesional and non-lesional skin of MAL.....................................................268 
9.6.4. TGF-β1 is weakly nitrated in non-lesional MAL ...................................270 
10. Discussion (part II)...................................................................................272 
Presence of epidermal H2O2 and some oxidation products in MAL...............273 
 
Detection of a distinct p53 / p21 cascade in MAL ..........................................276 
 
           Could presence of p76
MDM2 
explain p53 accumulation in MAL?....................277 
 
MDM4 in MAL is phosphorylated and therefore may not be involved in  
p53 regulation...................................................................................................278 
 
SPARC nitration - can it explain the different p53 expression pattern 
 between vitiligo and MAL?..............................................................................280 
 
Could increased VEGF-A support up-regulated SPARC protein expression 
 In MAL? ..........................................................................................................282 
 
Can TGF-β1 explain p53-independent expression of p21 in MAL?...............282 
 
11. Conclusion......................................................................................................286 
 
12. Future work..................................................................................................293 
 
13. References......................................................................................................294 
 
 
 
 
 
 
 
 
16 
 
List of Figures 
 
Figure   1:   General structure of the human skin.......................................................29 
Figure   2:  Structure of the basement membrane......................................................30 
Figure   3:   Structure of the epidemis........................................................................31 
Figure 4:  Biogenesis of melanosomal maturation stages and their transportation 
 to keratinocytes.......................................................................................37 
Figure  5:  Scheme of melanogenesis........................................................................42 
Figure  6:       H2O2 generation in the human epidermis.................................................53 
Figure 7:       Domain structure of full-length p53........................................................62 
Figure 8:      Activation and function of p53................................................................64 
Figure 9:   Protein structural homology of p76
MDM2
 and p90
MDM2
............................68 
Figure 10:      Protein structural homology of MDM2 and MDM4................................68 
Figure 11:   Modes of MDM4 function following different DNA damages..............72 
Figure 12:  Structure of human SPARC protein........................................................75 
Figure 13:  p21
 
expression through p53-independent mechanism via TGFβ-1    
canonical signal transduction pathway....................................................78 
Figure 14:  Low epidermal catalase expression in vitiligo........................................99 
Figure 15:  Significant lower expression of epidermal catalase in vitiligo..............100 
Figure 16:      Significantly decreased epidermal catalase expression in skin of  
patients with vitiligo………………………………………...................102 
Figure 17:  Decreased in situ catalase expression in epidermal melanocytes in 
vitiligo....................................................................................................104 
Figure 18:       In vitro expression of catalase in normal human epidermal 
melanocytes............................................................................................105 
Figure 19:   In vivo FT-Raman spectra from 3 patients with vitiligo.......................106 
Figure 20:  Higher epidermal expression of p53 in vitiligo.....................................108 
Figure 21:  Significantly higher p53 expression in vitiligo......................................109 
Figure 22:  Significantly higher epidermal p53 levels in patients with vitiligo…...110 
17 
 
Figure 23:  Increased p53 expression in epidermal melanocytes in vitiligo............111 
Figure 24:   Up-regulated p21 expression throughout the entire epidermis in 
vitiligo....................................................................................................113 
Figure 25:  Significantly increased p21 expression in vitiligo.................................114 
Figure 26:  Significantly up-regulated p21 expression in skin of patients with 
vitiligo…………………………………………………………………115 
Figure 27:  Increased p21 expression in epidermal melanocytes in vitiligo.............117 
Figure 28:  Up-regulated epidermal expression of p76
MDM2
 in vitiligo....................120 
Figure 29:  Significantly increased p76
MDM2
 expression in skin of patients with 
vitiligo....................................................................................................121 
Figure 30:  Significantly up-regulated p76
MDM2
 expression in skin of patients…...123 
Figure 31:  Significantly higher expression of MDM4 in vitiligo............................125 
Figure 32:  Significantly increased expression of MDM4 in vitiligo.......................126 
Figure 33:  Up-regulated MDM4 expression in lesional epidermis of 
patients….…128 
Figure 34:   In situ MDM4 expression in epidermal melanocytes in vitiligo...........130 
Figure 35:   In vitro expression of MDM4 in human epidermal melanocytes..........131 
Figure 36:  MDM4 is not detectable in normal human epidermal melanocytes.......132 
Figure 37:  Increased expression of MDM4-phospho in vitiligo.............................133 
Figure 38:  Significantly increased MDM4phospho expression in vitiligo..............134 
Figure 39:  Epidermal MDM4phospho expression differs in patients…………….135 
Figure 40:   High in situ expression of MDM4phospho in melanocytes of 
patients...................................................................................................138 
Figure 41:   In vitro expression of MDM4phospho in human epidermal 
melanocytes...........................................................................................139 
Figure 42:  MDM4phospho is not detectable in epidermal melanocytes.................140 
Figure 43:  High expression of SPARC in vitiligo...................................................142 
Figure 44:  Significantly up-regulated expression of SPARC in vitiligo.................143 
Figure 45:  Significantly up-regulated epidermal SPARC expression in vitiligo….145 
Figure 46:  The effect of H2O2 on SPARC protein...................................................146 
Figure 47:  Increased SPARC expression in epidermal melanocytes of non-lesional 
vitiligo....................................................................................................148 
18 
 
Figure 48:  In vitro expression of SPARC in human epidermal melanocytes.........149 
Figure 49:  SPARC is present in human epidermal melanocytes............................150 
Figure 50:  Increased in situ expression of nitrated SPARC in vitiligo...................153 
Figure 51:  Significantly up-regulated nitration in vitiligo......................................154 
Figure 52:  In vitro nitration of SPARC in nuclei of normal melanocytes...............155 
Figure 53: Computer modelling of the1
st 
EF- hands binding site of SPARC in 
 the presence of H2O2.............................................................................158 
Figure 54:  Computer modelling of the 1
st 
EF-hands binding site of SPARC in 
 the presence of ONOO
- 
and the combination of ONOO
- 
and H2O2......159 
Figure 55:  Computer simulation of the 2
nd
 EF- hands binding site of SPARC in 
 the presence and absence of H2O2.........................................................160 
Figure 56:  Computer simulation of the 2
nd 
EF-hands binding site of SPARC in  
the presence of ONOO
- 
and the combination of ONOO
- 
and H2O2.......161 
Figure 57:  High expression of VEGFi-A in the entire epidermal compartment 
 in vitiligo...............................................................................................163 
Figure 58:  Significantly increased protein expression of VEGF in vitiligo............164 
Figure 59:  Significantly higher epidermal VEGF-A levels in vitiligo…………....165 
Figure 60:  VEGF-A expression in intra basal epidermal melanocytes of vitiligo 
skin.........................................................................................................167 
Figure 61:  VEGF-A is not expressed in human epidermal melanocytes under in 
vitro conditions......................................................................................168 
Figure 62:  VEGF-A is not detectable in epidermal melanocytes...........................169 
Figure 63:  Up-regulated expression of TGF-β1 in the epidermal basal layer of 
vitiligo patients......................................................................................171 
Figure 64:  Significantly increased epidermal TGF-β1 expression in vitiligo.........172 
Figure 65:  TGF-β1 expression in basal and suprabasal layers of patients with 
vitiligo....................................................................................................174 
Figure 66:  In vitro expression of TGF-β1 in human epidermal melanocytes.........175 
Figure 67:  TGF-β1 is absent in epidermal melanocytes.........................................176 
 
19 
 
Figure 68:  Up--regulated in situ expression of nitrated TGF-β1 in the basal layer  
of vitiligo...............................................................................................177 
Figure 69:  Proposed molecular alterations associated with the initiation and 
progression of melanoma......................................................................198 
Figure 70:  Facial MAL under WOOD‟s light in a 53 year old patient with 
melanoma (skin phototype III, Fitzpatrick classification)....................208 
Figure 71:   In vivo FT-Raman spectrum in MAL....................................................216 
Figure 72:   In situ expression of catalase in MAL..................................................218 
Figure 73:  Image analysis of catalase protein levels in MAL.................................219 
Figure 74:   Absent catalase expression in epidermal melanocytes of MAL...........220 
Figure 75:  High expression of p53 in epidermis of MAL.......................................222 
Figure 76:  Significantly increased p53 expression in MAL...................................223 
Figure 77:  p53 in MAL is not expressed in melanocytes under in situ  
conditions...............................................................................................224 
Figure 78:  Significantly increased epidermal p53 protein expression in MAL......226 
Figure 79:  Up-regulated basal / suprabasal p21 expression in MAL……………..228 
Figure 80:  Significantly higher p21 expression in MAL........................................229 
Figure 81:  Significantly up-regulated p21 expression in skin of MAL..................231 
Figure 82:  p21 expression in epidermal melanocytes of MAL and control 
 skin........................................................................................................232 
Figure 83:  Up-regulated basal / suprabasal expression of p76
MDM2
 in lesional  
MAL.......................................................................................................235 
Figure 84:  Significant increase in p76
MDM2 
expression in MAL.............................236 
Figure 85:  Up-regulated p76
MDM2
 expression in MAL….......................................237 
Figure 86:   Increased expression of MDM4 in MAL.............................................239  
Figure 87:  Significant increase of MDM4 expression in MAL..............................240 
Figure 88:  Evidence for MDM4 expression in melanocytes of MAL....................241 
Figure 89:  Up-regulated expression of MDM4phospho in MAL throughout the 
entire epidermis.....................................................................................243 
Figure 90:  Significantly increased MDM4phospho expression in MAL................244 
20 
 
Figure 91:  Weak expression of MDM4phospho in melanocytes of MAL..............245 
Figure 92:  High expression of SPARC in MAL.....................................................247 
Figure 93:  Significantly increased SPARC expression in MAL.............................248 
Figure 94:  Significantly up-regulated SPARC levels in skin of MAL………........249 
Figure 95:  Weak in situ expression of SPARC in a dermal melanocyte of  
MAL.......................................................................................................250 
Figure 96:  High 5- nitro-tyrosine expression indicates ONOO
-
-formation in    
MAL.......................................................................................................252     
Figure 97:  5-nitro-tyrosine expression in MAL follows a gradient with an  
increase from basal / suprabasal layers to upper layers.........................253 
Figure 98:   Positive nitration of SPARC in the upper epidermis of MAL..............255 
Figure 99:       Strong expression of VEGF-A in MAL................................................257 
Figure 100:  Significantly higher VEGF-A expression in MAL...............................258 
Figure 101:  Significantly increased VEGF-A levels in MAL……….......................260 
Figure 102:  VEGF-A expression in epidermal melanocytes of MAL......................261 
Figure 103:  Evidence for nitration of VEGF-A in MAL..........................................262 
Figure 104:  Increased cytosolic TGF-β1 expression in the basal/suprabasal  
layers of MAL........................................................................................264 
Figure 105:  Significantly higher TGF-β1 expression in the basal/suprabasal  
layers of   MAL......................................................................................265 
Figure 106:  Absence of TGF-β1 expression in epidermal melanocytes of MAL.....267 
Figure 107:  Significantly increased TGF-β1 expression in skin of MAL................269 
Figure 108: Weak nitration of TGF-β1 in non-lesional MAL.........................................271 
Figure 109:     Hypothetical pathway involved in depigmentation in MAL................285  
Figure 110a:    Absence of all our proteins in question in control skin except 
catalase...................................................................................................289 
Figure 110b:  Distribution of the proteins in question in MAL non-lesional 
epidermis................................................................................................290 
Figure 110c:  Distribution of the proteins in question in MAL lesional epidermis......291 
 
21 
 
List of Tables 
 
Table 1:   List of primary and secondary antibodies and conditions for in vitro 
immuno-fluorescence labelling in melanocytes and melanoma cells…....85 
Table 2:  List of primary and secondary antibodies and conditions for in situ 
immuno-Fluorescence labelling.................................................................88                                                                                             
Table  3:   List of primary antibodies used in Western blot........................................93  
Table  4:   List of secondary antibodies used in Western blot.....................................95  
Table 5:  MDM4-MDM4phospho ratio in individual vitiligo patients ..................136 
Table 6:  List of primary antibodies and conditions for in situ immuno- 
fluorescence labelling...............................................................................212 
Table 7:   List of primary antibodies used in Western blot in MAL........................214 
Table 8: List of Secondary antibodies used in Western blot..................................215  
Table 9:  MDM4phospho-MDM4 immuno-fluorescence ratio in the basal /  
suprabasal and upper layer of MAL.........................................................244 
Table 10 :    5-nitro-tyrosine ratio in vitiligo / MAL patients‟ skin…………………...254 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
List of abbreviations 
 
1
O2   Singlet oxygen 
5-cysdopa  5-cysteine-S-YL-dopa  
6BH4     (6R)-L-erythro 5, 6, 7, 8 tetrahydrobiopterin   
8-oxo-dG  8-oxo- 7, 8-dihydro-2„-deoxyguanine 
8-oxo-G  8-oxo- 7, 8-dihydro-2„- guanine 
AC   actinic keratoses 
AchE    acetylcholinesterase 
ACTH   adrenocorticotropic hormone 
AP1   adaptor protein1 
AP3     adaptor protein 3 
APE1       apurinic / apyrimidinic endonuclease 1 
Arf   alternate reading frame 
Asp                                asparagine   
ATM   ataxia telangiectasia mutated 
ATP   adenosine 5'-triphosphate 
ATPase   adenosine 5'-triphosphatase 
ATR   ataxia telangiectasia and Rad3-related protein 
BAX   Bcl-2–associated X protein 
BCC   basal cell carcinoma 
BchE    butyrylcholinesterase 
Bcl-2   B-cell lymphoma 2 
BER   base-excision repair 
bFGF    basic fibroblast growth factor 
BM-40                            basement-membrane-40 
BMZ   basement membrane zone  
BSA    bovine serum albumin 
CAT    catalase 
23 
 
CDC25A  cell division cycle 25 homologue  A 
CDK   cyclin-dependent kinase  
CHK1,2  check point kinases 1 and 2 
CMV   cytomegalovirus 
CIs                                  confidence intervals  
DAPI   4, 6-diamino-2-phenylindole 
DHI   5, 6, dihydroxyindole    
DHICA               5, 6-dihydroxyindole-2carboxylic acid 
DMSO   dimethyl sulphoxide 
DNA   deoxyribonucleic acid 
DTT   dithioerythriol  
EBV   Epstein Barr virus 
ECL   enhanced chemiluminescence 
EDTA   ethylene diamine tetra-acetic acid 
EGF   epidermal growth factor 
ERK    extracellular regulated kinase  
FITC   fluorescein isothiocyanate 
FS                                   follistatin  
GADD45  growth arrest DNA damage inducible 45 
GPx   glutathione peroxidase 
GR   glutathione reductase 
GV   generalized vitiligo 
GWAS   Genomewide association studies 
H2O2   hydrogen peroxide 
HATs    histone acetyltransferases 
HCV   hepatitis C virus 
HDAC2  histone deacetylase 2 
hOgg1   8-oxoguanine-DNA glycosylase 1 
HR   hazard ratio  
ILVs    intralumenal vesicles 
24 
 
kDa   kilo Dalton 
L-DOPA  3, 4-dihydroxy-L- phenylalanine   
LTBP    latent TGF-beta binding protein 
MAL   melanoma associated leucoderma 
MC1-R               melanocortin-1 receptor  
MC4-R               melanocortin-4 receptor  
MDM2/4              mouse double minute 
MITF   microphtalmia-associated transcription factor    
TPH   tryptophan hydroxylase 
MLph   melanophilin 
mRNA   messenger ribonucleic acid 
MSR   methionine sulfoxide reductase 
MT   microtubule   
MYO5A  myosin 5A 
NADPH  nicotinamide adenine dinucleotide phosphate 
NES                                nuclear export signal  
NDS   normal donkey serum 
NFκB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NLS   nuclear localisation signals  
NMSCs              non-melanoma skin cancers 
NO   nitric oxide 
NoLS                              nucleolar localization signal  
NSV   non –segmental vitiligo  
O2
.-
   superoxide radical 
OA1                                oculocutaneous albinism type 1 
ORs   odds ratios  
OCT   optimal cutting temperature compound  
-
OH   hydroxyl radical 
ONOO
-
               peroxinitrite 
P/S   penicillin/streptomycin 
25 
 
p15   cyclin-dependent kinase 4 inhibitor B (CDKN2B) 
p21
  
 cyclin-dependent kinase inhibitor
 
 
p53C p53central DNA-binding domain  
PACE4               paired basic amino-acid-cleaving enzyme-4 
PAH   phenylalanine hydroxylase   
PBS   phosphate buffered saline 
PC1    prohormone convertase 1 
PC2    prohormone convertase 2 
PC-KUS  pseudocatalase Karin U Schallreuter 
PDGF   platelet derived growth factor 
PNMT                phenylethanolamine N-methyltransferase 
POMC   pro-opiomelanocortin 
PRR    proline-rich region  
PUMA   p53 upregulated modulator of apoptosis 
PVDF    polyvinylidene difluoride 
RGP   radial growth phase 
RNS   reactive nitrogen species 
ROS   reactive oxygen species 
RT   room temperature 
RTK   receptor tyrosine kinase  
SCC   squamous cell carcinoma 
SCF   stem cell factor 
SDS   sodium dodecyl sulphate 
SDS-PAGE  sodium dodeyl sulphate polyacrylamide gel electrophoresis 
Ser   serine 
Smad2, 3  mothers against decapentaplegic homolog 2, 3 
SOD   superoxide dismutase 
SPARC               secreted protein acidic and rich in cysteine 
TAD   transactivation domain  
TAFs   TATA - binding protein-associated factors 
26 
 
TBP   TATA - box binding protein 
TBS   tris-buffered saline 
TET tetramerization domain  
TAFs   TATA box binding protein-associated factors 
TGF-β   transforming growth factor-β 
TGF-βR  TGF-beta receptor 
THI   tyrosine hydroxylase I 
TEMED  tetramethylethylenediamine 
TNFα   tumour necrosis factor α 
TPx   thioredoxin peroxidase 
TR   thioredoxin reductase 
TRITC   tetramethyl rhodamine isothiocyanate 
TRP-1, 2  Tyrosinase related proteins-1 and 2 
Tween 20  polyoxyethylenesorbitanmonolaureate 
TYR   tyrosinase  
Tyr tyrosine 
TβR-I   TGF-β type I receptor  
UVR   ultraviolet radiation   
UVA   ultraviolet A 
UVB   ultraviolet B 
VEGF   vascular endothelial growth factor 
VEGFR1  vascular endothelial growth factor receptor 1 
VGP    vertical growth phase 
W /W   wild type 
Zn                                   zinc  
α-MSH   α-melanocyte stimulating hormone 
β –LPH   β -lipotropic hormone 
β-END   β-endorphin 
 
 
27 
 
 
 
 
 
Part I 
 
 
Studies on the p53 / p76
MDM2
/ MDM4 / 
SPARC/ VEGF-A and TGFβ 1 
cascade in vitiligo  
 
 
 
 
 
 
 
 
28 
 
1. Introduction 
1.1 Human Epidermis 
1.1.1 Structure and function of the skin 
The skin represents the largest, complex, multilayered organ of the human body which 
is constantly renewed and differentiated.  It consists of several layers including horny 
layer, epidermis, basement membrane, dermis and subcutis (Figure 1). The skin 
represents a biological barrier between external environment and internal organs 
(Hollbrook and Wolff, 1993; Hall, 2000) protecting the body against physical, thermal 
and mechanical injuries. Moreover, it hinders body fluids and protein loss and defends 
against ultra violet radiation (UVR). It regulates body temperature, and sweating in 
addition to vitamin D synthesis (Graham-Browns and Bourke, 1998; Graham-Brown 
and Burns, 2011; Hollbrook and Wolff, 1993). 
1.1.1.1 Subcutis and Dermis 
The subcutis is the innermost layer of the skin which holds nerves and blood vessels. 
Moreover, it is the part of the skin where storage of fat takes place. It contains the 
largest adipose tissue volume in the body (Hall, 2000). 
The dermis holds a network of connective tissue. This network mainly consists of 
collagen fibres and some elastin fibres surrounded by a mucopolysaccharide matrix. 
These fibres are responsible for strength and elasticity (Graham-Browns and Bourke, 
1998; Graham-Brown and Burns, 2011). The dermis is rich in blood and lymphatic 
vessels, nerves, sensory receptors in addition to pilosebacious, eccrine and apocrine 
tissue. Many types of cells are situated in the dermis including fibroblasts, the cells 
producing collagen and elastin. In addition, there are e.g. mast cells which play a critical 
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role during immune and inflammatory responses of the skin by stimulating chemotaxis 
and phagocytosis, changing vasotension and vascular permeability (Graham-Browns 
and Bourke, 1998; Graham-Brown and Burns, 2011; Haak et al., 2001). The dermis 
contains the papillary dermis which is located directly beneath the basement 
membrane. This layer contains thin collagen fibres, reticular or deep dermis, holds 
thick collagen bundles (Hall, 2000). 
 
 
Figure 1: General structure of the human skin.  
Skin consists of three main layers: epidermis, dermis and subcutis. Epidermis is a stratified 
squamous epithelium that extends from basal to superficial layers. Epidermis is separated from 
the underlying dermis by the basement membrane. The dermis holds a network of connective 
tissue and is rich in blood and lymphatic vessels, nerves, sensory receptors in addition to 
pilosebacious, eccrine and apocrine tissue (from Shier et al., 1999). 
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1.1.1.2 The basement membrane zone (BMZ) 
The BMZ is a multilayered narrow zone, located between epidermis and dermis playing 
a crucial role in maintenance of adhesion. (Graham-Browns and Bourke, 1998; Graham-
Brown and Burns, 2011) (Figure 2 shows a schematic view of the BMZ). 
 
 
Figure 2: Structure of the basement membrane.  
The membrane consists of three layers: lamina fibrorecticularis, lamina densa and lamina lucida. 
Basal keratinocytes attach to the lamina lucida via hemidesmosomes. Anchoring filaments and 
anchoring fibrils connect the lamina densa to both hemidesmosomes and dermis respectively  
(from Graham-Browns and Bourke, 1998). 
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1.1.1.3 The epidermis 
The epidermis is formed by a continuously renewed stratified squamous epithelium. It 
spans from basal to superficial layers holding proliferation and differentiation including 
keratinisation and cornification (Haak et al., 2001). It can be divided into living layers, 
i.e. basal layer, spinous layer and granular layer. The stratum corneum contains mainly 
superficial dead end-products without nuclei (Hall, 2000).  The epidermis contains 
different types of cells, including keratinocytes, melanocytes, Langerhans and Merkel 
cells. In addition, stem cells are found along the basal lamina border (Lavker and Sun, 
1982)  (Figure 3).  
 
Figure 3: Structure of the epidemis.  
The epidermis consists of four distinct layers classified according to location and stage of cell 
differentiation: the stratum basale attached to the basement membrane, followed by stratum 
spinosum, stratum granulosum and stratum corneum, the most superficial layer of epidermis 
(adapted from Graham-Browns and Bourke, 1998).  
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1.1.1.3.1 Keratinocytes 
Keratinocytes are keratin forming cells providing the majority of cells in the epidermis, 
with about 90% of the epidermal cell population. Basal keratinocytes actively divide 
and differentiate producing different layers including spinous and granular layers which 
eventually form the stratum corneum with a layer of non-nucleated cells at the surface 
of the skin. This layer contains mainly keratin. This physiological turnover process 
takes about 30 days (Graham-Browns and Bourke, 1998; Hollbrook and Wolff, 1993). 
Basal cells are columnar in shape with large nuclei and pigmented melanosomes which 
are transferred from adjacent melanocytes. Those keratinocytes are adhered to the 
basement membrane via hemidesmosomes. They proliferate approximately every four 
days, followed by differentiation to generate three to four layers of polyhedral shaped 
spinous cells with rounded nuclei. These cells are held together by desmosomes which 
appear ultra-structurally as spines. Gradually, they show more signs for differentiation 
e.g. an increase of keratin granules content in addition to nuclei disintegration, forming 
in turn an upper layer of flattened granular cells. Odland bodies or membrane-coating 
granules provide a thin film of lipids covering the surface of keratinocytes of the 
cornified layer yielding waterproof and cohesion. N.B. 10 % of the stratum corneum 
weight is lipids (Elias and Feingold, 1992; Feingold et al., 1990; Feingold, 2007; 
Graham-Browns and Bourke, 1998; Hollbrook and Wolff, 1993; Sevilla et al., 2007). 
Keratinocytes live in symbiotic relationship with melanocytes, regulating melanocyte 
proliferation, migration, survival and differentiation via releasing several ligands which 
bind to melanocyte receptors (Abdel-Naser, 1999). In this context, it is noteworthy that 
keratinocytes hold extensive endocrine function, including production of pro-
opiomelanocortin (POMC) derived peptides such as α-melanocyte stimulating hormone 
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(α-MSH), β-endorphin and ACTH, to name a few. However, here it should be noted that 
melanocytes produce also POMC-peptides in an autocrine manner (Yaar and Gilchrest, 
1991; Slominski et al., 1993; Kunisada et al., 2001; Kauser et al., 2004; Slominski et al., 
2004; Haass and Herlyn, 2005). 
1.1.1.3.2 Langerhans cells and Merkel cells 
Langerhans cells are bone marrow derived mononuclear dendritic cells present in the 
stratum spinosum. They represent 2 to 8 % of the epidermal cell population and are 
considered as members of the immune system (Hollbrook and Wolff, 1993; Graham-
Browns and Bourke, 1998). Merkel cells are basal layer located cells. Ultra-structurally 
they contain a dense core of neuro-secretory granules. Moreover, it is thought that 
Merkel cells act as specialized epidermal nerve endings (Graham-Browns and Bourke, 
1998; Hall, 2000). 
1.1.1.3.3   Melanocytes 
Melanocytes are dendritic melanin-producing cells, deriving from the neural crest. The 
first description goes back to 1819 by Sangiovanni, who detected chromatophores in 
squid (Sangiovanni, 1819), while the first description of human melanocytes was by 
Henle in 1837 (Henle, 1837). These cells are found in the skin, hair matrix, central 
nervous system, around blood vessels, inner ear, mucous membranes, peripheral nerves 
of the sympathetic chain as well as in the heart. The epidermal melanocytes are by far 
the most studied ones amongst them. These cells are located in the basal layer of the 
epidermis and differ in number, depending on the body location (Cramer,  1991). They 
are attached to the basement membrane, where they remain in contact with surrounding 
keratinocytes (Burns et al., 2004; Haass and Herlyn, 2005). Each melanocyte is 
connected approximately to 36 kerationocytes via its dendrites forming the epidermal 
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melanin unit (Fitzpatrick and Breathnach 1963; Fitzpatrick, Miyamoto et al. 1967). 
Surrounding keratinocytes can supply melanocytes e.g. with ligands which can bind to 
MC receptors affecting in turn proliferation, migration, survival and differentiation. At 
the same time melanocytes transport melanosomes, the melanin-laden organelles, to 
surrounding keratinocytes (Slominski, et al., 1993; Kunisada, et al., 2001; Slominski, et 
al., 2004; Haass and Herlyn, 2005).  
1.1.1.3.3.1  Origin, migration and differentiation of melanocytes 
As mentioned above, melanocytes are neural crest derived cells. They originate from the 
neural crest in the second month of gestation as melanoblasts, which migrate dorso-
laterally from the head region towards the skin, where they differentiate into mature 
melanocytes in the epidermis, dermis and hair follicles. Stem cell factor (SCF) and its 
melanocyte receptor, receptor tyrosine kinase (RTK) c-Kit, are playing a crucial role in 
the migration of melanocytes into the epidermis and their survival (Holbrook, 1998; 
Yoshida, et al., 2001). C-kit gene mutation results in hypopigmentation due to the 
absence of melanocytes migration appearing in the skin as hypopigmented patches 
(Fleischman, et al., 1991). This is the case in Piebaldism and in Waardenburg syndrome. 
Moreover, Wnt5a/Frizzled and its melanocyte receptor, Frizzled-5 receptor, were also 
found to be important for migration of melanocytes. It was shown that overexpression 
of the ligand related to the increase in motility and invasion in melanomas (Christiansen, 
et al., 2000; Weeraratna, et al., 2002; Bachmann, et al 2005). The number of 
melanocytes starts to increase in the dermis between weeks 10 and 12, arriving in the 
epidermis between weeks 12 and 14. However, they have also been detected in the 
epidermis between weeks 8 and 10 (Sagebiel and Odland, 1972).   
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Some melanoblasts may differentiate into melanocytes before entering the epidermis in 
response to some growth factors e.g. endothelium 3 (Yoshida, 1996). Undifferentiated 
melanoblasts are able to proliferate and differentiate to epidermal and to hair follicle 
melanocytes, where some of them depart from the epidermis towards the dermis 
developing hair follicles (Yoshida, 1996).   
1.1.1.3.3.2   Melanogenesis 
1.1.1.3.3.2.1  Melanosome biogenesis and transportation 
Melanosomes are the cellular sites for melanin production, storage and transport. They 
are lysosome-related organelles. Melanosomes originate from endosomes (Raposo and 
Marks, 2007). Biogenesis of melanosomes takes place in four distinct stages (Figure 4). 
Stage I (pre-melanosomes; non-pigmented endosomes). They contain PMEL17 protein, 
a melanosomal protein present on the outer surface membrane of pre-melanosomes. 
Thereafter it penetrates to the intralumenal vesicles (ILVs), where it breaks down 
forming fibrillar striations. Pre-melanosomes also have a segmental clatherin coat which 
may be implicated in the entrance of PMEL17 to the ILVs (Clague, 2002; Theos et al., 
2006; Raposo and Marks, 2007; Valencia et al 2007; Harper et al., 2008). In stage II the 
organelle becomes more elongated with more fibrillar striations. At the same time the 
melanogenic enzymes, tyrosinase and TRP-1, originating from the Golgi apparatus, are 
transferred to stage II melanosomes either via transport vesicles or via early endosomal 
intermediates. They start melanin production on the fibrillar striations, leading to 
transformation of stage II to stage III melanosomes (Hearing, 2005; Raposo and Marks, 
2007). The limiting membrane of tyrosinase and TRP-1 positive early endosomes have 
adaptor complex proteins (AP1 or AP3) coated buds. These adaptor proteins are playing 
a critical role in the transportation of tyrosinase and TRP-1 to melanosomes (Huizing, et 
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al., 2001; Theos, et al., 2005). Moreover, it was found that other protein complexes such 
as BLOC1 and BLOC2 are involved in transport of melanogenic enzymes from 
endosomes to melanosomes. It was shown that lack of each of them leads to 
accumulation of TRP-1 in early melanosomes (Di Pietro, et al., 2006; Setty, et al., 
2007). With increased melanin production in stage III melanosomes, the organelles 
become dense, forming fully matured stage IV melanosomes (Raposo and Marks,2007). 
Mature melanosomes are classified into eumelanosomes and pheomelanosomes. 
Eumelanosomes (electron-dense melanosomes) are about 1µm in length, ellipsoidal 
with a network of intramelanosomal fibrillar striations. They also contain glycoprotein 
matrix, which is important for eumelanin biosynthesis. They are mainly distributed 
singularly. Pheomelanosomes are small, variable in shape, but probably spherical with 
a vesicular matrix and less glycoprotein matrix. They aggregate in membrane bound 
complexes within keratinocytes (Imokawa and Mishima, 1986). 
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Figure 4: Biogenesis of melanosomal maturation stages and their transportation to 
keratinocytes. 
In Stage I, PMEL17 protein penetrates to the intralumenal vesicles (ILVs) of pre-
melanosomes. In stage II the organelle becomes more elongated with more fibrillar 
striations. Deposition of melanin on this fibrillar striations leads to the transformation of 
stage II melanosomes to stage III melanosomes. The limiting membranes of tyrosinase 
and TRP-1 positive early endosomes have AP1 or AP3 coated buds. With the increase 
in melanin production in stage III melanosomes, the organelles become dense and the 
cellular architecture is no longer detectable. Mature melanosomes transport from the 
perinuclear region to the dendrites via microtubule (MT)-dependent long-distance 
transport of melanosomes. They detach from microtubules after binding of GTPase 
Rab27a and its MLph to MYO5A in turn enhancing the binding of melanosomes to the 
cortical actin (from Wasmeier et al., 2008).  
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Mature melanosomal transport starts from the perinuclear region to the dendrites. The 
first step involves the microtubule (MT)-dependent long-distance transport by kinesin 
and dynein motors to the dendrite tips. The second step involves the detachment of 
melanosomes from microtubules after binding of GTPase RAB27a and its effector 
melanophilin (MLph) which acts as melanosomes-associated receptor to myosin 5A 
(MYO5A (Wu et al., 1998; Hammer and Wu, 2002; Seabra and Coudrier, 2004). 
Several theories have been proposed for melanosomal transfer from melanocytes to 
keratinocytes (for review see Van den Bossche, et al., 2006):  
1- Cytophagocytosis of melanin loaded tips of melanocytic dendrites by its 
neighboring keratinocytes (Okazaki et al., 1976; Cruickshank and Harcourt, 1994; 
Yamamoto and Bhawan, 1994). 
2- Exocytosis that involve fusion of melanosomal membrane with melanocyte plasma 
membrane releasing melanin to the extracellular matrix, followed by engulfment 
from keratinocytes (Swift, 1964; Yamamoto and Bhawan, 1994). 
3- Transfer by membrane-bound vesicles (Cerdan et al., 1992). 
4- Filopodia dependent melanosomal transfer from melanocytes to keratinocytes 
(Scott et al., 2002; Singh, et al., 2010). 
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1.1.1.3.3.2.2  Regulation of melanogenesis  
Melanins are the final product of melanogenesis. They are large multimorphous 
biopolymers. Both eumelanin and pheomelanin are resulting from oxidation of L-
tyrosine to L-DOPA in the presence or absence of sulfhydryl groups from cysteine. 
Eumelanin (black) derives from oxidative polymerization of 5, 6-dihyroxyindoles, while 
pheomelanin (yellow-red) derives from oxidative polymerization of cystein-S-YL dopas 
and containing in addition to nitrogen some sulphur groups (Prota et al., 1998; Ito, 2003) 
(see melanogenesis pathway in Figure 5). L-tyrosine is transported through plasma 
membrane via facilitated diffusion rather than active transport (Schallreuter and Wood 
1999c). Because of too low tyrosine levels inthe periphery, facilitated diffusion seems to 
be insufficient for melanogenesis (Schallreuter and Wood 1999c; Schallreuter et al., 
2005c). In this context it has been recognised that tyrosine is formed intra-cellularly in 
melanocytes via hydroxylation of L-phenylalanine by the action of intracellular 
phenylalanine hydroxylase (PAH) (Embden and Baldes 1913; Schallreuter et al., 2005c) 
in the presence of the cofactor (6R)-L-erythro 5, 6, 7, 8 tetrahydrobiopterin (6BH4). The 
cofactor reduces the iron in the catalytic region of PAH from the inactive ferric state to 
the active ferrous form (Kaufman 1957; Kaufman 1958; Kaufman 1959; Schallreuter 
and Wood 1999c). Calcium controls the active transport of L-phenylalanine into 
melanocytes and its turnover to L-tyrosine via a calmodulin dependent Ca
2+-
ATPase 
(Schallreuter and Wood, 1999c; Schallreuter et al., 2005c) 
The second step includes production of 3, 4-dihydroxyphenylalanine (L-DOPA) in the 
presence of tyrosine hydroxylase I (THI) again in the presence of the co-factor 6BH4. 
Once tyrosinase is activated to met-tyrosinase via a 2-electron reduction by THI, the 
enzyme can oxidize L-tyrosine to L-DOPA (Wood et al., 1995; Olivares et al., 2002; 
Marles et al., 2003). Here it is noteworthy that the cofactor 6BH4 is also required 
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regulation of tyrosinase. (Kaufman, 1997; Marles et al., 2003; Pey et al., 2006). 6BH4 is 
an allosteric inhibitor of tyrosinase, only when L-tyrosine is the substrate (Wood et al., 
1995).This result showed that tyrosinase has 2 distinct binding sites, one for L-tyrosine 
and the other for L-DOPA (Wood et al., 1995; Olivares et al., 2002).  
Melanogenesis can be affected by many factors. These factors can originate from 
paracrine and endocrine sources or by the external environment including ultraviolet 
radiation. These signals are targeting MITF amongst many others (Lin and Fischer, 
2007). MITF is a transcription factor for several genes that are implicated in melanocyte 
development and melanosomal biogenesis (tyrosinase, TRP-1, TRP-2, tryptophan 
hydroxylase (TPH), PMEL17, OA1 and Rab27) (Levy et al., 2006; Chiaverini et al., 
2008; Cheli et al., 2009, Schallreuter et al., 2012a). 
Melanocortins are derivatives of the precursor hormone proopiomelanocortin (POMC) 
and play crucial a role in melanogenesis via binding to melanocortin-1 receptor (MC1 - 
R) (Eipper and Mains, 1980; Lin and Fisher, 2007). POMC gives rise to many bioactive 
peptides including α-melanocyte stimulating hormone (α -MSH), β-MSH, β-lipotropic 
hormone (β -LPH), adrenocorticotropic hormone (ACTH) and β-endorphin (β-END) via 
cleavage by pro-hormone convertase 1 and 2 (Benjannet et al., 1991; Seidah et al., 
1994). Notably, the MC4 - R has been implicated in regulation of pigmentation via β-
MSH (Spencer and Schallreuter, 2009).   
UVR enhances the production of H2O2 which in turn increases p53 via NFκB (Vile, 
1997; Xie et al., 1999). These observations suggested a role for H2O2 in skin 
pigmentation via a p53 dependent pathway. It was demonstrated that p53 up-regulation 
enhances the POMC machinery specifically through α-MSH⁄ MCR-1 (Cui et al., 2007). 
A regulatory role for low (10
-6 
M) H2O2-levels has been shown on melanin synthesis via 
activation of tyrosinase (Wood et al., 2004). However,  H2O2 in millimolar 
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concentrations, as it exists in vitiligo,  can oxidise many proteins and peptides, 
including tyrosinase (Schallreuter et al., 2000a; Schallreuter, 2014) and the prohormone 
convertases PC1, PC2, Furin, PACE4 as well as the POMC-derived peptides α-MSH 
and β-endorphin (Spencer et al., 2007). Furthermore, H2O2 oxidises methionine residues 
to methionine sulfoxide in the active site of tyrosinase in position 374 leading in turn to 
its deactivation (Wood et al., 2004; Wood et al., 2005, Wood et al 2008). It has been 
shown that H2O2 can oxidise the calcium binding protein calmodulin, affecting in turn 
calmodulin dependent Ca
2+
-ATPase of L-phenylalanine uptake by melanocytes which 
in turn would hamper L-tyrosine supply for melanogegesis (Schallreuter and Wood, 
1999c;  Schallreuter et al., 2004b; Schallreuter et al., 2007c). 
 
 
 
 
 
 
42 
 
L-TYROSINE L-DOPA DOPAquinone
Pheomelanin
Eumelanin
Tyrosinase
5,6-dihydroxyindole-
2carboxylic acid (DHICA) 
DOPAchrome
5,6, dihydroxyindole
(DHI) 
Indole-5,-6quinone Indole-5,-6quinone 
carboxylic acid 
CyteinylDOPA
L-PHENYLALANINE
Phenylalanin hydroxylase (PAH)
TRP-2
TRP-1
GlutathionyldDOPA
tyrosine 
hydroxylase
isoform I (THI)
6-BH4
6-BH4
 
 
Figure 5: Scheme of melanogenesis. 
Eumelanin and pheomelanin biosynthesis is starting with uptake and hydroxylation of 
L-phenylalanine to L-tyrosine. L-tyrosine is catalysed by THI to 3,4-
dihydroxyphenylalanine (L-DOPA) (Schallreuter and Wood, 1999c; Schallreuter et al, 
2004b). 6BH4 regulates both enzymes, PAH and tyrosinase (Wood et al., 1995: 
Schallreuter and Wood, 1999c, Schallreuter 2014). After activation of tyrosinase by THI, 
the enzyme catalyses the oxidation of L-DOPA to dopaquinone. At this point 
eumelogenesis and pheomelanogenesis pursue two different pathways. In 
eumelanogensis, cyclization of dopaquinone results in formation of cyclodopa 
(leukodopachrome). Oxidation of cyclodopa gives rise to formation of a red compound 
called dopachrome which becomes rearranged to form 5,6, dihydroxyindole (DHI) or 
5,6-dihydroxyindole-2carboxylic acid (DHICA) which are polymerized to produce 
eumelanin (Pawelek,1990; Prota, 1992; Prota, 1995; Ito, 2003). In pheomelanogensis, 
via non enzymatic reactions dopaquinone gains one SH group from cysteine to form 
cysteinyl dopa which has two forms, 2-cysteine-S-YL-dopa (2-cysdopa) and 5-cysteine-
S-YL-dopa (5-cysdopa). Furthermore, dopaquinone can also bind to gluathione forming 
glutathione dopa (colourless product) which in turn can be transferred to cysteinyldopa 
forming pheomelanin (Prota, 1992; Prota, 1995; Ito, 2003). 
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1.2 Vitiligo  
1.2.1  Definition and epidemiology of vitiligo  
The name vitiligo originates from the Latin words, vitium = anomaly or vitelius = white 
patches on calf‟s fur (Kovacs, 1998; Pavlović et al., 2000; Ortonne et. al., 2003). 
Vitiligo is an idiopathic, acquired and non-contagious skin disorder, characterised by 
loss of pigmentation due to either complete absence of melanocytes or loss of their 
functionality, leading in turn to white patches with different sizes, shape and locations. 
These days it is without any doubt that keratinocytes and Langerhans cells are also part 
of the game (Nordlund and Ortonne, 1992; Le Poole et al., 1993, Ortonne and Bose, 
1993; Passi et al., 1998; Tobin et al., 2000; for review see Schallreuter et al 2008a, 
Schallreuter 2014). 
Wood`s light examination is used for correct diagnosis of vitiligo as it helps 
distinguishing between vitiligo and other leukodermas, based on the fact that vitiligo 
lesions show a distinct fluorescence when exposed to Wood`s light (UVA 351nm). This 
fluorescence is due to the presence of oxidised pterins which are absent in other skin 
depigmentations (Schallreuter et al., 1994a,b). 
According to the world health organization, vitiligo is a disease which is considered as a 
common disorder of skin pigmentation. Its prevalence is ranging between 0.5 and 1% 
worldwide (Alkhateeb et al., 2003; Parsad et al., 2003;  Daneshpazhooh et al., 2006; 
Moretti et al., 2006; Sehgal and Srivastava, 2007; Wolff et al., 2007; Szczurko and 
Boon, 2008; Lotti et al., 2008; Krüger and Schallreuter, 2012) regardless of gender, skin 
color and age (Lebwohl et al., 2006; Moretti et al., 2006; Lotti et al., 2008 a;b; Wolff et 
al., 2007; Schallreuter 2014). 
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Different studies have reported a predominance for childhood or young adulthood, 
where vitiligo seems to appear with a peak between10-30 years (Tonsi, 2004; James et 
al., 2006; Wolff et. al., 2007). However, it can develop at any age (Behl and Bhatia, 
1971; Mehta et al., 1973; Halder and Nootheti, 2003; Wolff et. al., 2007; Schallreuter et 
al 2008b; Szczurko and Boon, 2008). Vitiligo is rare in older people and infants and its 
rate seems to be declining with age (Tonsi, 2004; Lotti et al., 2008a; b). 
1.2.2 Diagnosis and clinical classification of vitiligo 
Vitiligo lesions are diagnosed as chalk- or milk- white patches that can occur at any 
place of the body of healthy individuals including face the dorsal surface of hands, 
sacrum, axillae, nipples, umbilicus and inguinal / anogenital regions as well as flexor 
wrists, digits, knees and elbows (El-Din Anbar et al., 2008; Alikhan et al., 2011). As 
said above, correct diagnosis is made by Wood`s light (351 nm) (Schallreuter et al., 
1999a;b). According to distribution and location of the white spots, the disease is 
classified.  
1.2.2.1   Localized vitiligo 
It is characterized by the presence of few white macules. It can be subtyped into 
segmental and focal (Hann and Im 2004; Gawkroger et al., 2008). 
1.2.2.1.1   Segmental vitiligo (dermatomal and /or Blasckolinear) 
Unilateral vitiligo is characterized by an appearance of depigmented skin on one side of 
the body (Hann and Lee, 1996; Hann, 2000c). Clinically the depigmentation can affect 
one or several dermatomes or Blaschko lines (Schallreuter et al, 2007e). Accordig to the 
literature it affects children more than adults (Koga and Tango, 1988; Hann and Lee, 
1996; Grimes and Billips, 2000; Hann and Im, 2004). After the onset of the 
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depigmentation, it mostly takes 1 to 2 years to spread, but then it usually stops. It is rare 
that unilateral vitiligo patients develop bilateral vitiligo (Koga and Tango, 1988; Hann 
and Lee, 1996; Hann and Im, 2004), leading to mixed vitiligo. The latter entity has been 
surprisingly missed over decades (Schallreuter et al., 2008b; Ezzedine et al., 2012). 
1.2.2.1.2 Focal vitiligo 
Focal vitiligo refers to depigmentation of skin in one or more patches with random 
distribution (Nordlund and Lerner, 1982; Lotti et al., 2008b). In some patients these 
patches remain localized, while in other less fortunate cases, it develops to more 
aggressive subtypes such as vitiligo vulgaris (Liu et al., 2005). 
1.2.2.2 Generalized vitiligo 
Generalized vitiligo is considered to be the most common type of vitiligo that can be 
divided into two subtypes namely acrofacial and vitiligo vulgaris. Recently a new 
classification has been suggested by the European Task Force group (Taïeb and Picardo, 
2007). For generalised vitiligo the term non-segmental vitiligo (NSV) has been 
introduced. 
1.2.2.2.1 Acrofacial vitiligo 
This term refers to depigmented patches of skin that start to appear on distal extremities 
(fingers and feet) and acrofacial areas (around mouth and eyes) including the perianal 
and genital area. Patients of this type of vitiligo represent 3 to 16 % of all vitiligo cases 
(Schallreuter et al., 1994c; Parsad et al., 2004; Zhang et al., 2004; Dogra et al., 2005; 
Liu et al., 2005; Nordlund et al., 2008). 
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1.2.2.2.2 Vitiligo vulgaris 
The most common subtype of vitiligo shows symmetrical appearance of large white 
macules anywhere on the entire integument (Nordlund et al., 2008; Gawkrodger et al., 
2008; Arycan et al., 2008; Halder and Taliaferro, 2008). It represents about 40 -80% of 
all vitiligo cases (Handa and Kaur, 1999; Dogra et al., 2005; Liu et al., 2005). 
When vitiligo spreads involving >80% of the skin, it is described as universal vitiligo 
(also vitiligo totalis) (Shajil et al., 2006; Nordlund and Lerner, 1982). 
1.2.2.3 Vitiligo with unusual patterns 
1.2.2.3.1. Vitiligo ponctuè (guttate vitiligo) 
It is a frequent type of vitiligo appearing as confetti-like, separated, tiny depigmented 
macules spread on normal or hypermelanotic skin. The prevalence increases with age 
(Ortonne, 2008). Whether this entity presents classical vitiligo is still under debate. 
1.2.2.3.2   Trichrome and quadrichrome vitiligo 
Trichrome vitiligo patients show 3 different skin color patterns. The hypopigmented 
area has higher number of melanocytes, compared to amelanotic lesions, but lower 
numbers than non-lesional skin. Moreover, it shows an increase in the number of 
Langerhans cells, inflammatory cells and melanophages in comparison with both 
lesional and non-lesional skin of these patients (Lerner, 1959; Fitzpatrick, 1964; Hann et 
al., 2000b). 
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1.2.2.3.3      Blue vitiligo (pentachrome vitiligo) 
It shows additional blue-grey macules that may be due to epidermal melanocyte absence. 
These patients are supposed to have melanophages in their dermis (Chandrashekar, 
2009). 
1.2.2.3.4     Inflammatory vitiligo 
This type of vitiligo exhibits raised red borders around the depigmented macules which 
may be accompanied with mild pruritus due to irritation caused by an inflammatory 
process and lymphocytic/histocytic infiltration (Fitzpatrick and Mihm, 1971; Hann and 
Im, 2004;  Sharquie et al., 2004; Halder and Taliaferro, 2008; Ortonne, 2008). Recently 
pruritus in vitiligo has been attributed to extreme oxidative stress in acute vitiligo 
(Schallreuter, 2014). 
 1.2.2.3.5       Blaschko-linear vitiligo 
Blaschko-linear vitiligo is a peculiar depigmentation following Blaschko`s lines. Those 
lines were first described and delineated in 1901 by Alfred Blaschko (Blaschko, 1901). 
In this case depigmentation shows fountain-like lines on the chest/abdomen and 
perpendicular lines on face and limbs (Jakson, 1976; Happle, 1977; Bolognia et al., 
1994;). 
Although Blaschko-linear pattern is rare in the literature (El Mofty, 1968; Punshi, 1975; 
Schallreuter et al., 2007e), some studies claim its occurrence in a fairly high rate (49.6%) 
in segmental vitiligo (Khaitan et al., 2007). 
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1.2.3 Etiology of vitiligo 
The cause of this disease is still unknown. Several theories have been evolved, reaching 
from destruction of functioning melanocytes to complete loss with subsequent 
appearance of vitiligo macules.  
 
1.2.3.1 Autoimmune hypothesis 
This theory involves implication of autoimmune response for melanocyte destruction 
and pathogenesis of vitiligo and how components of the autoimmune system, including 
memory cytotoxic T-cells or autoantibodies are directed against surface antigens of 
melanocytes in addition to the presence of thyroid, parietal mucosa and adrenal 
antibodies (Naughton et al., 1983; Ongenae et al., 2003; Farrokhi et al., 2005; Le Poole 
and Luiten 2008; Schallreuter et al., 2008a; Schallreuter et al., 2012 b). 
 
1.2.3.2 Neural hypothesis  
As melanocytes are derived from neural crest during embryogenesis, it was proposed 
that vitiligo represents an abnormal interaction between neurochemical mediators such 
as neuropeptides including catecholamines and / or their metabolites with melanocytes 
(Schallreuter et al., 1994b; Orecchia, 2000). 
An elevated level of catecholamines and its metabolites have indeed been reported in 
urine of vitiligo patients and levels were proportionally increasing in association with 
disease activity (Morrone et al., 1992; Cucchi et al., 2003). Low epidermal 
phenylethanolamine-N-methyl transferase (PNMT) levels in vitiligo correspond to high 
norepinephrine levels, suggesting involvement of this catecholamine (Schallreuter et al., 
1994b. In this context it is of note that higher expression of epidermal β2-adreno-
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receptors has been documented in vitiligo (Schallreuter et al., 1993). Moreover, the 
entire epidermal cholinergic system is affected in these patients (Schallreuter and 
Elwary, 2007a). It was also reported that levels of acetylecholine are up-regulated in 
vitiligo due to loss of functioning regulatory enzymes including AchE 
(acetylcholinesterase) and BchE (butyrylcholinesterase) (Schallreuter et al. 1996a; 
Schallreuter et al., 2004a; Schallreuter et al., 2007b; Glassman, 2011). Regulatory 
factors for melanogenesis, derived from pro-opiomelanocortin (POMC), are affected in 
vitiligo (Peters et al., 2000). These peptides involve α-MSH (α-melanocyte-stimulating 
hormone) and β-endorphin (Graham et al., 1999; Spencer et al., 2005; Spencer et al., 
2007). 
 
1.2.3.3 Autocytotoxic hypothesis 
During melanogenesis some toxic products, such as phenols or quinones, are produced 
and their accumulation may lead to melanocyte damage (Hann and Chun, 2000). L-
tyrosine is a phenol that oxidizes to L-dopaquinone during melanin synthesis. Oxidation 
of L-dopaquinone releases several phenolic compounds (free radicals or indoles) that 
can harm melanocytes (Boissy and Manga, 2004). In this context it is of interest that 
patients with vitiligo are extremely sensitive to those compounds, affecting even 
lymphocytes (Schallreuter et al., 2006; Schallreuter and Salem, 2010). Moreover, the 
Slominiski group suggested in 1989 post-tyrosinase inhibition of melanin production 
due to activation of melatonin receptors causing accumulation of toxic intermediates 
and free radical accumulation in melanocytes which in turn would lead to its destruction 
(Slominiski et al., 1989). However, very recently it was shown that the entire 
melatoninergic as well as the serotoninergic pathway are severely affected in vitiligo 
leading to absence and /or low levels of melatonin and serotonin. Accordingly there 
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would not be any ligand available for melatonin and / or serotonin receptors 
(Schallreuter et al 2012 a). 
1.2.3.4 Genetic hypothesis 
Many familial cases of vitiligo were documented ranging 1.5- 45%.incidence rates. This 
fact prompted many studies to suggest the implication of genetic abnormalities in 
vitiligo (Singh et al., 1985; Schallreuter et al., 1994b; Alkhawajah, 1997). Genetically, 
vitiligo is defined as an inherited disorder with non-Mendelian, multifactorial and multi 
genetic pattern, with incomplete penetrance (Alkhateeb et al., 2003; Sun et al., 2006). 
Some studies reported aberrant expression of melanocyte specific proteins including c-
Kit and stem cell factor (SCF). Both represent an important receptor/ligand system in 
regulation of melanocyte differentiation and melanogenesis (Chabot et al., 1988; Zsebo 
et al., 1990). Moreover, the catalase gene was documented, to be affected by several 
point mutations. This observation can support both, a genetic and oxidative stress 
hypothesis (Casp et al., 2002; Wood et al., 2008). 
Recently two large-scale genomewide association studies (GWAS) of generalized 
vitiligo (GV), one in Caucasians and the other in a Chinese population, were reported. 
At least 16 different genetic loci were associated with susceptibility in generalized 
vitiligo. All of these genes, except one, are encoding proteins that are part of the 
immune system regulation and/or have been genetically associated with susceptibility to 
other autoimmune diseases.  The only identified gene with no association to the immune 
system was TYR, encoding tyrosinase, the key enzyme of melanin biosynthesis (Jin et 
al., 2010; Quan et al., 2010). Future work needs to unravel the connection between 
bench and bedside. Importantly, these novel data need to be brought together with all 
current and old knowledge on the subject vitiligo. 
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1.2.3.5 Viral hypothesis 
This theory proposes the implication of viral infections in the pathogenesis of vitiligo, 
as some authors suggested a relationship between this disease and some 
viruses,including human cytomegalovirus (CMV), hepatitis C virus (HCV) and Epstein 
Barr virus (EBV) (Grimes et al., 1996; Grimes et al., 1999; Galarza et al., 2004), while 
other studies could not confirm any significant connection between vitiligo incidence 
and viral infections (Würfel, 1999; Akbayir et al., 2004; Schallreuter, 2004b; Jadali et 
al., 2005). 
 
1.2.3.6 Oxidative stress hypothesis 
Oxidative stress refers to a disturbance in the cellular redox status in form of an 
imbalance between production and manifestation of oxygen containing molecules, 
called reactive oxygen species (ROS) including H2O2 and the ability of an effective 
antioxidant system to promptly detoxify these ROS. Accumulation of these 
intermediates in the cells may lead to oxidation of cellular components, affecting in turn 
different pathways, including gene and protein expression in addition to signal 
transduction (Sies and Cadenas, 1985; Wiseman et al., 1995; Migliore and Coppede, 
2002; Stadtman, 2004; Schallreuter, 1999b, 2005a, 2008a; 2014). ROS lead to 
production of free radicals, which are unstable molecules owning unpaired electrons in 
an orbit such as superoxide radical (O2
.-
), hydroxyl radical (
.
OH) and ONOO
- 
to name a 
few (Sies and Cadenas, 1985; Cobbs et al., 1995; Cobbs et al., 2001; Migliore and 
Coppede, 2002,; Schallreuter et al 1999b, 2005a; 2014). 
H2O2 production in epidermal cells originates from multiple endogenous or exogenous 
sources. Endogenously it involves activation of various enzymes; including tyrosinase 
(Wood et al., 2004), monoamine oxidase A (Barzu and Dansoreanu, 1980; Maker et al., 
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1981; Schallreuter et al., 1996b, xanthine oxidase (Olson et al. 1974; Kellogg and 
Fridovich, 1975; Parks and Granger, 1986; Schallreuter et al.,1996b; Shalbaf et al ., 
2008) , NADPH oxidase (Rossi et al., 1985), tyrosine hydroxylases (Adams et al., 1997) 
and the nitric oxide synthases, (Salem et al., 2009) in addition to various growth factors 
including  transforming growth factor-β (TGF-β) (Shibanuma et al., 1991; Thannickal et 
al., 1993), platelet derived growth factor (PDGF) (Sundaresan et al., 1995), epidermal 
growth factor (EGF) (Bae et al., 1997) and tumor recrosis factor α (TNFα) (Hoffman 
and Weinberg, 1987) as well as aromatic steroids such as estrogen (Schallreuter et al., 
2006) and progesterones (Martinoli et al., 1984) . Exogenously, phenols, ortho / para 
quinols in addition to UVA /  UVB and X-rays can also contribute to the H2O2 
production and consequently to the radical pool (Schallreuter et al., 1999b; Schallreuter 
and Wood, 2001) (see Figure 6). 
Superoxide anion radicals  (O2
.-
) can release iron from cellular molecules and this iron 
takes part in the Fenton reaction  producing 
.
OH
.
 from H2O2 as shown below (Stohs and 
Bagchi, 1995; Schallreuter et al., 2012a). 
 
Fe (II) + H2O2                           Fe (III) + 
.
OH+ OH
- 
 
OH
.
 can react with amino acids and fatty acids affecting cell membranes and protein 
function, enzyme activity and transcription processes (Stohs and Bagchi, 1995; 
Pekarkova et al., 2001; Liochev and Fridovich, 2002; Leonard et al., 2004; Smith, et al., 
2004; Schallreuter et al., 2012a). 
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Figure 6: H2O2 generation in the human epidermis. 
 
TNF-α indirectly leads to H2O2 formation via the induction of manganese superoxide 
dismutase (Schallreuter, 2005a; Moretti et al, 2002; Wong and Goeddel, 1988). TGF-β, 
EGF and PDGF were reported to generate H2O2 (Thannickal et al., 2000). Epidermal 
monoamine oxidase A activities generate H2O2 (Darr and Fridovich, 1994). NADPH 
oxidase activities from neutrophils and macrophages generate H2O2 (oxygen burst) 
(Darr and Fridovich, 1994). Photo-oxidation of epidermal 6BH4 and sepiapterin yields 
H2O2 generation (Schallreuter, 1999). Nitric oxide synthases can spontaneously foster 
the synthesis of H2O2 in the absence of the substrate L-arginine (Schallreuter, 2005; 
Schallreuter, 1999). Generation of H2O2 by estrogen and progesterone has been 
demonstrated (Jimbow et al., 2001). Xanthine oxidase degrades purin bases to uric acid 
and this step generates H2O2 (Shalbaf, et al., 2008). Phenols, o-and p-quinols as well as 
UVA/UVB and X-rays can generate H2O2 in the mM range (Schallreuter et al., 1999b, 
Boissy and Manga, 2004). Topical application of Q10 generates hydrogen peroxide 
(H2O2) via semiquinone radical formation. Recently we see increasing numbers with the 
onset of facial vitiligo in susceptible individuals after the use of those Q10 containing 
cosmetic creams (Schallreuter et al., 2013) (modified from Schallreuter et al., 2009, 
2014). 
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In normal skin ROS production is regulated by antioxidant defence mechanisms that 
involve either enzymes including catalase (CAT), thioredoxin reductase (TR) / 
thioredoxin , thioredoxin peroxidase (TPx), glutathione reductase(GR) / glutathione, 
glutathione peroxidase (GPx), superoxide dismutase (SOD) and methionine sulfoxide 
reductases A and B or non-enzymatic systems such as vitamin C, amino acids as L-
methionine, L-cysteine and L-tryptophan in addition to 6- and 7- tetrahydrobiopterins 
(Schallreuter , 2005a;b; Schallreuter et al., 2008a; Schallreuter, 2014). 
In the case of vitiligo, Schallreuter‟s group were the first to demonstrate in vivo a 
massive increase in H2O2 -levels in the epidermis of both lesional and non-lesional skin 
of those patients, implicating “oxidative stress” via H2O2 in the pathogenesis of this 
disease. This oxidative stress can be measured by the concentration of H2O2 or its 
oxidation products including methionine sulfoxide and other oxidation products by 
using in vivo FT-Raman spectroscopy. Moreover, the epidermal accumulation of H2O2 
is accompanied with low levels of several epidermal enzymes, which control H2O2 
concentrations, including CAT, TR and GR, to name a few (Aronoff, 1965; Schallreuter 
et al., 1991b;  Schallreuter et al., 1999b; Schallreuter, 2004a; Chavan et al., 2006; 
Maresca et al., 2006; Wood and Schallreuter, 2006; Schallreuter et al., 2007 b; c; f; 
Spencer et al., 2007;  Schallreuter and Elwary, 2007a; Wood et al., 2008, Shalbaf et al., 
2008;  Salem et al., 2009, Schallreuter et al.,  2012 a; b;  Schallreuter, 2014). 
However, in this context it is well established that H2O2 in micromolar (10
-6
M) 
concentrations has a useful effect on melanogenesis and other important regulatory 
functions via up-regulating several important transcription factors, including MITF and 
p53, but also directly on enzyme activities including tyrosinase and  some antioxidant 
enzymes including CAT, TR, GR and methionine sulfoxide reductases (MSR A&B) 
(Wood et al., 2004; Wood et al., 2005; Schallreuter et al., 2005b; Schallreuter et al., 
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2006; Schallreuter et al., 2007c, f; Gibbons et al., 2006; Schallreuter, 2014).  Increase of 
H2O2 to the mM range (10
-3
M) can cause lipid peroxidation and appearance of 
intracellular vacuolation throughout the entire epidermis in vitiligo patients (Tobin et 
al., 2000; Bhawan and Bhutani, 1983; Moellmann et al., 1982). Moreover, H2O2 can 
affect melanogenesis negatively via disrupting many of its critical regulatory signals, for 
example calcium-uptake and its -homeostasis machinery via oxidation of tryptophan or 
methionine residues of calcium binding proteins including albumin and calmodulin, 
respectively. The decrease in calcium concentration in melanocytes has a critical effect 
on melanin production due to the impaired calcium-required active transport of L-
phenylalanine and subsequently its turnover into L-tyrosine (Schallreuter and Pittelkow, 
1988; Schallreuter et al., 1996a; Schallreuter and Wood, 1999c; Rokos et al., 2004; 
Schallreuter et al., 2004c). Furthermore it was shown that H2O2 influences synthesis and 
regulation of the essential cofactor 6BH4 which can affect melanogenesis via regulating 
the activity of melanogenic enzymes, including tyrosinase, THI and PAH. H2O2 oxidises 
6BH4 to L-biopterin which is cytotoxic to melanocytes under in vitro conditions 
(Schallreuter et al., 1994d; Schallreuter, 1999a). In fact, as said above, accumulation of 
oxidised pterines in the skin of patients with vitiligo leads to the characteristic blue / 
green fluorescence under Wood`s light (351nm) (Schallreuter et al., 1994a,b).  
Although H2O2 is considered as one of the main players in oxidative stress-mediated 
vitiligo, other factors are found to contribute to the pathogenesis, such as nitric oxide 
(NO), a reactive nitrogen species (RNS) member.  Its reduction into hydroxyl amine is 
normally catalyzed by TR, but this enzyme is also deactivated by H2O2 in the case of 
vitiligo. Deactivation of TR leads to accumulation of NO which in turn reacts with O2
.-
 
producing the damaging ROS peroxinitrite (ONOO
-
) (Salem et al 2009). ONOO
-
 leads 
to nitration of tyrosine residues affecting in turn all proteins, which contain this residue 
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in the structure (van der Vliet et al., 1994; Oury et al., 1995; Groves, 1999). In vitiligo it 
was shown that epidermal ONOO
-
 levels are extremely high (Salem et al 2009). 
These hazardous effects of high H2O2 / ONOO
- 
concentrations on melanogenesis can be 
successfully controlled with a topical application of a narrow-band UVB activated 
pseudocatalase PC-KUS. This approach leads to H2O2 removal / reduction by oxidising 
this ROS back to O2 and H2O together with restoration of the missing skin colour 
(Schallreuter et al., 1995; Schallreuter et al., 2008a; Salem et al, 2009; Schallreuter 
2014). 
Repigmentation in the face occurs in 95% of all patients. About 80% of them achieved 
recovery on the integument, while hands / wrists and feet do not respond so well. This 
clinical result is considered as one important proof for the role of H2O2 - mediated 
oxidation in the pathogenesis of vitiligo (Schallreuter, 1999b; Schallreuter et al., 2008b; 
Salem et al., 2009; Schallreuter et al., 2012 a; b; Schallreuter 2014). 
Moreover, H2O2 and ONOO
-
 - mediated oxidative stress can trigger DNA-damage in 
patients with this disease. It was recognized that the production of the oxidised DNA 
base 8-oxoguanine (8-oxoG) is high in both, epidermis and plasma of these patients 
(Salem et al., 2009). This increase in DNA-damage is associated with epidermal 
accumulation of H2O2  and a functioning wild type p53 in this compartment 
(Schallreuter et al., 2003; Salem et al., 2009). Importantly, in vitiligo  this high p53 is 
associated with  elevated levels of p76 
MDM2 
splice variant , a competitive antagonist 
negative regulator of p53 degradation (Perry et al., 2000; Salem et al., 2009). 
In this context it was shown that both H2O2 / ONOO
-
 enhance DNA-binding on p53. 
Consequently it has been suggested that this stable up-regulated p53 accounts for 
induction of an efficient DΝΑ-repair via hOgg1, APE1 and DNA polymerase β 
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(Sengupta and Harris, 2005; Salem et al., 2009) that in turn lead to short-patch base-
excision repair (BER). Based on this result it was suggested that this cascade may lead 
to prevention of ROS-induced tumourigenesis in the epidermis of patients with vitiligo 
(Salem et al., 2009; Schallreuter, 2014). 
1.3 Vitiligo and skin cancer 
Still the dogma is that melanin is playing a major role in the protection against UVR 
induced cellular damage by absorbing these rays and transforming them into heat which 
consequently is dispersed between capillary vessels and hair. It also hinders DNA 
damage by the action of ROS such as OH
.
 and O2 , produced in the skin in response to 
UVR via scavenging these active metabolites (Hussein, 2005). However, some other 
studies had reported the deleterious influences of melanin itself via generating ROS 
after exposure to UVR causing in turn cellular DNA damage (Chedekel et al., 1977; 
Chedekel et al., 1978; Felix et al., 1978; Chedekel, 1982; Sarna et al., 1985; Korytowski 
et al., 1987; Prota, 1995; Marrot et al., 1999; Brenner and Hearing, 2008).  
Although, vitiligo patients lack protection against UVR due to absence of melanin in the 
depigmented skin, and hold extremely high ROS-induced oxidative stress in their 
epidermis due to the accumulation of H2O2 and ONOO
-  
accompanied with disturbances 
in the antioxidant system (Aronoff, 1965; Schallreuter et al., 1991b; Schallreuter et al., 
1999 a;b; Schallreuter et al., 2004b; Maresca et al., 2006; Wood and Schallreuter, 2006; 
Schallreuter et al., 2007a;b;c;d;f ; Wood et al., 2008, Salem et al., 2009; Schallreuter 
2014), surprisingly, these patients exhibit no significant elevated risk for skin photo-
sensitivity disorders such as polymorphous light reaction, solar urticaria and acute 
actinic dermatitis or non-melanoma skin cancer such as basal-cell, squamous cell 
carcinomas and the precursor actinic keratosis. Moreover, their skin appears younger 
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compared to healthy people of the same age (Oettle, 1963; Calanchini-Postizzi and 
Frenk, 1987; Schallreuter et al., 2002; Schallreuter et al., 2008a; Teulings et al., 2013;  
Schallreuter, 2014). 
Clearly both, lack of pigment as well as the high ROS-induced oxidative stress, are bad 
news, leading under normal circumstances to actinic skin damage as well as skin cancer 
in people with fair-skin and those with certain types of albinism (Kaidbey et al., 1979; 
Lookingbill et al., 1995; Marks, 1995; Naruse et al., 1997; Salasche, 2000). The crucial 
question to be answered is: what is the reason behind this enigma and how are patients 
with vitiligo protected against development of non-melanoma skin cancer? 
Schallreuter and colleagues documented in vivo and in vitro an up-regulated 
accumulation of H2O2-induced functioning wild type p53 throughout the entire 
epidermis of patients with vitiligo. While reduction of this epidermal ROS with a NB - 
activated pseudocatalase PC-KUS leads to arrest of the disease as well as to restoration 
of the skin colour, H2O2 -removal / reduction did not affect the high p53 protein level.  
This observation suggested that H2O2 levels in the case of vitiligo may be always high 
enough for triggering p53 transcription (Vile, 1997; Schallreuter et al., 2003; 
Schallreuter, 2014). Moreover, these patients hold normal levels of p90
MDM2
, the main 
negative regulator of p53 (Salem et al., 2009). These findings raised another important 
question. Why p53 levels are remaining high, if the protein, responsible for its 
degradation, is not affected as in the case of vitiligo? One explanation could be that 
those high levels can be attributed to continuous oxidative stress, causing an increase in 
the post-translational modification of p53 protein in form of phosphorylation in the C-
terminal as well as in the N-terminal regions of the protein. These modifications would 
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destabilize the interaction between p53 and MDM2, resulting in protection of p53 from 
degradation (Schallreuter et al., 2003, Salem et al 2009).  
Salem and colleagues, were the first to shed some more light on the scenario. These 
authors studied the expression of two splice transcripts of MDM2, namely, p90 
MDM2
 
and p76 
MDM2
 in the epidermis of patients with vitiligo. They confirmed normal levels of 
p90 
MDM2
, the negative regulator of p53 in association with an up-regulation of p76 
MDM2
 isomer, a competitive antagonist in binding to p90 
MDM2
 (Perry et al., 2000). Here 
it is noteworthy that this variant is not present in normal individuals. The presence of 
p76 
MDM2
 could provide an explanation for hindering p53 degradation and accumulation 
of p53 in the epidermis of these patients (Salem et al., 2009). Furthermore, despite the 
documented high levels of ONOO
-
 in these patients and the possibility that it can alter 
DNA-binding capacity of p53 via nitration of tyrosine residues present in its DNA-
binding element, it was shown that p53-DNA binding capacity is enhanced by the 
presence of both ONOO
-
 and H2O2 in 10
-3
 M concentrations. H2O2 is able to abolish the 
negative effect of ONOO
- 
via prevention of its ability to nitrate p53 ( Salem et al., 
2009). Taken together, p53 still seems to be the main master in DNA-repair for patients 
with vitiligo.  
 Based on these data it was then proposed that the normal risk of non-melanoma skin 
cancer in addition to absence of skin photodamage in vitiligo might be connected to this 
scenario (Calanchini- Postizzi and Frenk, 1987; Schallreuter et al., 2002; Salem et al., 
2009). 
Although it is now common consent that these patients have no increased risk for 
development of non-melanoma skin cancer.  The data on melanoma in association with 
vitiligo are controversial (Schallreuter et al., 1991a; Teulings et al., 2013).  
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Schallreuter and colleagues proposed a 180 - fold higher risk of developing melanoma 
for patients with vitiligo. The data originated from a study group with 623 patients with 
melanoma, where 23 had vitiligo and / or melanoma associated leucoderma (MAL). 
Eleven cases had true vitiligo before melanoma diagnosis, but 11 patients developed 
depigmentation after diagnosis with primary or / and metastatic melanoma, while in one 
case first appearance of vitiligo in association with melanoma was not exactly defined 
(Schallreuter et al., 1991). In this context it is noteworthy that vitiligo was reported as a 
good prognostic factor for melanoma survival (Boasberg et al., 2006; Cunha et al., 2009, 
Teulings et al., 2015). This was not the case for those patients in the Hamburg patient 
group. All patients died within the next 2 years after completion of this study 
(Schallreuter, unpublished data). 
 Clearly there is a need to show, whether true vitiligo and /or the presence of MAL is a 
good prognostic sign for the development of de novo melanoma and for prognosis / 
survival rates. To shed some more light on a possible association / connection with 
classical vitiligo and MAL is part of this thesis. 
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1.4 Regulation of p53 by SPARC, TGF-β and the possible 
involvement of the entire MDM2 family. 
1.4.1 p53 – as the ―guardian of the genome‖  
p53 is a transcription factor that can activate or suppress the expression of many genes 
via binding to their promoter regions (Song and Xu, 2007). In normal cells, p53 is 
frequently undetectable, as it is expressed in very low concentrations (approximately 
1000 molecules / cell) with a short half life (approximately 20 min). It is immediately 
ubiquitinated by the action of MDM2 and degraded in the proteasomes (Blagosklonny, 
1997; Haupt et al.,1997; Kubbutat et al., 1997). The p53 gene is located in chromosome 
17p13.1. The coding protein is 53 kDa in size and consists of 393 amino acids residues 
(Nikolova et al., 2000).  There are five major domains in p53 protein: 
 The N-terminal domain, (aa 1-42) that is important for transcriptional activation as it 
has binding sites for gene expression inducing factors as TATA box binding protein 
(TBP) and TATA box binding protein-associated factors (TAFs) (Dutta et al., 1993; He 
et al., 1993; Li and Botchan, 1993; Lu and Levine, 1995; Thut et al., 1995; Unger et al., 
1999). 
 A proline rich region (aa 63-97) containing five repeats of PxxP sequence which 
interacts with-SH3- domains of proteins (Src tyrosine kinase). It is also playing a role in 
non-transcriptional activation of the intrinsic apoptotic pathway (Walker and Levine, 
1996; Sakamuro et al., 1997; Venot et al., 1998). 
 The DNA-binding domain (aa 102-292) is able to interact with specific DNA 
sequences of p53 target genes including p21 and mdm2, to name a few (Bargonetti et 
al., 1993; Halazonetis et al., 1993; Pavletich et al., 1993; Wang et al., 1993; Ko and 
Prives, 1996). About  28% of mutations occur within the DNA-binding domain at 
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six hot spots of aa 175, 245, 248, 294, 273 and 282  (Raycroft et al., 1990; el-Deiry et 
al., 1993; Cho et al., 1994; Karen et al., 2002).  
 The C-terminal domain includes an oligomerization or tetramerization domain (a-
a 323-356). Moreover, it regulates the sub-cellular localization of p53 according to three 
nuclear localization signals (NLS). Therefore, a mutation in NLS1 (amino acids 316- 
325) causes p53 to locate in the cytoplasm, while NLS2 spanning from aa 369-375 and 
in NLS3 spanning from aa from 379-384) leads to location in cytoplasm and nucleus 
(Shaulsky et al., 1991).  
 The regulatory domain is spanning from aa 360-393 (Wang et al., 1993; 
Bakalkin et al., 1994; Bayle et al., 1995; Lee et al., 1995; Reed et al., 1995) 
(Figure 7). 
 
 
 
Figure 7:  Domain structure of full-length p53.  
The protein contains an N-terminal transactivation domain (TAD), followed by a 
proline-rich region (PRR), the central DNA-binding domain (p53C), the tetramerization 
domain (TET), and the C-terminus (CT). p53C, the domain where most cancer-
associated p53 mutations are located, is highlighted with a rainbow color gradient from 
blue at its N-terminus to red at its C-terminus. The bars above the diagram indicate the 
relative frequency of oncogenic missense mutations at each residue according to version 
R11 (October 2006, N = 17,015) of the International Agency for Research on Cancer 
TP53 mutation database (from Joerger and Fersht, 2008). 
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p53 is a member of a small family of proteins involving two other members, i.e. p63 
and p73 (Arrowsmith 1999; Levrero et al., 1999; Levrero et al., 2000) which show 
similar structural and functional features as p53 (Kaghad et al., 1997; Yang, Kaghad et 
al. 1998). 
In response to genotoxic stresses, for example UV and cytotoxic drugs , oncogenic 
stress (Myc, Ras V12) and viral infection, p53 mediates DNA-damage response, via 
several kinases including Arf (alternate reading frame), ATM, ATR, chk1 and chk2 
(protein kinases).  Phosphorylation of p53 at Ser 20 and Ser 15 leads to its activation. 
This phosphorylation within or near the MDM2-binding domain results in stabilization 
of p53, preventing MDM2 from binding to p53 which consequently causes an 
accumulation of p53 in the nucleus (Giaccia and Kastan, 1998; Chehab et al., 1999). 
p53 is modified by acetyl transferases such as p300, CBP and PCAF that acetylate p53 
at its C-terminal lysine residues (i.e Lys-370, Lys-371, Lys-372, Lys-381, Lys-382) 
leading in turn to activation of p53 DNA-binding activity (Gu and Roeder, 1997; 
reviewed in Kouzarides, 2000; Sterner and Berger, 2000) together with induction of 
transcriptional activity of numerous genes involved in cell cycle arrest (p21, 14-3-3α), 
DNA-repair (GADD45, Killer/Dr5), and apoptosis (BAX, PUMA, NOXA) or obstruct 
angiogenesis through up-regulation of thrombospondin. Taken together, these 
mechanisms reduce the risk of transformation of cells within a genetic and epigenetic 
lesion, preventing in turn tumour formation (Shieh et al., 1997; Unger et al., 1999; 
Chehab et al., 1999; Vousden and Lu, 2002; Yu and Zhang, 2005; Laptenko and Prives, 
2006; Pelengaris and Khan, 2006; Rozan and El-Deiry, 2007) (Figure 8). 
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Figure 8: Activation and function of p53. 
 
Step 1 and 2: In response to many types of cellular stress, signal mediator proteins are 
activated. Step 3: phosphorylation of p53 in its N-terminal domain preventing inturn its 
ubiquination by the action of MDM2 hence increase the p53 half-life which 
subsequently leads to p53 accumulation. Step 4: further p53 modifications takes place 
by acetyltransferases (CBP, p300, PCAF) and methyltransferases (SET9) which 
increase the p53 DNA-binding capacity. Step 5: deacetylation of p53 may takes place in 
responce to the deacetylase HDAC2 inhibiting inturn p53 binding to DNA. Step 6: 
binding of p53 tetramer to the p53 response element (RE). Step 7: recruitment of gene 
expression inducing cofactors such as histone acetyltransferases (HATs), TATA box-
binding protein and TATA box-binding protein-associated factors (TAFs). Step 8: 
initiation of p53 target genes translation. Step 9: production of various proteins involved 
in DNA-repair, cell-cycle arrest, and apoptosis. ATM, ataxia telangiectasia mutated; 
CHK2, checkpoint kinase-2 (modified from Riley et al., 2008). 
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Malfunction of the p53 pathway has been reported as the most common hallmark for 
human tumours (Vogelstein et al., 2000; Vousden and Lane 2007). It has been 
documented that mutated and / or deleted p53 accounts for approximately 50% of all 
human cancers (Hollstein et al., 1991, Vogelstein et al., 2000; Petitjean et al., 2007). 
Mutations can be divided into somatic cells mutations as a result of DNA-damage and 
these mutations appear in the DNA-binding domain of p53. Germline mutations have 
been identified in Li-Fraumeni syndrome affected people, leading to a high risk for 
malignant tumour formation (Whibley et al., 2009). 
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1.4.2 p76MDM2 and MDM4 interaction in the regulation of p53  
In 1987, murine double minute 2 (MDM2) gene was found to be over-expressed in the 
spontaneously transformed 3T3-DM mouse cell line (Cahilly-Snyder et al., 1987). The 
human gene homolog (also called MDM2 or HDM2) was found to be high in human 
sarcomas. More than 10% of 8000 human cancers, including lung or stomach cancer, 
showed elevation of the MDM2 gene (Toledo and Wahl, 2006). Wild-type human and 
mouse mdm2 gene encodes many mdm2 protein products. Some of these isoforms bind 
to p53. 
The most frequent isoforms are two proteins with different molecular weights.  One is 
the full length protein, p85/90
MDM2
, another is the smaller splice variant p74/76
MDM2 
in 
addition to p54/57
MDM2
 (Olson et al., 1993; Haines et al., 1994; Gudas et al., 1995; 
Saucedo et al., 1999; Cheng and Cohen, 2007) (Figure 9).  
In 1996, a structurally p90
MDM2
 – homolog was identified (Shvarts et al., 1996, Marine 
et al., 2007). This protein was firstly named MDMX, and then it was called MDM4 (the 
human homolog is known as MDM4, MDMX, HDM4 or HDMX).  
MDM4 was detected in 10-20% of more than 800 different tumours, including lung, 
colon, stomach and breast cancers (Toledo and Wahl, 2006). Strikingly, 65% of 
retinoblastomas show this regulator (Laurie et al., 2006). Moreover, high MDM4 levels 
were reported in approximately 65% of the melanomas examined (Gembarska et al., 
2012). 
Human p90
MDM2
 and MDM4 are consisting of 491 and 490 amino acids respectively, 
and can be divided into three well identified domains (Figure 10). 
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 N-terminal domain which is crucial for binding to Box I region of the p53-N-
terminal domain leading to a disruption in p53 interaction with the 
transcriptional machinery as well as the transcriptional co-activator p300 
(Joazeiro, and Weissman, 2000; Toledo and Wahl, 2007). 
 Zinc-finger domain (Joazeiro, and Weissman, 2000; Toledo and Wahl, 2007). 
 C-terminal RING domain that is characteristic to E3 ubiquitin ligases. It is also 
important for both homo- and hetero-dimerization, leading to more stability of 
MDM2 and MDM4 depending on their relative intracellular concentration 
(Toledo and Wahl, 2007; Joazeiro, and Weissman, 2000) (Figure 10). The 
RING finger domain is crucial for mdm2 binding to RNA (Elenbaas et al., 
1996). When mdm2 binds p53 mRNA, it promotes translation of p53 protein 
(Naski et al., 2009; Gajjar et al., 2012) and impairs E3 ligase activity (Candeias 
et al., 2008). 
p76
MDM2
 isoform can not bind to p53 protein, as it lacks the N-terminal 49 amino acids 
of the full length protein p90
MDM2
, which is the domain of p90
MDM2
 involved in 
interaction with p53 (Chen et al., 1993; Olson et al., 1993; Haines et al., 1994; Saucedo 
et al., 1999). Hence, p76
MDM2
 cannot promote p53 protein degradation via 
ubiquitination, but it can bind to p53 mRNA and promote efficient translation of the 
mRNA (Naski et al., 2009). In contrast to other mdm2 family members p76
MDM2
 acts 
positively towards p53 via antagonising the ability of p90
MDM2
 to target p53 protein 
degradation via inhibiting p90
MDM2
 association with p53 without affecting p90
MDM2 
levels (Perry et al., 2000; Giglio et al., 2010 ). 
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Figure 9: Protein structural homology of p76
MDM2
 and p90
MDM2
. 
p76
MDM2
 lacks the N-terminal 49 amino acids of the full length protein p90
MDM2
, the 
fraction of p90
MDM2
 involved in interaction with p53 (Olson et al., 1993; Haines et al., 
1994; Saucedo et al., 1999; Chen et al., 1993). Both have similar nuclear localization 
signal (NLS), nuclear export signal (NES), Zinc finger-(Zn), RING finger domain as 
well as nucleolar localization signal (NoLS). 
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Figure 10: Protein structural homology of MDM2 and MDM4. 
 
MDM2 and MDM4 have similar N-terminal p53 binding domain, Zinc finger-(Zn) as 
well as RING finger domain while Hdm2 characterizes by the presence of nuclear 
localization signal (NLS), nuclear export signal (NES) and nucleolar localization signal 
(NoLS). 
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p90
MDM2
and MDM4 proteins control p53 levels and activity in two ways: independently 
and dependently.  
 Independently p90MDM2 can function as an E3 ubiquitin ligase, catalysing not 
only the ubiquitination of p53, but also proteosomal degradation of itself as well 
as the action of MDM4 (Honda et al., 1997; Fang et al., 2000; Pan et al., 2003). 
p90
MDM2 
controls p53 activity in two distinct ways: 1. via binding to the N-
terminal domain of p53, preventing it from binding gene expression inducing 
factors causing in turn a blockade of the p53-dependent transcriptional 
machinery. 2. by ubiquitinating p53 and labelling it for proteasomal degradation 
(Oliner et al., 1993; Haupt et al., 1997; Kubbutat et al., 1997; Honda and Yasuda, 
2000). Importantly, p90
MDM2 
/ p53 binding alone in the absence of Mdm2 E3 
ubiquitin ligase activity is insufficient to suppress p53 activity (Itahana et al., 
2007).  Here it s of note that p90
MDM2
 can also promote mono-ubiquitination 
which does not directly cause p53 degradation. It can promote the export of p53 
from the nucleus to the cytoplasm especially to the mitochondria. p90
MDM2 
can 
also promote other modifications of p53 (Li et al., 2003; Carter et al., 2007).  
Similar to p90
MDM2
, MDM4 can bind to p53 via its p53 binding domain which is 
located on its N-terminus disturbing transcriptional activity of p53.  Therefore 
MDM4 has been hypothesized as a negative regulator of p53, but without 
triggering direct degradation of p53, as it does not have ubiquitin ligase activity 
(Honda et al., 1997; Fang et al., 2000; Pan and Chen., 2003; Danovi et al., 2004). 
However, some studies have reported a p53-positive regulation by MDM4, as 
they claimed its ability to inhibit p90
MDM2
- mediated p53 degradation by 
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competing with p90
MDM2
 for p53-binding, resulting in turn in accumulation of 
p53 (Sharp et al., 1999; Jackson and Berberich, 2000; Stad et al., 2000).  
 Despite of the independent MDM2 and MDM4 effect on p53, other studies 
highlighted the possibility that both proteins work together in control of p53 
levels / activity as p90
MDM2
 alone is a relatively ineffective E3 ubiquitin ligase 
(Kawai et al., 2007). It becomes more efficient for ubiquitinating p53 after 
heterodimerization with MDM4 (Linares et al., 2003). MDM4 dimerizes with 
p90
MDM2
, forming MDM protein complex which binds to p53, leading then to its 
inactivation. Both, MDM proteins co-localize with p53 at its DNA-consensus 
sequences, supporting the predominance of this complex in the nucleus (Tang et 
al., 2008; Wade and Wahl, 2009). Both, MDM2 and MDM4 proteins, play an 
essential role in controlling each other as MDM4 stabilizes p90MDM2 by 
interfering with its auto-ubiquitination. However, MDM4 has also been reported 
being ubiquitinated and degraded by p90
MDM2
 (Pan and Chen, 2003). The ratio 
of p90
MDM2 
/ MDM4 can be used to explain the p90
MDM2
 status in different 
situations i. e. p90
MDM2
 forms homodimers and is degraded by itself through 
ubiquitination, if the ratio is high. On the contrary, p90
MDM2
 is stabilized, if the 
ratio is low (Linke et al., 2008). 
p53 binds to p53-responsive elements, located within the p90
MDM2
 gene, and promote its 
transcription, thereby seting up a negative feedback regulatory loop (Barak et al., 1993; 
Perry et al., 1993), while p53 cannot transactivate MDM4. Because of this scenario, 
protein levels of p90
MDM2
 fluctuate widely upon p53 activation, whereas MDM4 level 
remain relatively constant (Barak et al., 1993; Perry et al., 1993).  
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Alterations in expression, localization as well as in activity of MDM proteins has been 
reported under certain stress and pathological conditions.  In response to UVR MDM4 
is phosphorylated by CHK1 which increases its association ability to 14-3-3γ, leading in 
turn to its retention in cytoplasm, promoting activation of p53 transcriptional function 
and G1 arrest. This p53 activation is accompanied by an increase in its stabilization and 
decrease in ubiquitination, suggesting that cytoplasmic phosphorylated MDM4 
(MDM4S367P) inhibits p90
MDM2 
ubiquitin ligase function (Jin et al, 2006). In 2008 it 
was suggested that under stress conditions endogenous MDM4 stabilizes induced p53 
due to its antagonism towards MDM2 (Barboza et al., 2008) (Figure 11). 
In response to DNA-damage, the ATM-pathway is activated. ATM is phosphorylating 
MDM4 either directly or indirectly through Chk2 kinase. This phosphorylation of 
MDM4 enhances its degradation by MDM2.  One consequence is activation of p53 
(Chen et al., 2005b; Pereg et al., 2005; Pereg et al., 2006a,b) (Figure 11). 
 
In 2009 Salem and colleagues reported, that epidermal p76
MDM2
 levels were 
significantly increased in patients with vitiligo in association with enhanced p53 activity.  
Based on these results, these authors suggested a crucial role of p76
MDM2
 in controlling 
DNA-damage / repair and prevention of photodamage and non-melanoma skin cancer in 
vitiligo (Salem et al., 2009). 
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Figure 11: Modes of MDM4 function following different DNA damage. 
 
Upon IR exposure, ATM and its target Chk2 phosphorylate MDM4 followed by rapid 
degradation by MDM2, resulting in p53 activation. Upon UV exposure, Chk1 
phosphorylates MDM4 and mediates its nuclear export, resulting in p53 activation. 
After lethal DNA-damage (e.g. by high UV doses, adramycin and cisplatin), MDM4 
promotes p53 phosphorylation at S46 and facilitates its recruitment to mitochondria, 
binding to Bcl2, and triggering of the mitochondrial apoptotic pathway. IR (infra red); 
ATM (ataxia telangiectasia mutated); CHK1 (checkpoint kinase-1); CHK2 (checkpoint 
kinase-2); ATR (ataxia telangiectasia and Rad3-related protein); Bcl-2 (B-cell 
lymphoma-2) (from Mancini et al., 2010). 
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1.4.3 SPARC (Secreted protein acidic and rich in cysteine) 
SPARC (also known as osteonectin or basement-membrane-40, BM-40), is a non-
structural glycoprotein component of extracellular matrix which was firstly identified in 
1981 by Termine and colleagues as osteonectin, a bone-specific phosphoprotein that can 
bind to collagen fibrils and hydroxyapatite (Termine et al., 1981; Tai and Tang, 2008). 
Later SPARC was known as a modulator for cell-matrix interactions, particularly during 
normal tissue development, remodelling and repair as well as neoplastic transformation 
as it functions as a regulator of the deposition of extracellular matrix (Bradshaw and 
Sage, 2001; Brekken and Sage, 2001; Chlenski and Cohn, 2010).  
SPARC is a 32.5 kDa protein consisting of three different domains (Figure 12);  
 Domain I: N-terminal domain which is an acidic region rich in asparagine (Asp) 
and glutamate (Glu), which can bind to 5–8 calcium ions, through the helix-turn-
helix structural domain (EF-hands motifs) (Hohenester et al., 1997,  Ribeiro et 
al., 2014).  
 Domain II: Follistatin (FS)-like domain which is a cysteine-rich region. This 
domain encloses bioactive peptides that have stimulatory as well as inhibitory 
effects on endothelial cells (Hohenester et al., 1997; Ribeiro et al., 2014). 
Bioactive peptides that show inhibitory effects on endothelial cells, involve 
peptide 2.1 which is structurally similar to epidermal growth factor-like S 
hairpin and inhibits endothelial cell proliferation. Peptide FS-E is reported as an 
inhibitor of in vitro migration as well as in vivo angiogenesis of endothelial cell 
(Hohenester et al., 1997; Chlenski et al., 2004; Ribeiro et al., 2014), Peptide FS-
K inhibits proliferation of endothelial cells (Ribeiro et al., 2014), while peptide 
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2.3 enhances proliferation and angiogenesis of these cells (Lane and Sage, 1994; 
Hohenester et al., 1997; Ribeiro et al., 2014).  
 Domain III: Extracellular Ca2+ domain binding to extracellular Ca2+ ions through 
EF-hands motifs. This domain encloses the peptide 4.2, which supports 
migration of endothelial cells, but is inhibiting proliferation (Hohenester et al., 
1997; Kupprion et al., 1998; Ribeiro et al., 2014). SPARC can bind to different 
types of collagen including fibril-forming collagen types I, III, and V, as well as 
the basement membrane collagen type (IV) in a Ca
2+
 dependent manner 
(Termine et al., 1981., Hohenester et al., 1997; Ribeiro et al., 2014).  
Receptors for SPARC are not detected yet, while some studies suggested that SPARC 
may compete with other ligands for interacting with their receptors (Bradshaw et al., 
2001).  
SPARC plays a fundamental role in promoting metastasis via acting with other 
extracellular matrix components. It functions as a de-adhesive molecule and as a cell 
cycle inhibitor (Yan and Sage, 1999; Bradshaw and Sage, 2001; Brekken and Sage, 
2001; Chlenski and Cohn, 2010). Many cell types including platelets, osteoblasts, 
endothelial cells and fibroblasts are SPARC-secreting cells (Termine et al., 1981; 
Brekken and Sage, 2000; Alford and Hankenson, 2006). 
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Figure 12: Structure of human SPARC protein. 
 
 
A ribbon diagram derived from crystallographic data shows the three domains of 
SPARC. The follistatin-like domain, shown in red (except the peptide 2.1), aa 55–74, 
and the peptide 2.3 (aa 114–130) shown in green and black, respectively. Domain III is 
shown in blue (except the aa 255–274, peptide 4.2 shown in yellow) (adapted from 
Hohenester et al., 1997). 
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SPARC exhibits different patterns of expression and activity according to the tumour 
position as well as its surrounding stromal cells (Tai and Tang, 2008). 
In 2011, it was reported that depletion of SPARC in melanoma cells results in an 
activation of p53 and induction of p21, leading in turn to G2/M cell cycle arrest and 
tumour growth inhibition (Fenouille et al., 2011a;b).  
Expression of SPARC was found to be regulated by several factors including some 
members of the transforming growth factor beta (TFG-β) super-family including TGF- 
β1, activin and bone morphogenetic protein (BMP). All increase the expression of either 
SPARC protein or its mRNA (Nakamura et al., 1996; Damjanovski et al., 1998). 
Moreover, VEGF induces the expression of SPARC in human vascular endothelial cells 
(Kato et al., 2001; Weninger, et al., 1996) but this induction of SPARC might be a 
negative regulatory feedback mechanism as it was reported that SPARC binds VEGF 
and prevents activation of VEGFR1 (Kupprion et al., 1998; Nozaki et al., 2006). In this 
context it is of interest that VEGF was detected in keratinocytes in the skin and this 
expression was established to be enhanced by NO and H2O2 (Brauchle, et al., 1996; 
Frank et al., 1999).  
SPARC regulates also the activity of basic fibroblast growth factor (bFGF), (Francki et 
al., 2004; Hasselaar and Sage, 1992) by inhibiting bFGF-stimulated migration of 
endothelial cells (Hasselaar and Sage, 1992). As SPARC induces the expression and 
secretion of TGF- β1 in vitro and in vivo, it is tempting to suggest that there is a 
reciprocal regulatory feedback loop between SPARC and TGF-β1 (Bassuk et al., 2000). 
Moreover, TGF- β1 is known as a negative regulator for melanogenesis as melanocytes, 
established under in vitro conditions in the presence of TGF- β, show a decrease of fully 
mature melanosomes and inhibition of melanin formation in association with clinical 
hypopigmentation (Martínez-Esparza et al., 2001).  
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1.4.4 Transforming growth factor- β1 (TGF- β1) 
TGF- β1 is a secreted multifunctional growth factor, expressed as a 55 KDa polypeptide. 
It dimerises, forming a precursor molecule that cleaves in the Golgi apparatus to 
produce its small latent form. Latent TGF-β binding protein (LTBP) supports latent 
TGF-β release to the extracellular matrix and its activation (Hyytiainen et al., 2004).  
TGF- β1 plays an important role in regulation of many biological processes, involved in 
tissue homeostasis, including cell proliferation and differentiation, apoptosis, deposition 
of extracellular matrix and cell adhesion (Derynck and Feng, 1997; Massagué, 1998; 
Roberts, 1998; Gumienny & Padgett, 2002; Lutz & Knaus, 2002). Moreover, TGF- β1 
was reported as a negative regulator for melanogenesis, causing degradation or 
inactivation of tyrosinase. It down-regulates the production of MITF, TRP-1 and TRP-
2, decreasing in turn the percentage of fully mature melanosomes, consequently leading 
to inhibition of melanin biosynthesis in association with clinical hypopigmentation 
(Martínez-Esparza et al., 1997; Martínez-Esparza et al., 2001; Kim et al., 2003). 
Effects of TGF-β1 take place via its binding to its transmembrane receptor serine / 
threonine kinases complex, TGF-βRI and TGF-βRII leading to recruitment and 
phosphorylation of Smad2 and / or Smad3 which in turn heteromerize with Smad4 and 
translocate into the nucleus, where it regulates the transcription of different genes 
including p21
 
(Datto et al, 1995; Li et al., 1995) (Figure 13). Kim and colleagues, 
proposed in 2005 that TGF-β1-induced receptor activation stimulates not only Smad 
pathway, but also a parallel H2O2-mediated ERK pathway, resulting then in p21
 
up-
regulation (Kim et al., 2006). Growth suppression and apoptosis inhibition properties of 
TGF- β1 involve induction of p21 expression through p53-independent mechanism and 
reduction of c-myc, CDC25A and Id family members (Figure 13). However, the data 
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are controversial. While some studies reported that malignant melanoma cells appear to 
be resistant to the TGF-β1-mediated effect (Rodeck et al., 1994; Krasagakis et al., 1999; 
Rodeck et al., 1999; Hoek et al., 2006), others claimed TGF-β1as a pro-oncogenic 
factor (Javelaud et al., 2008). 
 
Figure 13: p21
 
expression through p53-independent mechanism via TGFβ-1 
canonical signal transduction pathway. 
At the cell surface, TGFβ-1 assembles a complex of transmembrane receptor serine / 
threonine kinases (types I and II) and induces trans-phosphorylation and activation of 
the type I receptor (TβR-I, ALK5) by the type II receptor kinase (TβR-II). Activated 
TβR-I phosphorylates the main TGF-β downstream effectors, Smad2 and Smad3, at C-
terminal serines. Activated Smad2 and Smad3 then associate with Smad4 and the 
complexes translocate into the nucleus and regulate transcription of target genes, 
involved in TGFβ-induced growth inhibition. Downregulation of c-myc, CDC25A and 
Id family members and up-regulation of p15 and p21 CDK inhibitors are key events in 
this response (modified from Lasfar and Cohen-Solal; 2010).  
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2. Aim of the study (Part I) 
Surprisingly patients with vitiligo have no increased risk for development of solar 
induced non melanoma skin cancer (i.e. basal cell carcinoma, squamous cell carcinoma 
and actinic keratoses) despite  massive accumulation of H2O2 and ONOO
-
  in 
association with a seriously perturbed antioxidant defence system and the lack of 
pigment (Calanchini-Postizzi and Frenk, 1987; Schallreuter et al., 1991b; Schallreuter et 
al., 1999b; Schallreuter et al., 2002; for review Schallreuter et al., 2008b; Salem et al., 
2009; Teulings  et al., 2013, Schallreuter, 2014).  
As patients with vitiligo have a persistent up-regulated wild type functioning p53 
together with increased p21 throughout the entire epidermis in association with an 
efficient DNA-repair, it has been suggested that this cascade could be valid in 
prevention of solar induced photo-damage and solar induced skin cancer in these 
patients (Schallreuter et al., 2003; Salem et al., 2009).  As a consequence it was 
suggested that this p53 accumulation is associated with a perturbed degradation by the 
action of high p76
MDM2
 levels. This protein antagonises binding of p53 to its regulator 
p90
MDM2
 which is responsible for ubiquitination of p53 (Schallreuter et al., 2003; Salem 
et al., 2009). In this context it was shown that another MDM2 family member, i.e. 
MDM4 togther with its regulator MDM4phospso, can control p53 levels and activity 
(Honda et al., 1997; Sharp et al., 1999; Fang et al., 2000; Jackson and Berberich, 2000; 
Stad et al., 2000; Pan and Chen, 2003; Danovi et al., 2004). Moreover, SPARC was 
recently reported as a part of cellular anti-stress behaviour via inactivating the p53 / p21 
pathway through AKT-mediated MDM2 phosphorylation (Fenouille et al., 2011a;b). 
Therefore the first aim of this thesis was to get a better understanding of the mechanism 
behind the constantly up-regulated p53 together with increased p21 in vitiligo.  It 
appeared tempting to follow those proteins involved in negative and / or positive 
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regulation of p53 and p21, including p76
MDM2
, MDM4 and SPARC. As TGF-β1 can 
control p21 expression (Kim et al., 2006), we included this protein in our study. In this 
context it became of interest that VEGF-A induces expression of SPARC (Kato et al., 
2000; Weninger, et al., 1996). Therefore it seemed a logical consequence to include this 
arm for SPARC regulation. 
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3. Materials and methods 
3.1 Cell culture 
3.1.1 Establishment and maintenance of cell cultures 
Primary epidermal melanocyte cultures, established from waste skin after aesthetic 
surgery, were grown in T75 cm
2
 cell culture flasks. Briefly, fat from the skin was 
removed, followed by a quick washing step in phosphate buffered saline (PBS).  
Incisions were made on the epidermis to ease separation of the dermis from the 
epidermis and the skin samples were then incubated with dispase (Roche Applied 
Science, Roche Diagnostics Corporation, Indianapolis, USA) for 12 hours at 4°C. The 
following day the epidermis was peeled and washed in 5% penicillin / streptomycin 
(P/S) (Life Technologies, Paisley, UK) and 5% fungisone (Life Technologies, Paisley, 
UK) and placed into sterile PBS.  To produce a cell suspension from the processed 
epidermis, 1x trypsin / EDTA (TE) (Life Technologies, Paisley, UK) was added and 
incubated for 10 minutes at 37
o
C.  The reaction was stopped by the addition of medium 
154, containing keratinocyte specific growth factors, 0.1mM calcium chloride (Cascade 
Biologics, Mansfield, Nottinghamshire, UK) and 1% P/S.  The suspension was 
centrifuged at 500g for 10 minutes.  The supernatant was removed and the cell pellet, 
containing both melanocytes and keratinocytes, was resuspended in the prepared 
medium and seeded into 75cm
2
 culture flasks (Scientific Laboratory Supplies, 
Nottingham, UK).  The medium was changed every 2 days. In order to obtain single cell 
populations, separation of melanocytes from keratinocytes was required.  This was 
achieved via selective trypsination, whereby melanocytes detach from the flask in 
approximately 1-2 minutes, when TE solution is added, whereas keratinocytes take 
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around 5 minutes or more.  Once detached, melanocytes were transferred to complete 
2:1 MEM medium. MEM medium was from Invitrogen, Paisley, UK, containing, 
penicillin (100 units/ml) and streptomycin (100μg/ml), L-glutamine 2mM, fungizone 
0.2%, fetal calf serum 2%, concentrated non-essential amino acid mixture 1%, 
endothelin-1 (5ng/ml), basic fibroblast growth factor (5ng/ml) and  Ciprofloxacin 0.4%) 
in 500ml. One fold of keratinocyte serum free medium from Invitrogen, Paisley, UK 
was added.  500 ml medium contained bovin pitutary extract (25 mg/ml), epidermal 
growth factor (2.5μg/ml), fungizone 0.2%, penicillin (100 units/ml) and streptomycin 
(100 µg/ml) 5X, L-glutamine 2 mM, ciprofloxacin (0.4%). Cells were fed every 48-72 
hours. Melanoma cell cultures (FM 55 cells and FM 94 cells) were passaged into T75 
cm
2
 cell culture flasks and fed every 48 hours with complete RPMI 1640 medium 
(500ml RPMI 1640 (Invitrogen, Paisley, UK) containing penicillin (100 units/ml) and 
streptomycin (100μg/ml), L-glutamine 2mM, fungizone 0.2%, fetal calf serum (10%), 
ciprofloxacin (0.4%). Briefly, cell culture flasks were removed from the incubator and 
the medium was discarded into 2% Virkon. Subsequently, 10 ml of fresh medium was 
added to the cell culture flask under sterile conditions and the flask was placed back into 
the incubator. 
3.1.2 Thawing of frozen cell cultures 
Stored frozen cells were removed from liquid nitrogen and immediately placed in to a 
water bath at 37OC. Before thawing of the cells, 10 ml of complete medium was added 
to each T75 cm
2
 cell culture flask. The contents of the cryovials were then added 
gradually to the medium and the flasks were placed in the incubator for at least 24 hours 
to allow cells to attach to the surface of the flasks. 
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3.1.3 Passaging of cell cultures 
Cells were passaged, once the culture was 80% confluent and actively proliferating. The 
medium was removed from the T75 cm
2
 cell culture flasks and discarded into 2% 
Virkon. The cells were then rinsed with approximately 8 ml of PBS. Once PBS had 
been discarded into 2% Virkon, 1 ml of trypsin/EDTA was added to each flask covering 
the entire cells and then incubated at 37
0
C for 2-3 minutes until cells started to detach 
from the bottom of the flasks. Detachment of the cells from the culture flasks was 
observed under an inverted microscope. After complete detachment of the cells, 30 ml 
of complete medium were added to each flask to inactivate the trypsin / EDTA action. 
The total content of each flask was then split into three flasks, and returned to the 
incubator for further growth. 
3.1.4 Freezing of cell cultures 
Cells were trypsinized and pelleted by centrifugation at 1000rpm for 3 minutes. The cell 
pellet was resuspended in freezing down solution (dimethyl sulphoxide (DMSO) 10%, 
fetal calf Serum (90%) and transferred to 1ml cryovials. The cryovials were placed in 
isopropanol bath for 24 hours at -80 OC in order to prevent cell damage. Thereafter cells 
were transferred to liquid nitrogen for long term storage.  
3.2 Immunocytochemical Methods 
3.2.1 Cell culture chamber slide preparation  
To investigate the expression of different proteins in melanocytes by in vitro immuno- 
fluorescence, melanocytes (100 μl cell suspension ) were initially transferred to each 
well of chamber slides (Nalge Nunc International, Naperville, IL, USA) followed by the 
addition of 300 μl medium to each well. Once the culture was approximately 70-80% 
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confluent, the medium was removed and discarded into 2% Virkon. Cells were washed 
3-4 times with sterile 1x PBS, pH 7.4, followed by fixation in cold methanol at -20°C 
for 10 minutes. Slides were stored at -20°C until future work. 
3.2.2 In vitro immuno-fluorescence labelling 
Frozen slides were allowed to defrost at room temperature (RT) for about 10 minutes, 
followed by dehydration in 1x PBS for 5 minutes. Fixation was performed by 
immersing slides for 6 minutes in cold methanol (-20°C). The slides were then washed 
for 5 minutes in 1x PBS, followed by blocking with normal donkey serum (10 NDS, 
Jackson Immunoresearch Laboratories, Cambridgeshire, UK) for 90 minutes at RT. 
Slides were washed in 1x PBS for 5 minutes, followed by overnight incubation at 4°C 
with the primary antibodies, diluted in 1 NDS. Thereafter, slides were washed twice 
in 1x PBS for 5 minutes, followed by another wash once in Tween-20 0.05 for 5 
minutes and then once again in 1x PBS for 5 minutes, incubated for 1 hour at RT with a 
fluorescent secondary antibody in a dilution of 1:50 in 1% NDS for 1 hour (donkey anti-
rabbit, rat, mouse or sheep, depending on the primary antibody that was used (Jackson 
Immuno Research Laboratories, Cambridgeshire, UK). Slides were washed twice in 1x 
PBS for 5 minutes, then once in Tween-20 for 5 minutes, followed by a final wash in 1x 
PBS for 5 minutes. Finally, slides were dried and mounted, using Vectashield Mounting 
Medium containing 4, 6-diamino-2-phenylindole (DAPI) (Vector Laboratories, CA, 
USA) and covered with a coverslip. Viewing of the pictures was carried out by using a 
Leica DMIRB/E fluorescence microscope (Wetzlar, Germany). Images were captured 
using a Nikon Eclipse 80i microscope with a DS-U101 Nikon camera coupled to a 
Nikon ACT-2U capture programme (Nikon, Europe).  Control staining was carried out 
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by omitting the primary antibody from the staining procedure and substitution of 1% 
NDS / PBS. Antibodies used in our experiments are listed in (Table 1). 
 
Antibody Dilution Incubation 
time/T 
Source Company Cat. No. 
Alexa 488 1:50 1 hour/RT Donkey 
anti-Rabbit 
Invitrogen, 
Paisley, UK 
A21206 
Alexa 594 1:50 1 hour/RT Donkey 
anti-mouse 
Invitrogen, 
Paisley, UK 
A21203 
catalase  1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab16731 
MDMX 1:50 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab16058 
NKI/beteb 1:50 Overnight/ 
4°C 
Mouse 
monoclonal 
antibody 
Caltag-
Medsystems 
Ltd 
MON7006-1 
SPARC 1:50 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab14174 
TGF-β1 1:50 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab66043 
 
VEGF-A 1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab46154 
 
Table 1 
List of primary and secondary antibodies and conditions for in vitro immuno-
fluorescence labelling in melanocytes and melanoma cells. 
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3.3 Immunohistochemical Methods  
3.3.1 Cryosection preparation 
A 3 mm punch biopsy of full thickness skin was taken from consented normal healthy 
controls (n=10) and patients with vitiligo (n=20) under local anaesthesia from the volar 
proximal arm. The tissue samples originated from Professor Schallreuter`s tissue library 
(collected during 1992-2004). All skin biopsies were embedded in optimal cutting 
temperature compound (OCT) (Sakura, RA Lamb, Eastbourne, UK) and placed for 
about 5 minutes in liquid N2 to allow the skin to be shock frozen. 3-5 μm sections of 
this skin were cut using a Leica CM3050 S cryostat (Leica Microsystems, Milton 
Keynes, UK) and placed onto the poly-L-lysine coated slides (Sigma, Pool, Dorset, UK). 
Slides were saved at -80°C for future work. 
 
3.3.2 In situ immuno-fluorescence labelling 
Frozen slides were allowed to defrost at RT for 10 minutes followed by dehydration in 
1x PBS for 5 minutes. Fixation was performed by immersing slides for 10 minutes in 
ice cold-methanol. Then slides were washed in 1x PBS for 5 minutes, followed by 
blocking with normal donkey serum (10 NDS, Jackson Immunoresearch Laboratories, 
Cambridgeshire, UK) for 90 minutes at RT. Slides were washed once in 1x PBS for 5 
minutes, followed by another wash once in Tween-20 0.05 for 5 minutes and then 
twice again in 1x PBS for 5 minutes each. Afterward slides were incubated overnight at 
4°C with the primary antibodies, diluted in 1 NDS. Thereafter, slides were washed 
once in 1x PBS for 5 minutes, followed by another wash once in Tween-20 0.05 for 
5 minutes and then twice again in 1x PBS for 5 minutes each. Then, slides were 
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incubated for 1 hour at RT with a fluorescent secondary antibody in a dilution of 1:50 in 
1% NDS for 1 hour (donkey anti-rabbit or mouse, depending on the primary antibody 
that was used) (Jackson Immuno Research Laboratories, Cambridgeshire, UK). Slides 
were washed once in 1x PBS for 5 minutes, then once in Tween-20 for 5 minutes 
followed by two washes in 1x PBS for 5 minutes each. Finally, slides were dried and 
mounted using Vectashield Mounting Medium containing 4, 6-diamino-2-phenylindole 
(DAPI) (Vector Laboratories, CA, USA) and covered with a coverslip. For double 
immuno-fluorescence, after the incubation of tissue sections with the first secondary 
antibody they were washed in PBS and instead of being mounted and coverslipped, 
blocking with normal donkey serum (10 NDS, Jackson Immunoresearch Laboratories, 
Cambridgeshire, UK) was carried out. The whole procedure was repeated using the 
second primary and secondary antibodies. The first secondary antibody was FITC-
labelled and the second secondary antibody was TRITC-labelled. Negative control 
staining was carried out by omitting the primary antibody from the staining procedure 
and substitution of 1% NDS / PBS. Viewing the pictures was carried out by using a 
Leica DMIRB/E fluorescence microscope (Wetzlar, Germany). Images were captured 
using a Nikon Eclipse 80i microscope with a DS-U101 Nikon camera coupled to a 
Nikon ACT-2U capture program (Nikon, Europe). The antibodies and dilutions used are 
listed in (Table 2).  
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Antibody Dilution Incubation 
time/T 
Source Company Cat. No.  
Alexa 488 1:50 1 hour/RT Donkey 
anti-Rabbit 
Invitrogen, 
Paisley, UK 
A21206 
Alexa 594 1:50 1 hour/RT Donkey 
anti-mouse 
Invitrogen, 
Paisley, UK 
A21203 
catalase 1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab16731 
MDM2 1:20 Overnight/ 
4°C 
Mouse 
monoclonal 
antibody 
Santa cruz 
biotechnology 
sc-965 
MDMX 1:50 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab16058 
 
MDMX-
phospho 
1:50 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab70236 
5-nitro-
tyrosine 
1:50 Overnight/ 
4°C 
Mouse 
monoclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab78163 
NKI/beteb 1:50 Overnight/ 
4°C 
Mouse 
monoclonal 
antibody 
Caltag-
Medsystems 
Ltd 
MON7006-1 
p21 1:5 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab7960 
p53 1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab1431 
SPARC 1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab14174 
TGF-β1 1:50 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab66043 
 
VEGF 1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab46154 
Table 2: List of primary and secondary antibodies and conditions for in situ 
immuno-fluorescence labelling. 
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3.3.3 Quantification of fluorescence intensity 
To quantify the fluorescence, ImageJ version 1.37 was utilised (supplied online by NIH 
at http://rsb.info.nih.gov/ij/index.html). The region to be quantified was highlighted and 
the mean intensity in relation to the area was obtained. This was repeated for the rest of 
the layers. The procedure was repeated in at least three epidermal sections of each 
patient and the mean value was obtained and plotted using Microsoft Excel (Microsoft 
Corporation, USA). Significance of data was analysed statistically using the two-tailed 
unpaired t-test. 
3.4 SDS-PAGE and Western Blot 
3.4.1 Protein extraction from cells 
Media of melanocytes cell cultures was removed from the T75 cm
2
 cell culture flasks 
and discarded into 2% Virkon. Cells were washed with PBS. Trypsin/EDTA was added 
slowly to each flask. The flasks were then incubated at 37
0
C for 2-3 minutes until cells 
started to detach when 10ml of complete medium was added to each flask for 
inactivation of the trypsin/EDTA. The cell suspension was transferred to 25 ml 
universal tube. Additional 10ml medium was added to the flask to wash out any residual 
cells. Cells were then pelleted by centrifugation at 1200rpm for 6 minutes. The cell 
pellets were then resuspended in sample buffer (2.5 ml glycerol, 0.185 g EDTA, 1.5 g 
sodium dodecyl sulphate (SDS), 0.19 g tris, 25 ml distilled water) according to the 
volume of pellet. Cell suspensions were then transferred to 1.5 ml Eppendorf tubes. 
Protease inhibitor cocktail (1:20) was added and mixed well. Eppendorf tubes were 
placed in ice for three hours and were vortexed from time to time (approximately 30 
minutes). Eppendorf tubes were then centrifuged at 13000 rpm for 5minutes at 4
0
C. The 
supernatant was placed in -20
0
C freezer until use. 
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3.4.2 Protein extraction from tissue 
3 mm punch biopsies of full thickness skin plus 200µl of sample buffer (2.5 ml glycerol, 
0.185 g EDTA, 1.5 g sodium dodecyl sulphate (SDS), 0.19 g tris, 25 ml distilled Water) 
were grinded mechanically using mortar and pestle. Tissue suspensions were then 
transferred to 1.5 ml Eppendorf tubes. Protease inhibitor cocktail (1:20) was added and 
mixed well. Eppendorf tubes were placed in ice for 30 minutes and vortexed every 10 
minutes. Eppendorf tubes were then centrifuged at 13000 rpm for 5 minutes at 4
0
C. The 
supernatant was placed in -20
0
C freezer until further use. 
3.4.3 Quantification of protein content in cells and tissue extracts 
(Bradford protein assay) 
Five μl of protein standards (listed below) or protein samples of interest were added to 
the appropriate well on a 96 well-plate in triplicate following the manufacturer`s 
protocol. Briefly, to each well, 25 μl of reagent A‟ and 200 μl of reagent B were added. 
The plate was agitated for 20 minutes using a plate shaker before being placed in a plate 
reader. The absorbance of the samples was measured in each well at 750 nm. After 
calculating protein concentration in each cell extract protein aliquots were taken for 
loading in SDS-PAGE. 
Bovine Serum Albumin (BSA) Stock Sample Buffer 10 ml / Bovine Serum Albumin 
0.1 g (final concentration of 10 mg/ml) 
Protein Standards (Bovine Serum Albumin)   
Blank: 1000 μl sample buffer, 200 μl/ml: 980 μl sample buffer + 20 μl BSA stock 
400 μl/ml: 960 μl sample buffer + 40 μl BSA stock, 600 μl/ml: 940 μl sample buffer + 
60 μl BSA stock, 800 μl/ml: 920 μl sample buffer + 80 μl BSA stock, 1000 μl/ml: 900 
μl sample buffer + 100 μl BSA stock 
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3.4.4 SDS-PAGE of protein samples 
Electrophoresis analysis of protein samples was implemented by preparing 10% 
resolving gel [2 ml 30% acrylamide, 1.95 ml buffer 1 pH 8.8 (36.6 g tris base, 200 ml 
distilled H2O), 0.75 ml distilled H2O, 2.5μl tetramethylethylenediamine (TEMED), 50 
μl ammonium persulphate 10%, 0.5 ml 10% sodium dodecyl sulphate (1gm SDS, 10ml 
distilled H2O)] and the stacking gel (1.0 ml 30% acrylamide, 1.95 ml buffer 2 pH 6.8 
(12g tris base, 200 ml distilled H2O), 1.95 ml distilled H2O, 4μl 
tetramethylethylenediamine (TEMED), 50 μl ammonium persulphate 10%, 0.5 ml 10% 
sodium dodecyl sulphate SDS). The resolving gel was poured between two assembled 
gel plates with separating thickness 1.0 mm. Distilled water was added over the 
resolving gel to prevent drying of its surface. Thereafter the gel was left for about 60 
minutes at RT to ensure its polymerization. Subsequently the distilled water was 
discarded and stacking gel was added over the resolving gel. Immediately after the 
stacking gel was added the lane-dividing comb was added carefully to avoid introducing 
air bubbles into the gel, hence the gel was left for 30 minutes for the polymerization of 
the stacking gel.  
For preparation of loaded samples, they were transferred from -20°C and thawed at RT 
then loaded after been boiled for 4 minutes with DTT loading buffer (20ml 1M tris-
buffer  pH 6.8, 2ml glycerol, 5g SDS, 1.54g dithioerythriol (DTT), 13mg bromophenol 
blue, volume was made up to 50 ml using distilled H2O ). The gel was run at 200 Volts 
for about 1.30 hours in running buffer pH 8.3 (1.515g tris base, 7.2g glycine, 0.5g SDS, 
500ml distilled H2O) half-filled electrophoresis chamber. Afterwards the gel was 
immersed in Coomassie Blue staining solution for about 5 minutes (400 ml methanol, 
92 
 
70ml acetic acid, 0.250g Coomassie Brilliant Blue R-75, volume made up to 1000 ml 
using distilled H2O).  
In order to visualise any proteins, the gel was destained in destain solution (400 ml 
methanol, 70 ml glacial acetic acid, volume was made to 1000 ml using distilled H2O) 
for about 5 minutes. 
3.4.5 Western blot 
In order to perform Western blotting, the protein samples were first resolved in SDS 
PAGE gel electrophoresis as described before. After activation of polyvinylidene 
difluoride (PVDF) membrane (GE Healthcare, formerly Amersham Biosciences) by 
immersing it in methanol for about 2 minutes, the gel was sandwiched (1 sponge 
(cathode), 1 filter paper, gel, PVDF membrane, 1 filter paper, 1sponge (anode)) and 
placed in the electro blotting chamber filled with transfer buffer pH 8.3 (3g tris Base, 
14.4g glycine, 0.4g SDS, 1000 ml distilled H2O). The transfer was run at 30 Volts for 
about 3 hours. Afterwards the PVDF membrane was immersed in non-fat milk (5%) 
(2.5g non-fat milk, 50 ml TBS/Tween(8.28g NaCl, 2.42g tris, 0.47ml Tween 20, make 
volume to 1000ml using distilled water)) for 2 hours at room RT to block nonspecific 
binding sites.  
The membrane was incubated overnight at 4
o
C with primary antibody. The antibodies 
and dilutions are listed in Table 3. 
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Antibody 
 
Dilution 
 
Incubation 
time/T 
 
Source 
 
Company 
 
Cat. No. 
SPARC 1:500 Overnight at 
4
o
C 
Mouse 
monoclonal 
Santa cruz 
biotechnology 
sc-73051 
p53 1:500 Overnight at 
4
o
C 
Rabbit 
polyclonal 
Santa cruz 
biotechnology 
sc-6243 
GAPDH 1:5000 Overnight at 
4
o
C 
Rabbit 
polyclonal 
Abcam 
Cambridge, 
UK 
ab9485 
GAPDH 1:5000 Overnight at 
4
o
C 
mouse 
monoclonal 
Abcam 
Cambridge, 
UK 
ab8245 
p21 1:500 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab7960 
catalase 1:2000 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab16731 
MDM2 1:300 Overnight/ 
4°C 
Mouse 
monoclonal 
antibody 
Santa cruz 
biotechnology 
sc-965 
MDMX 1:1000 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab16058 
MDMX-
phospho 
1:1000 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab70236 
TGF-β1 1:500 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab66043 
 
VEGF-A 1:1000 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab46154 
 
Table 3 
 List of primary antibodies used in Western blot. 
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All the previous antibodies were diluted in 5% w/v non-fat dry milk powder in TBS / 
Tween. This was followed by 3 washing steps within 30 minutes in TBS / Tween under 
continuous shaking. The membrane was transferred into a plastic dish containing one of 
secondary antibodies which was diluted in 5% w/v non-fat dry milk powder in 
TBS/Tween depending on the host of the primary antibody and incubated for 1 hour at 
RT, followed by wash in TBS/Tween (Table 4). Positive immuno-reactivity was 
detected by the enhanced chemiluminescence‟s method (ECL). To do so, the membrane 
was immersed for 4 minutes in equal volumes of enhanced chemiluminescence‟s 
solution Ι (1 ml of 250 mM luminol in DMSO, 0.44 ml of 90 mM p-coumaric acid in 
DMSO, 10 ml of 1 M Tris-HCl pH 8.5 in a final volume of 100 ml) (Sigma, Pool, 
Dorset,UK) and solution Π (64 µl of 30% v/v H2O2, 10 ml of Tris-HCl pH 8.5 in a final 
volume of 100 ml) (Sigma, Pool, Dorset, UK). Positively stained protein bands send a 
luminescent signal which was visualised on a sheet of CL-XPosure Film (Thermo 
scientific, UK).  
Stripping of membrane was taking place by washing the membrane for 30 minutes in 
TBS/Tween then it was exposed to restore western blot stripping buffer (Thermo 
scientific, UK) for 15 minutes, followed by washing three times in TBS/Tween, 10 
minutes each. The rest of the experiment including blocking and incubation with 
primary and secondary antibodies and finally the developing process were exactly the 
same as described above. 
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Antibody 
 
Dilution 
 
Incubation 
time 
 
Company 
 
Cataloge 
number 
Anti-Mouse IgG Peroxidase 
antibody produced in goat 
 
1:1000 1h/RT Sigma-Aldrich, 
St. Louis, USA 
A2554-1ML 
 
Anti-Rabbit IgG (whole 
molecule)–Peroxidase 
antibody produced in goat 
1:1000 1h/RT 
  
Sigma-Aldrich, 
St. Louis, USA 
A9169-2ML 
 
 
Table 4 
List of secondary antibodies used in Western blot.  
 
Statistical analysis for Western blot 
The bands were evaluated by utilizing Image J version 1.37 (supplied online by NIH at 
http://rsb.info.nih.gov/ij/index.html). Each band was highlighted and the intensity was 
measured. The mean of the calculated values was normalized and plotted in relation to 
the corresponding GAPDH using Microsoft Excel (Microsoft Corporation, USA). 
Statistical analysis was carried out by un-paired t-test. 
3.5 Dot blot for SPARC  
To study, whether H2O2 (30%, Fluka, Sigma, Pool, Dorset, UK) can affect SPARC 
binding affinity to the antibody, dot blotting technique was carried out, using 
recombinant human SPARC (R&D systems, UK). Per dot, 1ul of recombinant human 
SPARC was used at a concentration of 0.2μg/µl. SPARC was incubated with different 
concentration of H2O2 (0.5, 1, 5, 10, 50 and 100mM) for 1 hour at RT. Thereafter some 
dry paper towel was placed on the work surface, and then 4 filter papers, immersed in 
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0.05% tween 20 in TBS, were put on top of these paper towels, followed by addition of 
a PVDF membrane (GE Healthcare, formerly Amersham Biosciences, UK). The 
membrane, soaked in methanol for 2 minutes, washed in distilled H2O and transferred to 
0.05% tween 20 in TBS for 2-3 minutes. Protein samples were spotted in a row onto the 
PVDF membrane and allowed to dry for approximately 5 minutes at RT. Thereafter, the 
membrane was incubated in blocking solution containing 5% non-fat milk in 
TBS/Tween 20 [2.5g non-fat milk, 50 ml TBS/Tween (8.28g NaCl, 2.42g Tris, 0.47ml 
Tween 20, make volume to 1000ml using distilled water)] on a shaker for 2 hours at RT. 
Then the membrane was washed for 3 times with TBS/Tween, 10 minutes each, 
followed by incubation with the primary antibody (mouse monoclonal for SPARC, 
Abcam, Cambridge, UK) at the dilution of 1:500 overnight at 4°C. The rest of the 
experiment, including the washing procedures and incubation with the secondary 
antibody and finally the developing process were the same as described above (Western 
blot). 
3.6 Fourier Transform (FT) -Raman spectroscopy 
FT-Raman spectra were acquired using a BRUKER RFS 100/S spectrometer (Bruker, 
Karlsruhe, Germany) with a liquid-nitrogen-cooled Germanium detector. Near-infrared 
excitation was produced by a Nd
3+
:YAG laser operating at 1064 nm. Each spectrum was 
accumulated over 17 min with 1000 scans and a resolution of 4 cm
-1
. Detection of H2O2 
is based on the O=O stretch at 875 cm
-1
. This experiment was done in collaboration 
with Dr H. Rokos.   
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3. 6 Computer modelling of native, oxidised and nitrated SPARC 
The crystal structure of SPARC was obtained from the protein data bank which is 
available online at: http://www.rcsb.org/pdb/home/home.do. Using the molecular 
modelling program “HyperChem” (Hypercube, Inc, Gainesville, FL, USA). The 
SPARC structure contains 4 methionine, 3 tryptophan and 7 tyrosine residues which are 
target to H2O2 / ONOO
-
-mediated oxidation / nitration. DeepView analysis was applied 
to compare and analyse changes between the native and oxidised states of the protein  
(Dr Nicholas Gibbons is acknowledged for molecular modelling). 
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4.  Results 
4.1 Confirmation of low epidermal catalase expression, up-
regulated p53, p21 in association with up-regulated p76
MDM2
 in 
vitiligo
 
as prerequisite for further investigation 
4.1.1 Significantly decreased in situ catalase levels in the entire 
epidermis of patients with vitiligo in comparison to healthy 
controls 
In 1991 Schallreuter et al. showed low catalase protein levels in both lesional and non -
lesional skin of patients with vitiligo. The enzyme catalase plays a crucial role in 
protection against oxidative stress based on its function in degrading the reactive 
oxygen species H2O2 to O2 and H2O (Aronoff, 1965; Schallreuter et al., 1991). Due to 
accumulation of epidermal H2O2 in 10
-3
M range, enzyme expression and functionality 
are severely affected, causing in turn degradation of its porphyrin ring as well as 
oxidation of target amino acids in the active site and in the teramerisation domain 
(Aronoff, 1965; Gibbons, et al., 2006; Maresca et al., 2006; Wood and Schallreuter, 
2006). Later epidermal catalase protein expression has been introduced as a biomarker 
for oxidative stress in vitiligo (Salem et al., 2009). Therefore we decided to use this 
protein to prove the presence of oxidative stress in situ in patients with vitiligo (n=36: 6 
patients, 6 pictures each) and healthy controls (n=36: 6 individuals, 6 pictures each) via 
immuno-fluorescence labelling. The results confirmed significantly lower catalase 
protein expression in the entire epidermal compartement in both lesional and non-
lesional skin of the patients compared to normal controls. This down-regulated 
expression is also seen in the epidermal cell‟s nuclei of lesional and non-lesional skin 
compared to those of normal skin (Figure 14). Image analysis of catalase staining 
intensity proves significantly decreased protein expression in both vitiligo lesional (p< 
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0.001, mean ±SE) and vitiligo non-lesional (p< 0.001, mean ±SE) throughout the entire 
epidermis compared to healthy controls (Figure 15).  
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Figure 14: Low epidermal catalase expression in vitiligo. 
Immuno-reactivity (FITC-labelling, green) shows low expression of catalase in non-
lesional (g) and almost absence in lesional (d) skin of the patients compared to controls 
(a) with skin phototype ІII (Fitzpatrick classification). Scale bar 50µm, Magnification x 
400. 
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Figure 15: Significantly lower expression of epidermal catalase in vitiligo.  
Image analysis of the average fluorescence intensity confirms significantly decreased 
catalase levels in patients lesional (n=36: 6 individuals, 6 pictures each) and non 
lesional (n=36: 6 individuals, 6 pictures each) skin compared to healthy controls (n=36: 
6 individuals, 6 pictures each) (Plots are mean ± SE) ( p0.001). 
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4.1.2 Confirmation of low catalase levels in vitiligo by Western blot 
In order to quantify catalase protein expression, we next employed Western blot. The 
results show decreased catalase expression in lesional (n=3) and non-lesional skin (n=3) 
of patients with vitiligo compared to skin of healthy controls (Figure 16a). Image 
analysis of catalase protein bands in relation to loading control protein GAPDH 
confirms significantly decreased expression in the epidermis of patients (Figure 16 b, c).  
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Figure 16: Significantly decreased epidermal catalase expression in skin of patients 
with vitiligo. 
 
(a) Western blot. Catalase protein shows significantly decreased expression in both 
lesional and non-lesional epidermis of patients compared to healthy controls.  Lane 1 
protein ladder, lane 2 control, lanes 3-8 lesional and non-lesional skin tissue extracts 
from 3 patients. GAPDH was used as loading control. 
(b) Normalization of catalase expression to the loading control. GAPDH was used to 
evaluate individual protein levels.  
(c) Quantification of catalase bands. Image analysis was performed in relation to 
loading control protein (GAPDH). The result proves significantly decreased catalase 
expression in both lesional (n=3) and non-lesional (n=3) skin of patients compared to 
the control (n=1). (Plots are mean ± SE) (NS p > 0.05, ** p<0.01). 
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4.1.3 Catalase is present in epidermal melanocytes 
After confirming decreased catalase expression throughout the entire epidermis of 
patients with vitiligo using both in situ imuno-fluorescence as well as Western blot, we 
looked at catalase expression and localization in normal and vitiliginous melanocytes 
under in situ conditions using double immuno-fluorescence with FITC-labelled catalase 
and TRITC-labelled NKI / beteb1. Melanocytes of non-lesional skin show almost absent 
catalase expression in the skin of patients with vitiligo, compared to control skin 
(Figure 17).  
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Figure 17: Decreased in situ catalase expression in epidermal melanocytes in 
vitiligo.  
Immuno-reactivity (FITC-labelling, green) shows decreased expression of catalase in 
lesional (d) and non-lesional (g) skin compared to control (a). Melanocytes are detected 
with TRITC-labelled NKI / beteb1. Overlay of NKI / beteb1 with catalase shows the 
presence of the enzyme in normal skin (yellow), but catalase expression is bearly 
detectable in melanocytes of non-lesional skin of patients. Scale bar 50µm. 
Magnification x 400. 
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Next, we looked at catalase expression under in vitro conditions.  Unfortunately we had 
no melanocytes from patients with vitiligo. However, catalase expression is high in 
melanocytes of healthy controls. Expression is seen throughout the cell in the nucleus as 
well as in the cytoplasm. Strong co-localisation with NKI / beteb1 marks the presence in 
melanosomes (inserts) (Figure 18).  
NKI/beteb
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Figure 18: In vitro expression of catalase in normal human epidermal melanocytes. 
Immuno-reactivity (FITC-labelling, green) reveals catalase expression in melanocytes. 
Patterns of expression indicate the presence of catalase in both, nucleus and cytoplasm 
(a, d and insert). Overlay of NKI / beteb1 positive epidermal melanocytes (TRITC-
labelling) and FITC-labelled catalase shows strong yellow co-localisation of catalase in 
melanosomes (b and insert). Magnification  x   400.  Scale bar 50µm. 
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4.1.4  In vivo FT-Raman spectroscopy confirms the presence of 10
-3
M 
H2O2 levels in the epidermis of patients with vitiligo 
In order to confirm the presence of H2O2 in vitiligo, we utilised in vivo FT-Raman 
spectroscopy. The results show the expected peak at the O=O stretch at 875cm
-1
. Based 
on these results we can conclude that H2O2 stress is present in the investigated patient 
samples (Figure 19). This result also confirms the influence of H2O2 on catalase protein 
expression, supporting in turn its role as a biomarker for evaluation of the epidermal 
H2O2 -mediated redox status in these patients (Gibbons et al., 2006, Schallreuter et al., 
2013). 
 
Figure 19: In vivo FT-Raman spectra from 3 patients with vitiligo. 
 The peaks at 875cm
-1
 are in agreement with the O=O stretch which is characteristic for 
H2O2. In this context it is noteworthy that detection of these peaks is only possible if the 
concentrations exceed 10
-3
M.  
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In summary, we confirm the presence of H2O2- mediated stress in the 10
-3
M range in the 
entire epidermal compartment by significantly lower epidermal catalase expression and 
protein levels in vitiligo samples and by in vivo FT-Raman spectroscopy as prerequisite 
for further studies. 
 
4.1.5 The role of p53 in vitiligo 
4.1.5.1 Significantly increased expression of epidermal p53 in the 
entire epidermis of patients with vitiligo 
H2O2 up-regulates expression and function of wild type p53 (Vile, 1997; Salem et al., 
2009).  However, surprisingly, reduction of epidermal H2O2 with pseudocatalase PC-
KUS does not affect the constant up-regulated expression of p53 protein in patients with 
vitiligo (Schallreuter et al., 2003; Salem et al., 2009). This result suggested that 
epidermal H2O2 levels were either still high enough to trigger p53 transcription or are 
regulated in a different way (Schallreuter et al., 2003). In this context it was suggested 
that up-regulated functioning p53 could serve as explanation of the non-elevated risk of 
skin photo-damage and non-melanoma skin cancer (basal-cell and squamous cell 
carcinomas) in these patients (Oettle, 1963; Calanchini- Postizzi and Frenk, 1987; 
Schallreuter et al., 2002; Salem et al 2009; Teulings et al, 2013).  
Our in situ p53 results confirm those earlier results in vitiligo (Schallreuter et al., 2003; 
Salem et al 2009) by demonstrating significantly higher levels of p53 in lesioal (d) and 
non-lesional (g) skin throughout the entire epidermis compared to controls (a) (Figure 
20). 
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Image analysis of p53 proves significantly higher p53 protein expression in vitiligo 
lesional and non-lesional epidermis compared to healthy controls (plots are mean ± SE) 
( p0.001, mean ±SE) (Figure 21). 
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Figure 20: Higher epidermal expression of p53 in vitiligo. 
Immuno-reactivity (FITC-labelling, green) shows higher expression of p53 in lesional 
(g) and non-lesional (d) skin of patients throughout the entire epidermal compartment 
compared to controls with skin phototype ІII (a). Scale bar 50µm, Magnification x 400. 
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Figure 21: Significantly higher p53 expression in vitiligo. 
Image analysis of average fluorescence intensity confirms significantly increased levels 
of p53 in lesional (n=18: 3 individuals, 6 pictures each) and non- lesional skin (n=18: 3 
individuals, 6 pictures each) compared to controls (n=24: 4 individuals, 6 pictures each). 
There are no significant differences in expression between lesional and non-lesional 
skin of patients with vitiligo. (Plots are mean ± SE) (NS p> 0.05,  p0.001). 
 
To further confirm up-regulated p53 expression, we employed Western blot. Once more 
the results document significantly up-regulated p53 expression in epidermal suction 
blister tissue from 3 patients in both lesional (n=3) and non-lesional skin (n=3) (Figure 
22a). Image analysis of p53 protein bands in relation to loading control protein 
(GAPDH) confirms significantly increased p53 expression in the entire epidermis of 
these patients (Figure 22b, c).  
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Figure 22: Significantly higher epidermal p53 levels in patients with vitiligo. 
(a)Western blot of p53 protein (approximately 53 KDa) shows increased levels of its 
expression in both lesional and non-lesional skin of patients compared to control.  Lane 
1 protein ladder, lane 2 control, lanes 3-8 lesional and non-lesional skin tissue extracts 
from 3 patients. GAPDH was used as loading control.  
(b) Normalization of p53 expression to the loading control. GAPDH was used to 
evaluate individual expression of the protein.  
(c) Quantification of the p53 bands. Image analysis was performed in relation to 
loading control protein (GAPDH). The result reveals significantly up-regulated 
expression in both lesional (n=3) and non-lesional (n=3) skin of patients compared to 
control (n=1). (Plots are mean ± SE) (NS p>0.05, * p<0.05, ** p<0.01). 
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4.1.5.2 p53 expression in vitiliginous melanocytes 
As p53 is strongly expressed in the entire epidermis of patients with vitiligo, it was 
tempting to investigate the in situ expression in the target cell i.e. the melanocyte. Our 
in situ results show the presence of p53 in vitiliginous melanocytes of non-lesional skin. 
This protein is absent in healthy control skin (Figure 23).     
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Figure 23: Increased p53 expression in epidermal melanocytes in vitiligo. 
Immuno-reactivity (FITC-labelling, green) shows higher expression of p53 in lesional 
and non-lesional (d, g) skin compared to healthy control (a). Intrabasal melanocytes are 
detected with TRITC-labelled NKI / beteb1. Overlay with p53 shows the presence of 
p53 protein in melanocytes (yellow) of non-lesional skin which is absent in control skin. 
Scale bar 50µm. Magnification x 400. 
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4.1.5.3 Significantly up-regulated in situ expression of p21 in 
both lesional and non-lesional skin of vitiligo compared to 
healthy control skin  
The multifunctional protein p53 is mediating transcription of many proteins involved in 
cell cycle arrest as well as DNA-repair and apoptosis (Lane, 1992; Harris, 1993; Prives, 
1994). One of these proteins, playing an important role in cell cycle arrest, is p21, 
interfering with cell cycle at the G1 phase (Kuerbitz et al., 1992; el-Deiry et al., 1993) 
and G2 phase (Lin and Lowe, 2001) providing in turn time for DNA repair (Hartwell, 
1992; Hartwell and Kastan, 1994). In this context Salem et al were the first to show up-
regulated p21 expression in vitiligo (Salem et al., 2009).  
Here we confirm those earlier results, showing increased p21 expression throughout the 
entire epidermis of both lesional (d) and non-lesional (g) skin compared to controls (a) 
(Figure 24). 
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Figure 24: Up-regulated p21 expression throughout the entire epidermis in vitiligo.  
Immuno-reactivity staining (FITC-labelling, green) shows increased p21 expression in 
lesional (g) and non-lesional (d) skin of patients compared to healthy control skin (skin 
phototype IIІ) (a). Scale bar 50µm. Magnification x 400. 
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Image analysis of p21 confirms significantly higher protein expression in lesional and 
non- lesional epidermis compared to controls (Figure 25).   
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Figure 25: Significantly increased p21 expression in vitiligo. 
Image analysis of the average fluorescence intensity cofirms significantly increased 
protein levels of p21 in vitiligo lesional (n=24: 4 individuals, 6 pictures each) and non-
lesional skin (n=24: 4 individuals, 6 pictures each) compared to healthy controls (n=18: 
3 individuals, 6 pictures each). (Plots are mean ± SE) ( p0.001 ,  p>0.05). 
 
In order to quantify protein expression, we used Western blot. The results confirm up-
regulated p21 expression in lesional (n=3) and non-lesional skin (n=3) compared to skin 
of controls (Figure 26a). Image analysis of p21 protein bands in relation to loading 
control protein GAPDH reveals significantly higher p21 expression in patient‟s skin 
(Figure 26 b, c).  
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Figure 26: Significantly up-regulated p21 expression in skin of patients with 
vitiligo. 
(a) Western blot. p21 protein shows significantly increased p21 levels in both lesional 
and non-lesional skin of patients compared to healthy controls.  Lane 1 protein ladder, 
lane 2 control, lanes 3-8 non- lesional and lesional skin extracts from 3 patients. 
GAPDH was used as loading control.  
(b) Normalization of p21 expression to the loading control. GAPDH was used to 
evaluate the individual protein expression.   
(c) Quantification of the p21 bands. Image analysis was performed in relation to 
loading control protein (GAPDH). The result reveals up-regulated expression in lesional 
(n=3) and non-lesional (n=3) skin of patients with vitiligo compared to the control (n=1). 
(Plots are mean ± SE) (NS p>0.05, * p<0.05, ** p<0.01).  
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4.1.5.4 Increased in situ p21 expression in melanocytes in 
vitiligo 
In order to show the presence of p21 protein expression in epidermal melanocytes of   
patients, we utilised double immuno-fluorescence labelling with FITC - labelled p21 
and TRITC - labelled NKI / beteb1 in full skin biopsies from healthy controls as well as 
patients. The in situ results show detectable p21 in situ expression (yellow) in 
melanocytes (Figure 27). 
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Figure 27: Increased p21 expression in epidermal melanocytes in vitiligo.  
 
Immuno-reactivity (FITC- labelling, green) shows higher expression of p21 in lesional 
and non lesional (d, g) skin compared to healthy controls (a). Melanocytes are detected 
with TRITC- labelled NKI / beteb1. The overlay with p21 shows the presence of p21 
protein in melanocytes (yellow) of non-lesional skin which is absent in healthy controls. 
Scale bar 50µm. Magnification x 400. 
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4.1.6 The effect of the MDM2 family on epidermal p53 levels, 
activity and stability in skin of patients with vitiligo 
4.1.6.1 A view at p53 regulatory factors, including, p76
MDM2
 and 
MDM4
 
p90
MDM2 
and MDM4 are homologous proteins in control of p53 levels. Briefly, p90
MDM2 
controls p53 activity via two distinct mechanisms. On the one hand, binding to the N-
terminal domain of p53, prevents in turn binding of gene expression inducing factors 
causing a stop in the p53-dependent transcriptional machinery. On the other hand, it 
leads to ubiquitination of p53 by targeting the protein for proteasomal degradation 
(Haupt et al., 1997; Honda and Yasuda, 2000; Kubbutat et al., 1997; Oliner et al., 1993). 
MDM4 stabilizes p90
MDM2 
by interfering with p90
MDM2 
auto-ubiquitination. However, it 
has also been reported that MDM4 is ubiquitinated and degraded by p90
MDM2
 (Pan et al., 
2003). In this context it is of note that the smaller MDM2 protein p76
MDM2
 acts 
positively towards p53 via antagonising the ability of p90
MDM2
 to target p53 protein 
degradation (Perry et al., 2000; Giglio et al., 2010). As shown above epidermal p53 
expression is high in vitiligo. These high levels were attributed to continuous oxidative 
stress, causing phosphorylation of p53 which in turn destabilizes the interaction between 
p53 and p90
MDM2
, 
 
resulting then in protection of p53 from degradation (Salem et al., 
2009). In this context it is noteworthy, that the same authors showed for the first time 
significantly elevated p76
MDM2 
levels in the skin of patients with vitiligo in association 
with enhanced p53
w//w  
functional activity.  Based on these results a crucial role in 
control of DNA damage / repair, prevention of photo-damage and non-melanoma skin 
cancer in vitiligo was proposed (Salem et al., 2009). In response to UV- radiation 
MDM4 was found to be phosphorylated by CHK1, increasing in turn the binding ability 
to 14-3-3γ, leading then to its retention in the cytoplasm. The overall result is activation 
of p53 transcriptional function and G1 cell cycle arrest. Importantly, this p53 activation 
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is accompanied with both, an increased stabilization and decreased ubiquitination, 
suggesting that cytoplasmic phosphorylated MDM4 (MDM4S367P) inhibits MDM2 
ubiquitin ligase function (Jin et al, 2006). 
To get a better understanding for possible involved mechanisms behind p53 
accumulation in the epidermis of patients with vitiligo, it was tempting to study MDM 
family members as p53-regulatory factors including p76
MDM2
, MDM4 and 
MDM4phospho.  
 
4.1.6.1.1 Up-regulated epidermal p76
MDM2
 expression in vitiligo 
Our in situ MDM2 immuno-fluorescence staining in vitiligo shows significantly higher 
levels of p76
MDM2
 splice variant throughout the entire epidermis of lesional and non-
lesional skin compared to controls. This up-regulated expression seems to be present 
also in the nuclei of epidermal cells (Figure 28). Image analysis reveals significantly 
higher p76
MDM2
 protein expression in lesional and non-lesional epidermis compared to 
control (Figure 29).  
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Figure 28: Up-regulated epidermal expression of p76
MDM2
 in vitiligo.  
Immuno-reactivity staining (TRITC-labelling, red) shows increased expression of 
p76
MDM2
 throughout the epidermis of both lesional (d) and non-lesional (g) skin 
compared to controls with skin phototype ІII (a). Scale bar 50μm.  Magnification x 400. 
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Figure 29: Significantly increased p76
MDM2
 expression in skin of patients with 
vitiligo. 
Image analysis of the average fluorescence intensity shows significantly increased 
levels of p76
MDM2
 in the epidermis of lesional (n=30: 5 individuals, 6 pictures each) and 
non-lesional (n=30: 5 individuals, 6 pictures each) skin of patients with vitiligo 
compared to controls (n=18: 3 individuals, 6 pictures each). (Plots are mean ± SE) (** 
p<0.01, *** p0.001). 
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4.1.6.1.2 Confirmation of elevated epidermal p76 
MDM2
 in vitiligo 
by Western blot 
Western blot was used to quantify p76
MDM2
. Our results reveal significantly up-
regulated p76
MDM2
 in lesional and non-lesional epidermal suction blister tissue extracts 
compared to controls (Figure 30 a, b).  
In summary, both immuno-fluorescence and Western blot results were in agreement 
with previous data of the Schallreuter group (Salem et al., 2009), who reported 
significantly increased expression of p76
MDM2
 in both lesional and non-lesional skin of 
patients with vitiligo. As they showed no differences in p90
MDM2
 expression between 
vitiligo and controls, we did not include this protein in our study.  
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Figure 30: Significantly up-regulated p76
MDM2
 expression in skin of patients. 
(a) Western blot for p76
MDM2
 shows up-regulated expression in lesional and non-
lesional skin of patients compared to controls. Lane 1 protein ladder, lane 2 control, 
lanes from 3-8 lesional and non-lesional epidermal suction blister tissue extracts from 3 
patients. GAPDH was used as loading control.  
(b) Normalization of expression to loading control. GAPDH was used for evaluation 
of individual protein expression. 
(c) Quantification of p76
MDM2
 expression. Image analysis of bands was used to 
quantify the expression of p76
MDM2
 protein in skin of patiets with vitligo in relation to 
the expression in control skin. The result confirms up-regulated p76
MDM2
 expression in 
lesional (n=3) and non-lesional (n=3) skin compared to the control (n=1). (NS p> 0.05,  
  p0.001). 
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4.1.6.1.3 In situ MDM4 and MDM4phospho expression 
in vitiligo 
After characterisation and confirmation of previous results, we turned our interest to a 
possible role of MDM4 in controlling p53 in vitiligo. For this purpose we studied 
expression of both MDM4 and its phosphorylated protein (MDM4phospho) in patients 
and compared those results with healthy controls. 
 
4.1.6.1.3.1 Significantly increased MDM4 expression in the entire 
epidermal compartment of patients with vitiligo 
 Our in situ results from MDM4 immuno-fluorescence labelling show higher levels of 
MDM4 throughout the entire epidermis in lesional and non-lesional skin of patients. 
Overlay of FITC-labelled MDM4 with DAPI suggests MDM4 expression in nuclei of 
epidermal cells (Figure 31).  Image analysis of MDM4 indicates significantly up-
regulated MDM4 protein expression in lesional and non- lesional epidermis compared 
to controls (Figure 32). 
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Figure 31: Significantly higher expression of MDM4 in vitiligo. 
Immuno-reactivity staining (FITC-labelling, green) shows high expression of MDM4 in 
lesional (g) and non- lesional (d) skin of patients compared to the control with skin 
phototype ІII (a). MDM4 seems to be present in nuclei as shown by overlay with DAPI. 
Scale bar 50µm. Magnification x 400. 
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Figure 32: Significantly increased expression of MDM4 in vitiligo.  
Image analysis of the average fluorescence intensity shows significantly up-regulated 
levels of MDM4 in vitiligo patients lesional (n=45: 5 individuals, 9 pictures each) and 
non-lesional (n=40: 5 individuals, 8 pictures each) skin when compared to healthy 
controls (n=27: 3 individuals, 9 pictures each). (Plots are mean ± SE) (*** p0.001, ** 
p<0.01). 
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4.1.6.1.3.2 Confirmation of up-regulated MDM4 expression in 
lesional skin of patients with vitiligo by Western blot 
In order to quantify protein expression, Western blot for MDM4 was carried out. The 
results show different protein levels among the 3 patients examined.  MDM4 levels are 
increased in lesional skin of all three patients. However, there are big differences in 
non-lesional skin between the three patients (Figure 33a). Densitometry analysis of 
MDM4 protein bands in relation to loading control confirms significantly up-regulated 
MDM4 expression in lesional (n=3) skin. Due to the variation in MDM4 expression of 
non-lesional skin, the calculated mean reveals no significant change in protein 
expression (Figure 33b, c).  
This observation holds an important message, namely, that the individual result needs to 
be taken into account for our complete understanding, as a look at the mean or median 
may give false answers.  
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Figure 33: Up-regulated MDM4 expression in lesional epidermis of patients. 
(a) Western blot. MDM4 (approximately 80KDa) shows an elevation in MDM4 
expression in lesional skin of all patients compared to control. Lane 1 protein ladder, 
lane 2 control, lanes from 3-8 lesional and non-lesional skin cell extracts from patients 
(n=3). GAPDH was used as loading control.  
(b) Normalization of expression to the loading control. This result shows the 
individual expression of the protein pointing to a wide range in between patients.  
(c) Quantification of the MDM4. Image analysis of bands was used to quantify the 
expression of MDM4 protein in lesional and non-lesional skin in relation to its 
expression in control skin. The result reveals significantly up-regulated MDM4 
expression in lesional (n=3) skin.  However, the overall result in non lesional (n=3) skin 
of patients is not representative considering the wide range of the individual data. These 
data need more work. (Plots are mean ± SE) (NS p< 0.05, *  p>0.05). 
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4.1.6.1.3.3 Up-regulated in situ MDM4 expression in non-lesional 
melanocytes  
Next we looked at MDM4 expression and localization in epidermal melanocytes using 
double immuno-fluorescence labelling with FITC-labelled MDM4 and TRITC-labelled 
NKI / beteb1. We detected positive MDM4 expression in melanocytes of non-lesional 
skin, while MDM4 expression is nearly absent in melanocytes of healthy controls 
(Figure 34). MDM4 expression was also not detectable by Western blot in cultured 
melanocytes of healthy control skin compared to the positive control (Figure 36).  
Hence, this observation supports our in vitro immuno-fluorescence result of MDM4 
expression in normal melanocytes (Figure 35).  
We were unable to test the expression in vitiliginous melanocytes under in vitro 
conditions due to shortage of cultured melanocytes from patients with vitiligo. 
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Figure 34: In situ MDM4 expression in epidermal melanocytes in vitiligo. 
Immuno-reactivity (FITC-labelling, green) shows in this example higher expression of 
MDM4 in lesional and non-lesional (d, g) skin compared to controls (a). Melanocytes 
are detected with TRITC-labelled NKI / beteb1. The overlay with MDM4 suggests a 
more pronounced MDM4 protein expression in melanocytes (orange) of non-lesional 
skin of a patient compared to controls ( insert i). Scale bar 50µm. Magnification x 400. 
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Figure 35: In vitro MDM4 expression is present in nucleoli in human epidermal 
melanocytes.  
Immuno-reactivity (FITC-labelling in green) shows almost absent MDM4 in 
melanocytes except in some nucleoli. Overlay of NKI-beteb1 positive epidermal 
melanocytes (TRITC-labelling) and FITC-labelled MDM4 shows no co-localisation of 
MDM4 (b and insert). Magnification  x 400.  Scale bar 50µm. 
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Figure 36: MDM4 is not detectable in normal human epidermal melanocytes.  
Western blot shows no MDM4 band in melanocytes. Lane 1 protein ladder, lane2 
normal human epidermal melanocytes and lane 3 +ve control (melanoma cells).  
 
 
 
 
4.1.6.1.3.4 Significantly increased MDM4phospho expression in 
the entire epidermis of patients with vitiligo  
 
Our results for MDM4phospho immuno-fluorescence labelling in vitiligo show strong 
expression of MDM4phospho in both lesional and non-lesional skin of patients. Overlay 
of FITC-labelled MDM4phospho with DAPI suggests elevated levels of 
MDM4phospho protein in nuclei of epidermal cells (Figure 37). Image analysis of 
MDM4phospho expression documents significantly increased MDM4phospho protein 
expression in vitiligo lesional and non-lesional epidermis compared to controls (Figure 
38). 
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Figure 37: Increased expression of MDM4-phospho in vitiligo.  
Immuno-reactivity (FITC-labelling, green) shows increased expression of 
MDM4phospho throughout the epidermis of both lesional (d) and non- lesional (g) skin 
of patients compared to controls with skin phototype ІII (a). Scale bar 50μm. 
Magnification  x  400. 
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Figure 38: Significantly increased MDM4phospho expression in vitiligo. 
Image analysis of the average fluorescence intensity shows significantly increased 
levels of MDM4phospho in the epidermis of lesional (n=45: 5 individuals, 9 pictures 
each) and non-lesional (n=35: 5 individuals, 7 pictures each) skin compared to controls 
(n=24: 3 individuals, 8 pictures each) (Plots are mean ± SE) (*** p˂0.001, NS p>0.05 
 
4.1.6.1.3.5 MDM4phospho expression levels differ between 
patients with vitiligo  
Western blot of MDM4phospho protein expression was utilised for protein 
quantification. The results show big variations between the patients, using normalization 
of MDM4phospho levels to the loading control GAPDH in lesional and non-lesional 
skin compared to controls (Figure 39 a, b). Image analysis confirms the results (Figure 
39 c). This result warrants further investigation as the data point to big differences in 
patients. Moreover, this result points to the limitation of statistics, because the overall 
result looses the increased levels shown in one patient. 
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Figure 39: Epidermal MDM4phospho expression differs in patients. 
(a) Western blot. MDM4phospho shows similar expression of MDM4phospho protein 
(approximately 80 KDa) in lesional and non-lesional skin of two patients with vitiligo 
compared to healthy control, while one patient shows significantly higher expression. 
Lane1 protein ladder, lane 2 control, lanes from 3-8 lesional and non-lesional epidermal 
suction blister tissue extracts from 3 vitiligo patients. GAPDH was used as loading 
control.  
(b) Normalization of expression to the loading control reveals different individual 
expression.  
(c) Quantification of the MDM4phospho. Image analysis of bands used to quantify 
the expression of MDM4phospho protein in lesional and non-lesional skin in relation to 
its expression in control skin. The overall result reveals no significant change in the 
levels of MDM4phospho expression in both lesional (n=3) and non-lesional (n=3) skin 
of patients with vitiligo compared to normal healthy control (n=1). (Plots are mean ± SE) 
(NS p>0.05). 
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The elevated MDM4phospho in only one of three patients` samples together with up-
regulated MDM4 expression in lesional skin of the same patients as well as the up-
regulated p21 levels in their skin got our attention for further evaluation. Therefore we 
looked at the MDM4/MDM4phospho ratio in these samples to get a better 
understanding about MDM4 and its possible role in vitiligo. Analyses of MDM4 / 
MDM4phospho ratio in these patients exhibit higher MDM4 levels than the 
corresponding phosphorylated protein in individual patients compared to healthy 
controls. This result suggests that not all MDM4 protein is phosphorylated in skin of 
these patients and phosphorylation levels can greatly vary between patients (Table 5). 
 
Protein levels  
control 
Pat 1 
non-les les 
Pat 2 
non-les les 
Pat 3 
non-les les 
MDM4 
1 2.26 2.55 1.06 1.77 0.71 1.69 
MDM4phospho 
1 1.651 1.81 0.68 0.83 0.23 0.91 
MDM4/ 
MDM4phospho ratio 1 1.37 1.41 1.54 2.14 3.10 1.85 
calculated un-
phosphorylated 
MDM4 0 0.61 0.74 0.37 0.94 0.48 0.78 
 
Table 5 
 
MDM4-MDM4phospho ratio in individual vitiligo patients (n=3). 
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4.1.6.1.3.6 MDM4phospho is highly expressed in non-lesional 
melanocytes in vitiligo 
To investigate the expression of MDM4phospo protein in epidermal melanocytes of 
non-lesional skin of patients, we again utilised double immuno-fluorescence labelling. 
Overlay of FITC-labelled MDM4phospho and TRITC-labelled NKI/beteb1 suggests 
higher MDM4phospho expression in melanocytes of non-lesional skin compared to 
almost absent expression in melanocytes of healthy control skin (Figure 40). 
MDM4phospho expression in normal melanocytes under in vitro conditions confirms 
almost absence in these cells. Very little MDM4phospho protein expression is present in 
nucleoli and perinuclear cytoplasm (Figure 41). To quantify levels of MDM4phospho 
expression in normal human epidermal melanocytes, Western blot was utilised. 
MDM4phospho expression was not detected in our samples compared to the positive 
control (Figure 42), supporting in turn the in vitro and in situ results. However, whether, 
there are some patients with higher expression still needs to be shown. 
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Figure 40: High in situ expression of MDM4phospho in melanocytes of patients. 
Immuno-reactivity staining (FITC-labelling green) shows considerable increased 
expression of MDM4phospho throughout the entire epidermis of both lesional (d) and 
non-lesional (g) skin in this example of vitiligo compared to control with skin phototype 
IIІ. Melanocytes of non-lesional skin (i) show stronger MDM4phospho expression 
compared to normal skin after overlay with NKI/beteb1 (c). Scale bar 50μm. 
Magnification  x 400. 
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Figure 41: Absent in vitro expression of MDM4phospho in human epidermal 
melanocytes.  
Immuno-reactivity (FITC-labelling in green) shows background MDM4phospho 
expression in normal melanocytes. Overlay of NKI / beteb1 positive epidermal 
melanocytes (TRITC-labelling) and FITC-labelled MDM4phospho shows no co-
localisation of MDM4phospho in melanosomes (b and insert). Magnification x 400.  
Scale bar 50µm. 
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Figure 42: MDM4phospho is not detectable in epidermal melanocytes.  
Western blot shows no MDM4phospho protein band in human epidermal melanocytes. 
Lane 1 protein ladder, lane 2 normal human epidermal melanocytes and lane 3 +ve 
control (melanoma cells).  
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4.2 Investigation of the SPARC- p53 axis in vitiligo 
4.2.1 Significantly up-regulated SPARC-expression in the entire 
epidermis of patients with vitiligo - a novel observation 
Briefly, SPARC is an important regulator of p53. Recently it was shown that depletion 
of SPARC in melanoma cells results in activation of p53 and induction of p21 leading 
in turn to G2/M cell cycle arrest and tumour growth inhibition (Fenouille et al., 2011).  
We therefore asked the question, whether SPARC could be a possible player in the up-
regulation of p53 in vitiligo. 
Our results show strong in situ expression of SPARC protein throughout the entire 
epidermis in lesional (d) and non-lesional (g) skin of patients compared to controls (a) 
(Figure 43). Image analysis of SPARC proves significantly elevated protein expression 
in lesional (p0.001, mean ± SE) and non-lesional (0.01>p>0.001±SE) epidermis 
compared to controls (Figure 44).   
To our knowledge this is the first report on high expression of SPARC in the entire 
epidermis of patients with vitiligo, together with persistent up-regulated functioning  
p53
w/w  
and increased p21 expression in the presence of 10
-3
M H2O2 confirmed by 
corresponding low catalase expression (Figures 14, 20, 24) and in vivo FT-Raman 
spectroscopy (Figure 18). 
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Figure 43: High expression of SPARC in vitiligo. 
Immuno-reactivity (FITC- labelling, green) shows an increased expression of SPARC in 
lesional (g) and non-lesional (d) skin of vitiligo patient compared to healthy control skin 
phototype ІII (a). Scale bar 50µm. Magnification x 400. 
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Figure 44: Significantly up-regulated expression of SPARC in vitiligo.  
Image analysis of the average fluorescence intensity supports significantly increased 
levels of SPARC in both vitiligo lesional (n=42: 7 individuals, 6 pictures each) and non-
lesional (n=42: 7 individuals, 6 pictures each) skin compared to controls (n=28: 4 
individuals, 7 pictures each). (Plots are mean ± SE) ( p0.001, ** p<0.01, * p<0.05). 
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4.2.2 More support for high epidermal SPARC protein levels in 
vitiligo 
For further support of our in situ SPARC protein expression, we utilised Western blot. 
The results show up-regulated SPARC expression at the expected size of approximately 
40 kDa in lesional (n=3) and non-lesional epidermal cell extracts (n=3) compared to 
skin of healthy controls (Figure 45a). Image analysis of SPARC protein bands in 
relation to loading control protein (GAPDH) reveals significantly increased SPARC 
expression in all samples (Figure 45b, c).  
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Figure 45: Significantly up-regulated epidermal SPARC expression in vitiligo. 
(a) Western blot. SPARC protein is seen at ~43KDa with elevated expression in both 
lesional and non-lesional skin of patients compared to healthy controls.  Lane 1 protein 
ladder, lane 2 is control, lanes 3-8 lesional and non-lesional skin cell extracts from 3 
vitiligo patients. GAPDH was used as loading control.  
(b) Normalization of SPARC expression to the loading control. GAPDH was used to 
evaluate the expression of the individual protein levels. The results confirm increased 
levels in all patients examined.  
(c) Quantification of SPARC bands. Image analysis was performed in relation to 
loading control protein (GAPDH). The result reveals up-regulated expression in both 
lesional (n=3) and non- lesional (n=3) skin of patients with vitiligo compared to control 
(n=1). (Plots are mean ± SE) (NS p > 0.05, * p<0.05, ** p<0.01).   
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4.2.3 H2O2 does not affect the antibody binding site of SPARC 
Next we needed to ensure that the epitope for the antibody used for immuno- 
fluorescence and Western blot is not affected by mM levels of H2O2. Therefore we 
performed dot blot analysis with recombinant SPARC protein after incubation with 
different mM concentrations of H2O2. Our results demonstrated no differences in 
reaction of the antibody with SPARC protein in the presence of different H2O2 
concentrations. Based on this result, we can conclude that the epitope for antibody 
binding is not affected by oxidation (Figure 46).  
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Figure 46: The effect of H2O2 on SPARC protein.  
Dot blot shows no effect of H2O2 on the immuno reactivity of the SPARC epitope. 
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4.2.4 SPARC expression is increased in non-lesional melanocytes 
We next looked at in situ and in vitro SPARC expression and localization in 
melanocytes using double immuno-fluorescence labelling with FITC-labelled SPARC 
and TRITC- labelled NKI / beteb1. The in situ results identify strong SPARC 
expression (in yellow) after overlay of NKI / beteb1 and SPARC in non-lesional 
melanocytes, while SPARC is absent in melanocytes of control skin (Figure 47). 
Moreover, our in vitro results of SPARC expression in normal epidermal melanocytes 
show strong localisation of SPARC protein in nuclear envelop, nucleoli and cytoplasm 
but without overlap with melanosomes (Figure 48). For quantification of SPARC 
expression in normal human epidermal melanocytes, Western blot was utilised. The 
results confirmed the in situ expression of SPARC protein in normal melanocytes 
compared with the band of a positive control (Figure 49).   
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Figure 47: Increased SPARC expression in epidermal melanocytes of non-lesional 
vitiligo. 
Immuno-reactivity (FITC-labelling, green) shows strong expression of SPARC in 
lesional and non-lesional (i) epidermis of patients, while SPARC cannot be detected in 
healthy controls (c) with skin phototype ІII. Overlay of NKI / beteb1 positive epidermal 
melanocytes (TRITC-labelling) and FITC-labelled SPARC identifies SPARC 
expression (yellow) in vitiligo (f; i) and insert, while SPARC is absent in normal control 
melanocytes (c) and insert.  Magnification x 400.  Scale bar 50µm. 
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Figure 48: In vitro expression of SPARC in human epidermal melanocytes. 
Immuno-reactivity (FITC-labelling, green) shows that SPARC is expressed in 
melanocytes under in vitro conditions. Patterns of expression indicate that SPARC is 
present in peri-nuclear cytoplasm and possibly in nucleoli (a insert). Overlay of NKI / 
beteb1 positive epidermal melanocytes (TRITC-labelling) and FITC-labelled SPARC 
shows no co-localisation of SPARC in melanosomes (b and insert). Magnification  x 
400.  Scale bar 50µm. 
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Figure 49: SPARC is present in human epidermal melanocytes.  
Western blot supports the presence of SPARC in human epidermal melanocytes. The 
band observed at approximately 40 kDa is in agreement with the size of SPARC. Lane 1 
protein ladder, lane 2 normal human epidermal melanocytes and lane 3 +ve control 
(Santa Cruz Biotechnology Inc, sc-3811). 
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4.2.5 Does elevated nitric oxide (NO) affect epidermal SPARC in 
vitiligo?   
  
One question to be answered was, whether peroxynitrite (ONOO
-
) could affect SPARC 
functionality in vitiligo. 
Briefly, NO is synthesised from the terminal guanido nitrogen atom of L-arginine by the 
NADPH- dependent enzymes i.e.NO- synthases (NOS). Rapid reaction of NO with O2
.-
 
generates peroxinitrite anion (ONOO
-
) (Burney et al.,  1999) which in turn can nitrate 
the phenol ring of L-tyrosine in cellular proteins (Mannick and Schonhoff,  2004). 
Previously it was shown that ONOO
- 
is highly expressed in skin of patients with vitiligo 
(Salem et al., 2009). 
Hence, it was tempting to evaluate the effect of SPARC on p53 regulation in the 
presence of this radical, using 5-nitro- tyrosine expression as the foot print for ONOO
-
 .  
 
4.2.5.1 High expression of 5-nitro-tyrosine in the epidermis of 
patients with vitiligo confirms the presence of ONOO
- 
 
In order to study possible nitration of SPARC in vitiligo, we evaluated the presence of 
ONOO
-
 via immuno-fluorescence staining using TRITC-labelled 5-nitro-tyrosine. Our 
in situ results confirmed the presence of 5-nitro-tyrosine throughout the entire epidermal 
compartment in both lesional and non-lesionl skin of patients (Figure 50).  From this in 
situ result we can conclude that ONOO
-
 is indeed present in our patients. Moreover, 
these results are in agreement with our previous findings. (Salem et al 2009).  
152 
 
Overlay with DAPI indicates the presence of ONOO
-
 also in the nucleus. Image analysis 
of 5-nitro-tyrosine expression reveals significantly up-regulated ONOO
- 
levels in 
lesional and non-lesional epidermis compared to controls (Figure 51).   
 
4.2.5.2 In vitiligo SPARC is nitrated throughout the entire 
epidermis  
Double immuno-fluorescence labelling of FITC-labelled SPARC and TRITC-labelled 
5-nitro-tyrosine proves for the first time high expression of nitrated SPARC in lesional 
and non-lesional skin of patients with vitiligo. This elevated expression of nitrated 
SPARC is more pronounced in cellular walls in addition to some nuclei (Figure 50). 
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Figure 50: Increased in situ expression of nitrated SPARC in vitiligo.  
Double immuno-fluorescence of TRITC-labelled 5-nitro-tyrosine and FITC-labelled 
SPARC shows strong expression of nitrated L-tyrosine in vitiligo lesional (e) and non-
lesional (h) skin. Overlay of nitrated tyrosine with DAPI suggests its localization in the 
nuclei (purple) throughout the epidermis of vitiligo lesional and non- lesional skin (e,h 
inserts). It also identifies the presence of nitrated SPARC in the entire skin of patients 
with witiligo.  Nitrated SPARC is present in the cell wall and in some nuclei. It is absent 
in healthy controls (c) (skin phototype III, Fitzpatrick classification). Scale bar 50µm. 
Magnification x 400. 
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Figure 51: Significantly up-regulated nitration in vitiligo.  
Image analysis of the average fluorescence intensity shows significantly increased 
levels of 5-nitro-tyrosine in vitiligo lesional (n=24: 4 individuals, 6 pictures each) and 
non-lesional (n=24: 4 individuals, 6 pictures each) skin compared to controls (n=20: 2 
individuals, 10 pictures each). (Plots are mean ± SE) ( p0.001, NS p >0.05). 
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4.2.5.3 Weak SPARC in vitro nitration in normal epidermal 
melanocytes  
Under in vitro conditions SPARC and 5-nitro-tyrosine are expressed in normal human 
melanocytes with weak nuclear co-localization (Figure 52). 
 
SPARC nitro-tyrosine overlay
a b c
 
 
Figure 52: In vitro nitration of SPARC in nuclei of normal melanocytes. 
 
Immuno-fluorescence of TRITC-labelled 5-nitro-tyrosine and FITC-labelled SPARC 
shows almost absent nitration of SPARC by the overlay of both chromophores. 
However, melanocytes nuclei show  weak co-expression (a, b, c insert). Scale bar 50µm. 
Magnification x 400. 
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4.2.5.4 Computer modelling supports deactivation of SPARC-
functionality by H2O2-mediated oxidation and ONOO
-
- mediated 
nitration 
Mature SPARC is 286 amino acids in length, and consists of 3 domains: an acidic 
flexible N-terminal domain (1-52), a Follistatin (FS) like domain which contains a 
single (52-137) glycosylation site (Maurer et al., 1995), and a C-terminal EC domain. 
X-ray crystallographic studies have revealed much of the structure and function of 
SPARC. The structure of the isolated EC domain was solved first, followed by the 
combined structures of the FS and EC domains (Hohenester et al., 1996, 1997). The 
structure of the C-terminal domain has not been solved yet, as it appears to be random. 
SPARC function is known to be calcium dependent. The main site for calcium binding 
is in the EC domain, which contains two high affinity EF-hands binding sites for 
calcium (Hohenester et al., 1996, 1997). It is also thought that the C-terminus, which is 
rich in glutamic acids may bind calcium and hydroxyapatite, but with lower affinity 
(Maurer et al 1992). These EF-hands are unusual; the first contains an insertion of 
amino acid, which is accommodated by a cis - peptide bond and the substitute of a 
backbone carbonyl for the more usual side chain. The second EF-hand is stabilised by a 
disulfide bond. Subsequent structural studies, involving a recombinant mutant as well as 
site directed mutagenesis, investigated the binding of SPARC to collagen. It is known 
that SPARC can be activated by proteolytic cleavage by either metalloproteinases or 
other endogenous proteinases (Sasaki et al., 1997). These studies implicated several 
residues critical or significant to binding. Moreover, they revealed that proteolytic 
cleavage of a specific α-helix exposes some of these residues which are buried, making 
in turn collagen binding easier and increasing affinity. The initial studies suggested 
several hydrophobic residues important for binding (Sasaki et al., 1998).  
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4.2.5.4.1 H2O2-mediated oxidation and ONOO
-
-mediated
 
nitration alter calcium binding of native SPARC  
As said above, there are 2 calcium binding sites in SPARC, situated in the EC domain 
(Figures 53and 55). Both sites are differently affected by H2O2, ONOO
- 
and the 
combination of H2O2 and ONOO
-
 appear to affect the EF-hands binding sites 
considerably as a result of shifts in the backbone structure and the spatial positioning of 
residue side chains. Measuring shifts in distances for O-donor atoms from residues in 
EF-hands from their native positions shows that there seem to be variations in shifts in 
distances for residues depending on the effect of H2O2, ONOO
- 
or the combination of 
both leading in turn to relevant differences. For the EF-hand 1, ONOO
- 
appears to have 
a more severe effect alone compared to H2O2 alone or to the combination of ONOO
-
/H2O2.  After nitration alone co-ordination is lost from 4 out of 5 residues, compared to 
3 out 5 for H2O2 and ONOO
-
/H2O2 combined (Figure 54C/D) .  
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Figure 53: Computer modelling of the1
st 
EF- hands binding site of SPARC in the 
presence of H2O2. 
 
A. 1st EF-hands site in native SPARC. Calcium is bound by 5 O-donor atoms from 5 
residues Asp
222
, Pro
225
, Asp
227
, Tyr
229
 and Glu
234
. 
B. The effect of H2O2 on the 1
st
 EF-hands binding site. There are substantial shifts in the 
side chains of calcium co-ordination residues, resulting in loss of co-ordination from 
over  half the O-donor atoms in all cases. 
(With kind permission from Dr NCJ Gibbons). 
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Figure 54: Computer modelling of the 1
st 
EF-hands binding site of SPARC in the 
presence of ONOO
- 
and the combination of ONOO
- 
and H2O2. 
 
C. The effect of ONOO- on the 1st EF-hands binding site of SPARC. 
D. The effect of combined ONOO- and H2O2 on the 1
st
 EF-hands binding site of 
SPARC.  
(With kind permission from Dr NCJ Gibbons). 
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Figure 55: Computer simulation of the 2
nd
 EF- hands binding site of SPARC in the 
presence and absence of H2O2. 
 
A. 2nd EF-hands site in native SPARC. Calcium is bound by 6 O-donor atoms from 5 
residues Asp
257
, Asp
259
, Asp261, Tyr
263
 and Glu
268
.  
B. The effects of H2O2 (a) on the 2
nd
 EF-hands binding site of SPARC. 
(With kind permission from Dr NCJ Gibbons). 
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Figure 56: Computer simulation of the 2
nd 
EF-hands binding site of SPARC in the 
presence of ONOO
- 
and the combination of ONOO
- 
and H2O2. 
 
C. The effect of ONOO- on the 2nd EF-hand binding site of SPARC 
D. The effect of H2O2 / ONOO
-
 combined. While H2O2 and H2O2/ ONOO
- 
combined 
lead to loss of at least 4 out of 6 donor O-atoms, suggsesting the probable loss of 
calcium, ONOO
-
 has a slightly weaker effect with the loss of only 3 out of 6 donor 
atoms. For the EF-hand 2, however, the effect of H2O2 alone and ONOO
-
/H2O2 
combined appear to be more severe than ONOO
-
 alone with 4 out of 6 O-atoms lost, 
compared with 3 out of 6 lost for ONOO
-
.  
(With kind permission from Dr NCJ Gibbons). 
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To sum up, the computer modelling results strongly suggest that SPARC is considerably 
affected by H2O2-mediated oxidation and ONOO
-
 - mediated nitration.  Those changes 
to the structure affect calcium binding and co-ordination via both EF-hands binding 
sites. As the majority of O-donor atoms in both sites of native SPARC are lost either 
due to H2O2-mediated oxidation and combined oxidation / nitration by H2O2/ ONOO
-
, it 
is likely that calcium will be lost from both binding sites. 
Based on the results, it is tempting to conclude that SPARC can neither induce p53 nor 
phosphorylate p90 
MDM2
 via AKT.  
 
4.3  VEGF-A expression in vitiligo 
4.3.1 Significantly up-regulated expression of VEGF-A as 
SPARC regulator in the epidermal compartment of patients with 
vitiligo  
In an attempt to obtain a more comprehensive view of a possible cellular regulator 
behind SPARC accumulation in vitiligo, we decided to evaluate VEGF-A levels. Based 
on previous data it was shown that VEGF-A can induce expression of SPARC in 
endothelial cells. Furthermore VEGF-A levels showed significant increase in 
keratinocytes in response to NO and H2O2 (Brauchle, et al., 1996; Weninger, et al., 1996; 
Frank et al., 1999; Kato et al., 2001). 
Our own results show strong in situ expression of VEGF-A protein throughout the 
entire epidermis in both lesional (d) and non-lesional (g) skin of patients compared to 
controls (a) (Figure 57). Image analysis of VEGF-A confirms significantly elevated 
protein expression in vitiligo lesional (p0.001, mean ± SE) and non-lesional (p0.001, 
mean ± SE) epidermis compared to controls (Figure 58). 
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Figure 57: High expression of VEGF-A in the entire epidermal compartment in 
vitiligo. 
Immuno-reactivity (FITC-labelling green) shows increased expression of VEGF in 
lesional (d) and non-lesional (g) skin of patients compared to healthy controls with skin 
phototype ІII (a). Scale bar 50µm. Magnification x 400. 
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Figure 58: Significantly increased protein expression of VEGF in vitiligo.  
Image analysis of the average fluorescence intensity reveals significantly increased 
levels of VEGF in both vitiligo lesional (n=30: 5 individuals, 6 pictures each) and non-
lesional (n=30: 5 individuals, 6 pictures each) skin compared to controls (n=21: 3 
individuals, 7 pictures each). (Plots are mean ± SE) ( p0.001). 
 
 
4.3.2 More evidence for increased VEGF-A level in vitiligo 
In order to further substantiate VEGF-A protein expression, Western blot was carried 
out. The results confirm up-regulated VEGF-A levels in both lesional (n=3) and non-
lesional skin (n=3) of patients compared to healthy controls (Figure 59 a). Image 
analysis of VEGF-A protein bands in relation to loading control protein GAPDH reveals 
significantly up-regulated VEGF-A expression in all samples examined (Figure 59 b, c). 
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Figure 59: Significantly higher epidermal VEGF-A levels in vitiligo. 
(a)Western blot. VEGF-A protein ~43KDa shows increased levels of its expression in 
both lesional and non lesional skin of patients compared to control.  Lane 1 protein 
ladder, lane 2 control, lanes 3-8 lesional and non-lesional skin tissue extracts from 3 
vitiligo patients. GAPDH was used as loading control.  
(b) Normalization of VEGF-A expression to the loading control. GAPDH was used 
to evaluate the expression of the protein in each sample. N.B. levels are increased in all 
samples examined.  
(c) Quantification of the VEGF-A bands. Image analysis was performed in relation to 
loading control protein (GAPDH). The result reveals up-regulated expression in both 
lesional (n=3) and non-lesional (n=3) skin of patients compared to normal healthy 
control (n=1). (Plots are mean ± SE) (NS p>0.05,  p0.001). 
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4.3.3 Presence of VEGF-A in epidermal melanocytes 
After verification of up-regulated levels of VEGF-A expression in epidermal suction 
blisters of vitiliginous skin using both in situ imuno-fluorescence as well as Western 
blot, we looked at VEGF-A expression and localization in normal melanocytes and 
vitiliginous melanocytes under in situ conditions using double immune-fluorescence 
with FITC-labelled VEGF-A and TRITC-labelled NKI / beteb1. Melanocytes of non-
lesional skin show stronger VEGF-A expression compared to control skin (Figure 60) 
as indicated by the strong yellow colour in non-lesional skin (Figure 60 c, i and 
inserts).  
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Figure 60: VEGF-A expression in intra-basal epidermal melanocytes of vitiligo 
skin. 
Immuno-reactivity staining (FITC-labelling, green) shows an increase in the expression 
of VEGF-A in lesional (d) and non-lesional (g) skin of vitiligo compared to control (a) 
with skin phototype ІII (a). Overlay of NKI / beteb1 positive epidermal melanocytes 
(TRITC-labelling) and FITC-labelled VEGF identifies VEGF expression (yellow) in 
non-lesional skin of vitiligo patients, while it is absent in melanocytes of control skin (c 
and insert).  Magnification x 400.  Scale bar 50µm. 
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We then examined expression in melanocytes under in vitro conditions. Unfortunately 
we had no cells from patients with vitiligo. The results show only background VEGF-A 
expression in normal melanocytes using double immuno-fluorescence labelling with 
FITC-labelled VEGF-A and TRITC-labelled NKI / beteb1 (Figure 61). To further 
substantiate this result, we used Western blot. The results confirm absence of VEGF-A 
expression in these cells (Figure 62).     
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Figure 61: VEGF-A is not expressed in human epidermal melanocytes under in 
vitro conditions. 
Immuno-reactivity staining (FITC-labelling, green) shows only background VEGF-A 
expression in melanocytes. Overlay of NKI / beteb1 positive epidermal melanocytes 
(TRITC- labelling) and FITC - labelled VEGF-A shows no co-localisation of VEGF-A 
(b and insert).  Magnification  x 400.  Scale bar 50µm 
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Figure 62: VEGF-A is not detectable in epidermal melanocytes. 
 
Western blot shows no band for VEGF-A in human epidermal melanocytes Lane 1 
protein ladder, lane 2 normal human epidermal melanocytes and lane 3 +ve control 
(melanoma cells). 
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      4.4 TGF-β1 expression in skin of patients with vitiligo 
 4.4.1 Increased expression of TGF-β1 in the epidermal basal / 
suprabasal layers of vitiliginous skin 
TGF-β1 plays a significant role as a negative regulator for melanogenesis via promoting 
degradation or inactivation of tyrosinase leading in turn to hypopigmentation. Moreover, 
it decreases the production of MITF, TRP-1 and TRP-2, affecting melanosome 
maturation consequently leading to inhibition of melanin formation (Martínez-Esparza 
et al., 1997; Martínez-Esparza et al., 2001; Kim et al., 2003). In addition it also induces 
p21
 
expression through p53-independent mechanisms (Rodeck et al., 1994; Krasagakis 
et al., 1999; Rodeck et al., 1999; Hoek et al., 2006).  
As we showed increased p21 expression in the skin of patients with vitiligo, it was 
tempting to include a closer look on the expression of TGF-β1 expression in this patient 
group. Our results show significantly elevated expression of TGF-β1 in the outer cell 
membrane of the basal and suprabasal layers in lesional (d) skin, while the expression is 
restricted to the basal layer only in non-lesional (g) skin. There is some expression in 
the upper layers of vitiligo epidermis. There is only weak basal expression of TGF-β1 in 
normal control skin (a) (Figure 63). Image analysis of TGF-β1 confirms significantly 
higher expression in vitiligo lesional and non-lesional epidermis compared to healthy 
controls (Figure 64).  
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Figure 63: Up-regulated expression of TGF-β1 in the epidermal basal layer of 
vitiligo patients. 
Immuno-reactivity staining (FITC- labelling, green) shows high TGF-β1 expression in 
the basal suprabasal layers in lesional (d) and non-lesional (g) skin of patients with 
vitiligo compared to control skin (a). Scale bar 50µm. Magnification x 400. 
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Figure 64: Significantly increased epidermal TGF-β1 expression in vitiligo.   
Image analysis of the average fluorescence intensity shows significantly increased 
levels of TGF-β1 in the basal / suprabasal layers as well as in the upper layers of both 
lesional (n=40: 5 individuals, 8 pictures each)  and non-lesional (n=35: 5 individuals, 7 
pictures each)  skin, compared to healthy controls (n=21: 3 individuals, 7 pictures each). 
(Plots are mean ± SE) ( p0.001) 
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4.4.2 TGF-β1 in epidermal melanocytes 
After our observation of high in situ TGF-β1 protein expression throughout the entire 
epidermis of patients with vitiligo, the presence and localization of this protein was 
investigated in normal and vitiliginous melanocytes under in situ conditions. 
Interestingly, in skin of patient with vitiligo, melanocytes from non-lesional skin 
showed some TGF-β1, while it was absent in melanocytes of control skin (Figure 65). 
N.B. It was also absent in a detached melanocyte in lesional skin. 
 Normal melanocytes under in vitro conditions showed only background TGF-β1 
expression. Some expression is present in nucleoli (Figure 66). Western blot fosters 
absence of this protein in normal human epidermal melanocytes utilised (Figure 67).     
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Figure 65: TGF-β1 expression in basal and suprabasal layers of patients with 
vitiligo.  
Immuno-reactivity staining (FITC-labelling, green) shows high expression of TGF-β1 
in lesional (basal and suprabasal layers) (d) and non-lesional (g) skin of patients with 
vitiligo compared to control (a) NKI / beteb1 positive TRITC-labelled melanocytes of 
non-lesional skin (b; e; h) show some expression of TGF-β1 (in yellowish orange; i and 
insert) compared to melanocytes of lesional and control skin.  NB. One detached 
suprabasal NKI / beteb 1 positive/ TGF-β1 negative melanocyte in lesional vitiligo (f 
and insert). Scale bar 50µm. Magnification x 400. 
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Figure 66: In vitro expression of TGF-β1 in human epidermal melanocytes. 
Immuno-reactivity staining (FITC-labelling, green) shows little TGF-β1 expression in 
melanocytes. Overlay of TGF-β1 positive epidermal melanocytes (TRITC-labelling, red) 
and FITC - labelled TGF-β1 shows no co-localisation of TGF-β1 (b and insert). 
Magnification  x  400.  Scale bar 50µm. 
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Figure 67: TGF-β1 is absent in epidermal melanocytes.  
Western blot confirms absent expression of TGF-β1at ~44KDa in human epidermal 
melanocytes. Lane 1 protein ladder, lane2 normal human epidermal melanocytes and 
lane 3 is +ve control (melanoma cells).  
 
 
 
 
4.4.3 Epidermal TGF-β1 is nitrated in vitiligo 
 
Double immuno-fluorescence staining of FITC-labelled TGF-β1 and TRITC-labelled 5-
nitro-tyrosine reveals significant co-localisation between the highly expressed TGF-β1 
protein and 5-nitro-tyrosine in lesional and non-lesional skin of patients. This elevated 
expression of nitrated TGF-β1 is pronounced in the basal and suprabasal layer of 
lesional and non-lesional skin in patients with vitiligo (Figure 68). 
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Figure 68: Up--regulated in situ expression of nitrated TGF-β1 in the basal layer of 
vitiligo.  
 
Immuno-fluorescence reactivity of TRITC-labelled 5-nitro-tyrosine and FITC-labelled 
TGF-β1 represents nitrated TGF-β1 in vitiligo lesional (f) and non-lesional (i) skin. 
Overlay of TGF-β1 and nitrated tyrosine identifies the presence of nitrated TGF-β1 
through the epidermis of vitiligo lesional and non-lesional skin (f, i respectively) 
compared to healthy controls (c) (skin phototype III, Fitzpatrick classification). Scale 
bar 50µm. Magnification x 400. 
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5. Discussion 
To date there is convincing evidence that H2O2-mediated oxidative and ONOO
- 
-
mediated nitrative stress in the entire epidermis of patients with vitiligo is implicated in 
the pathogenesis of this disease (for review see Schallreuter, 2014). In this context 
oxidation / nitration  of proteins and peptide structures at various amino acid residues, 
including L-methionine, L-tryptophan, L-cysteine, seleno cysteine and L-tyrosine has 
been widely documented, leading in turn to complete or partial loss of function (Rokos 
et al., 2002; Gillbro et al., 2004; Hasse et al., 2005; Schallreuter et al., 2005b; Spencer et 
al., 2005; Chavan et al., 2006; Elwary et al., 2006; Gibbons et al., 2006; Schallreuter et 
al., 2008a; Shalbaf et al., 2008; Wood et al., 2009; Salem et al., 2009; Schallreuter et al.,  
2012 a; b ; Schallreuter,  2014) 
Moreover, 10
-3
M concentrations of H2O2 can trigger cellular lipid peroxidation, leading 
in turn to appearance of cellular vacuolation in this disease (Moellmann et al., 1982; 
Bhawan and Bhutani, 1983; Boissy et al., 1991; Nordllund and Ortonne, 1992; 
Schallreuter., 1999a; Schallreuter et al., 1999b; Tobin et al., 2000). 
H2O2-mediated oxidation affects epidermal antioxidant enzymes disturbing in turn the 
entire antioxidant defence machinery for prompt removal of oxidative toxic 
intermediates (Aronoff, 1965; Schallreuter et al., 1991b; Schallreuter 1999a; 
Schallreuter et al., 1999b; Schallreuter, 2005a; Maresca et al., 2006; Wood and 
Schallreuter, 2006; Schallreuter et al., 2007d; Schallreuter and Elwary, 2007a; Spencer 
et al., 2007;  Shalbaf et al., 2008; Wood et al., 2008;  Salem et al., 2009, Schallreuter et 
al., 2012 a; b, Schallreuter, 2014). 
The enzyme catalase, amongst others, is one important member of the antioxidant 
system. Under normal conditions catalase promotes degradation of H2O2 in to H2O and 
O2 (Aronoff, 1965; Schallreuter et al., 1991b). 
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Low catalase levels have been documented in the entire epidermis in vitiligo 
(Schallreuter et al., 1991b). In this context it has been shown that H2O2 affects the 
porphyrin ring of the enzyme in addition to oxidation of methionine and tryptophan 
residues in the active site and the cofactor NADPH-binding site, leading in turn to 
enzyme degradation and loss of functionality.Here it is of note that catalase expression 
in vitiligo emerged as an excellent biomarker for oxidative stress (Aronoff, 1965; 
Gibbons, et al., 2006; Maresca et al., 2006; Wood and Schallreuter, 2006; Salem et al., 
2009; Schallreuter et al., 2012a; b; Schallreuter 2014). H2O2 can also deactivate 
thioredoxin reductase (TR), another important enzyme for turnover of 1. H2O2 to H2O 
and O2 and  2. for turnover of nitric oxide (NO) to hydroxyl amine. One consequence is 
accumulation of NO which reacts with O2
.
, forming peroxinitrite (ONOO
-
).  This radical 
nitrates tyrosine residues to 5-nitro-tyrosine in different protein structures, contributing 
in turn to more imbalances in functionality (van der Vliet et al., 1994; Oury et al., 1995; 
Groves, 1999; Salem et al., 2009).  
In this context it is of interest that both, H2O2 and NO, increase the expression of 
VEGF-A in keratinocytes (Brauchle, et al., 1996; Frank et al., 1999). Moreover, this 
growth factor enhances SPARC expression and activity in human vascular endothelial 
cells (Weninger et al., 1996; Kato et al., 2000). Expression and activation of SPARC 
has been reported in melanoma to down-regulate as well as inactivate p53, leading in 
turn to inhibition of p21 mediated cell cycle arrest (Fenouille et al., 2011a;b). Given our 
documented up-reguated wild type p53 levels  in classical vitiligo together with up-
regulated  p76 
MDM-2
 (Perry et al., 2000; Schallreuter et al., 2003; Salem et al., 2009), it 
was tempting to investigate levels and activity of other important p53 regulators . 
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Our study included the p53-negative regulator, MDM4 and its phosphorylated form, 
MDM4phospho.  Moreover, we looked at expression and signalling of SPARC and its 
possible contribution in stabilizing wild type p53 in the skin of patients with vitiligo.  
Here it becomes of interest that SPARC induces TGF-β (Bassuk et al., 2000). As TGF-β 
acts as negative regulator of melanogenesis via decreasing maturation of melanosomes 
through degradation or inactivation of tyrosinase in addition to inhibition of MITF, 
TRP-1 and TRP-2 production (Martínez-Esparza et al., 1997; Martínez-Esparza et al., 
2001; Kim et al., 2003), we hypothesized a possible link between SPARC and the 
depigmentation process. One rationale behind this idea was, that patients with vitiligo 
lack protection against UVR threats due to absence of melanin in addition to massive 
epidermal oxidative stress. In this context up-regulated p53 was proposed as one 
possible mechanism behind a normal risk for non-melanoma skin cancer and lack of 
extensive skin photo-damage (Calanchini-Postizzi and Frenk, 1987; Schallreuter et al., 
2002; Salem et al., 2009).  
Taken together, to get a better understanding on the permanent up-regulated wild type 
p53 in vitiligo, we followed epidermal catalase, p53, p21, p76 
MDM2
, MDM4, 
MDM4phospho and SPARC expression in the same patient‟s skin. Moreover, as VEGF-
A induces SPARC (Kato et al., 2000; Weninger, et al., 1996) and VEGF-A expression 
is enhanced in human epidermal keratinocytes by NO and H2O2 , (Brauchle, et al., 1996; 
Frank et al., 1999), we included this signal and its possible role as a regulator for 
increased SPARC and  p53 levels in our study. Our first approach involved in situ 
investigation of the above protein panel in comparison to healthy controls. In addition 
Western blot analysis was utilized for assessment of protein levels. Moreover, our 
analyses included in situ and in vitro studies of epidermal melanocytes and in vivo FT-
Raman spectroscopy as well as computer simulation. 
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Low epidermal catalase levels and high 5-nitro-tyrosine expression 
support the oxidative stress theory in vitiligo 
Our in situ studies of epidermal catalase expression in patients and controls confirm 
significantly down-regulated expression of the enzyme throughout the entire epidermal 
compartment, in lesional and non-lesional skin (Figure 14, 16). Together with our 
results from in vivo FT-Raman spectroscopy, which confirmed the presence of H2O2 in 
10
-3
M concentration, identified by the O=O stretch at 875cm
-1
 (Figure 19), low 
epidermal catalase expression levels reflect H2O2–mediated oxidation of the protein in 
these patients (Schallreuter et al 1991b, Schallreuter et al 1999b; Schallreuter et al., 
2008a, Schallreuter, 2014). Here it is of note, that catalase levels follow melanogenesis 
in normal melanocytes (Maresca et al., 2007). Our data, presented in this thesis, confirm 
high in vitro and in situ catalase expression in melanocytes of healthy control skin 
(Figure 18), while expression in melanocytes of non-lesional skin of patients with 
vitiligo is almost absent (Figure 17). 
Moreover, the presence of these massive epidermal H2O2 concentrations in our vitiligo 
samples is accompanied with significantly higher 5-nitro-tyrosine levels (Figure 50). 
Hence, our results are in agreement with previous data, published by Salem and 
colleagues, who were the first to document significant increased ONOO
-
 levels in both 
lesional and non-lesional skin of patients with vitiligo (Salem et al., 2009).  
To sum up, characterisation of our vitiligo samples confirmed the presence of massive 
H2O2 and ONOO
-
 accumulation in the entire epidermal compartment of vitiligo in all 
patients investigated.  
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Confirmation of up-regulated epidermal functioning wild type p53 
together with up-regulated p21 expression throughout the entire 
epidermis in vitiligo 
Given, the dramatic epidermal H2O2 / ONOO
-
 accumulation together with significantly 
lower / almost absent  catalase levels in vitiligo lesional and non-lesional skin (Aronoff, 
1965; Schallreuter et al., 1991b; Schallreuter et al., 1999b; Schallreuter, 2004b; Wood 
and Schallreuter, 2006; Schallreuter and Elwary, 2007a;  Schallreuter et al., 2008a; 
Spencer et al., 2007; Shalbaf et al., 2008; Wood et al., 2008; Salem et al., 2009; 
Schallreuter et al., 2012 a;b; Schallreuter, 2014), we re-examined in situ expression of 
both, p53 and p21, in the epidermal compartment of these patients and compared those 
to healthy controls. Our results confirm high expression of cytoplasmatic and nuclear 
p53 throughout the entire epidermis (Figures 20, 22). This expression is also 
pronounced in melanocytes of non-lesional skin compared to melanocytes in healthy 
controls (Figure 23). Here it is of note that p53 levels are not affected by H2O2-
reduction after treating patients with a topical application of narrowband UVB-activated 
pseudocatalase PC-KUS (Schallreuter et al., 2003; Salem et al., 2009). This observation 
suggests that H2O2-levels in the epidermis of these patients, although reduced, could 
still be high enough to trigger p53 transcription (Vile, 1997).   Moreover, combination 
of both, ONOO
-
 and H2O2, increases the efficiency of DNA-binding capacity of p53 in 
vitiligo, which is not the case, if only ONOO
-
 is present (Salem et al., 2009).  
According to previous reports, localisation of p53 in the nuclei of epidermal cells may 
refer to its stabilization.  Increased p53 stability after continous oxidative stress prevents 
binding of the p53 negative regulator MDM2 to p53 after its phosphorylation at or near 
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the MDM2-binding domain, which would prevent p53 ubiquination, leading in turn to 
accumulation of p53 in the nuclei (Giaccia and Kastan, 1998; Chehab et al., 1999).  
Therefore, our question of interest was, whether p53-functionality as a transcriptional 
factor via binding to its target genes was affected in vitiligo.  For this purpose we 
studied the expression of p21 (cyclin-dependent kinase inhibitor 1), a protein member of 
the cell cycle arrest orchestra.  It is well established that p21 interferes with the cell 
cycle at the G1-phase (Kuerbitz et al., 1992; el-Deiry et al., 1993) and G2 - phase (Lin 
and Lowe, 2001) providing in turn time for DNA-repair (Hartwell, 1992; Hartwell and 
Kastan, 1994).  
Our in situ immuno-fluorescence labelling of p21 as well as Western blot data confirm 
up-regulated p21 expression and levels throughout the entire epidermis in vitiligo 
(Figures 24, 26). Epidermal melanocytes of non-lesional skin show significantly higher 
expression of p21 (Figure 24). These findings are in agreement with the previously 
published data by Salem and colleagues, who showed increased p21 levels in vitiligo 
skin (Salem et al., 2009). Clearly, this result points to the positive switch for p53-
downstream signaling and the efficiency of p53 in enhancing cell cycle arrest at G1 and 
G2 phases, preventing in turn proliferation of injured cells and giving time for DNA- 
repair via up-regulated base excision repair (BER) as reported earlier (Salem et al., 
2009).  
Taken together, our data confirm once more up-regulated functioning p53 in vitiligo.  
 
In vitiligo epidermal cells induce p76
MDM2
 expression, hindering in turn 
p53 degradation 
As mentioned above, p90
MDM2 
controls p53 stability and activity via two distinct 
mechanisms. On one hand, the protein causes a hold in the p53-dependent 
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transcriptional machinery via binding to the N-terminal domain of p53, preventing in 
turn binding of gene expression inducing factors.  On the other hand, p90
MDM
 controls 
ubiquitination of p53 and targets the protein for proteasomal degradation (Oliner et al., 
1993; Haupt et al., 1997; Kubbutat et al., 1997; Honda and Yasuda, 2000). The family 
member p76
MDM2
 lacks the p53 binding domain of p90
MDM2
 (Chen et al., 1993; Olson et 
al., 1993; Haines et al., 1994; Saucedo et al., 1999). By contrast to other MDM2 family 
members, p76
MDM2
 acts positively towards p53.  It antagonizes p53-regulation by 
p90
MDM2
 via inhibition of p90
MDM2
 binding to p53, without affecting p90
MDM2
levels 
(Perry et al., 2000; Giglio et al., 2010). Hence, p76
MDM2
 prevents p53 degradation.  
However, it is of note, that p76
MDM2   
binds to p53 mRNA, promoting in turn efficient 
translation of mRNA (Naski et al., 2009). These data motivated us to re-investigate the 
expression of p76
MDM2
 in our characterised patient group.  Our in situ immuno-
fluorescence results, together with the Western blot data (Figure 28, 30), proved 
significantly higher p76
MDM2 
protein levels in the entire epidermis of patients which are 
absent in healthy skin. Hence, our data support the overriding control via p76
MDM2
 in 
maintaining stability and activity of p53 through prevention of p90
MDM2 
- p53 binding.  
Taken together, our data are in agreement with previously published results by Salem 
and colleagues, who documented for the first time significantly up-regulated p76
MDM2
 
expression in lesional and non-lesional vitiligo skin, accompanied by high levels of p53 
and p21 (Schallreuter et al., 2003; Salem et al., 2009).  Once more, it is tempting to 
invoke these data as an explanation for the low incidence of solar-induced non-
melanoma skin cancer as well as absence of increased photo-damage, photo-aging, and 
low sunburn sensitivity in these patients, despite the presence of massive oxidative 
stress in the skin together with the absence of protecting pigment (Calanchini-Postizzi 
and Frenk, 1987; Schallreuter et al., 2002, Salem et al., 2009, Teulings et al 2013). 
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Up-regulated MDM4 / MDM4phospho levels support up-regulated 
functioning p53 expression in vitiligo – a novel result 
 
After confirmation of stability and functionality of p53 in association with high 
p76
MDM2
 and normal p90
MDM2
 levels, we then looked in to MDM4 interaction as MDM4 
controls p53 levels through inhibition of p90
MDM2
-mediated p53 degradation. Moreover, 
MDM4 directly affects p53 activity via disturbing its transcriptional machinery (Honda 
et al., 1997; Sharp et al., 1999; Fang et al., 2000; Jackson and Berberich, 2000; Stad et 
al., 2000; Pan and Chen., 2003; Danovi et al., 2004). 
Our in situ immuno-fluorescence results demonstrate for the first time significantly 
increased MDM4 expression throughout the entire epidermis in both lesional and non-
lesional skin (Figure 31).This result was confirmed by Western blot in lesional skin of 
three different patients (Figure 33). These data, together with the results of increased 
p21 expression (Figure 26) in the skin of the same three patients in both lesional and 
non-lesional skin, could point to MDM4-independent control of p53 transcriptional 
activity.  On one hand, our data are in sharp disagreement with reports by Danovi and 
colleagues, who demonstrated a major role of over-expressed MDM4 for p53 tumour 
suppressor activity inhibition in MDM4-infected cultures by showing a striking 
reduction in p21 expression (Danovi et al., 2004).  On the other hand, our results are in 
agreement and supported by data published in the same year by Mancini and colleagues. 
These authors demonstrated under stress conditions in non-tumour cells, that MDM4 
over-expression enhances p53 protein levels and transcriptional activity together with 
increased dissociation of p53 from its negative regulator p90
MDM2
 (Mancini et al., 2004).  
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This scenario portrays exactly the condition in vitiligo with  
 the presence of oxidative stress suffering cells  
 up-regulated wild type p53  
 normal p90MDM2 levels  
 efficient p53-transcriptional machinery, 
 supported by high p21 levels 
 significantly  up-regulation of MDM4 
In this context it was suggested that under stress conditions endogenous MDM4 is 
stabilizing stress-induced p53 due to its antagonism towards MDM2 (Barboza et al., 
2008). Based on these data, it is tempting to speculate that different MDM4 actions may 
exist between tumour and non-tumour- stressed cells.  
Moreover, it has been shown that UV-radiation affects MDM4 activity via 
phosphorylation (Jin et al., 2006). As UV induces de novo melanogenesis, but patients 
with vitiligo hold a partial loss of their inherited skin colour and de novo UV- regulated 
epidermal pigment, we decided to investigate phosphorylation of MDM4 for further 
elucidation of p53 accumulation in our characterised vitiligo samples. As shown by our 
Western blot results, we found variable phosphorylation levels in MDM4 protein 
amongst the three patients analysed (Figure 39).  Only one of them showed elevated 
MDM4phospho in lesional and non- lesional skin, while expression levels are very low 
in the two other patients. Here it is important to note, that the protein levels were 
originating from the same Western blots after stripping. Hence, the variable results are 
real with no artefacts. Consequently we analysed the MDM4 / MDM4phospho ratio in 
these samples, hoping for a further answer. Analyses of the individual results (Table 5) 
reveal higher MDM4 levels than the corresponding phosphorylated protein in patients 
compared to healthy controls, suggesting, that not all MDM4 is phosphorylated in each 
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patient. However, the MDM4 / MDM4phospho ratio is higher in all patients examined. 
Given, we accept the results of Mancini‟s and Barboza‟s group, who reported and 
confirmed that MDM4 in stressed cells positively regulate p53, then our data imply that 
some epidermal MDM4 protein is still un-phosphorylated. As a consequence MDM4 
could still function to antagonise p90
MDM2 
binding to p53, providing in turn p53 - 
stabilisation and activity. Clearly in vitiligo oxidative stressed cells are present in the 
epidermal compartment. On the other hand if MDM4 would function as a negative p53-
regulator in a tissue or cell type-independent manner, the remaining un-phosphorylated 
MDM4 could be inhibited / lost its control on p53. In this context it was reported that 
hetero-dimerization of p90
MDM2
 and MDM4 is crucial for degradation of p53 (Linke et 
al., 2008). Whereas Giglio and colleagues in 2010 suggested that p76
MDM2
 interferes 
with MDM complex formation, reducing in turn its degradation activity on p53 (Giglio 
et al, 2010).  
Our results revealed, almost absent, expression of both MDM4 and MDM4phospho in 
melanocytes in vitro and in situ in healthy controls (Figures 34, 35, 36, 40, 41, 42).  
These results are in agreement with recent data, where very low and / or undetectable 
MDM4 expression in these cells was reported (Gembarska et al., 2012). Surprisingly, 
expression of these proteins is high in melanocytes of non-lesional skin in our patients, 
(Figures 34, 40), associated with increased p53 (Figure 23) and p21 expression (Figure 
27). Taken together, MDM4 function in vitiligo may proceed through one of the 
following mechanisms. 
Inhibition of negative regulatory function towards p53 via  
 impaired heterodimer formation with p90MDM2   
 preventing p53 degradation based on high levels of p76MDM2, hindering in turn 
MDM complex formation  and MDM4 binding to p53. 
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The overall result is a positive up-regulation of p53 and contribution to its documented 
accumulation. Up-regulated p21 supports enhanced transcriptional activity for genes 
involved in cell cycle arrest. Importantly, these data also point to p53 induced p21 up-
regulation in vitiligo.  Our MDM4 data suggest selective tissue damage-dependent 
activity. This later assumption requires more work. 
 
Up-regulated epidermal SPARC expression – a radical scavenger in 
vitiligo skin? A novel result.   
Highly expressed matrix cellular protein SPARC is an important marker for melanoma 
aggressiveness via facilitating invasion and metastatic behaviour of melanoma cells 
(Ledda et al., 1997; Sturm et al., 1997; Massi et al., 1999; Alvarez et al., 2005; Alonso 
et al., 2007).  Recently Fenouille and colleagues suggested a novel role for SPARC in 
melanoma. These authors reported that melanoma cells with high SPARC expression 
are characterised by low levels of p53. Moreover, these authors showed induction of 
G2/M cell cycle arrest and promotion of p53-dependent p21 up-regulation via SPARC 
depletion. In the same year this group also introduced a role for SPARC in triggering 
AKT-dependent phosphorylation of MDM2, leading in turn to its stabilization, followed 
by degradation of p53 (Fenouille et al., 2011a;b). 
In our context, we decided to examine expression of SPARC in vitiligo to get a better 
understanding of the possible mechanism behind of up-regulated functioning  wild type 
p53 in association with no increased risk of solar induced non-melanoma skin cancer, 
younger-appearing skin compared to age matched healthy persons (Calanchini- Postizzi 
and Frenk, 1987; Schallreuter et al., 2002; Salem et al., 2009; Teulings et al., 2013;  
Schallreuter, 2014) but with a possible significantly higher risk for melanoma 
(Schallreuter et al., 1991a).  
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Our in situ immuno-fluorescence labelling of SPARC as well as Western blot 
investigations identified for the first time up-regulated SPARC in the entire epidermis in 
lesional and non-lesional skin of classic vitiligo (Figures 43, 45). Therefore, our data 
support the reported increase in SPARC expression in kerationcytes in response to 
different cellular stresses including the exposure to sodium arsenite (Kudo et al., 1994) 
which later on was documented as an oxidative stress / DNA damage-inducing agent in 
breast cancer cells via induction od ROS production (Ruiz-Ramos et al., 2009). Given, 
that oxidative / nitrative stress is present in vitiligo, it is tempting to conclude that up-
regulation of SPARC in vitiligo is very likely the consequence of cellular stress. 
Expression was also high in melanocytes of non-lesional skin (Figure 47). Our in vitro 
studies on epidermal melanocytes from healthy individuals confirm SPARC expression 
as shown by immuno-fluorescence and Western blot (Figures 48, 49). These results are 
supported by a publication from Robert and colleagues (Robert et al., 2006).  However, 
it is also of note, that two other publications reported absence of SPARC in normal 
epidermal melanocytes (Ledda et al., 1997 and Kato et al., 2000). 
 
Computer simulation supports loss of functional SPARC in classical 
vitiligo via oxidative and nitrative stress suggesting SPARC up-regulation 
as ROS scavenger. 
Given that, patients with vitiligo accumulate functioning wild type p53 in the presence 
of high H2O2 / ONOO- levels, we proposed the possibility of deactivation of epidermal 
SPARC by this ROS / RNS. One expected consequence would be prevention of 
p90
MDM2 
- phosphorylation by a dysfunctioning protein, leading in turn to loss of control 
on p53 up-regulation and p53 functionality.  
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To further elucidate this scenario, we utilised computer simulation to follow the effect 
of nitration and oxidation by H2O2 / ONOO
-
 on the protein structure of SPARC. As this 
protein is calcium dependent, containing two high affinity EF-hands calcium-binding 
sites, located at the α-helical domain (EC domain, residues 138–286) (Maurer et al., 
1995; Hohenester et al., 1996; Kretsinger, 1996, Hohenester et al., 1997), we 
investigated the effect of oxidative / nitrative stress specifically on SPARC-calcium 
binding capability. Co-localization of SPARC and 5-nitro-tyrosine revealed massive 
nitration of SPARC protein throughout the entire epidermis in vitiligo skin with more 
pronounced localization in cellular walls and some nuclei (Figure 50).   
The results of computer simulation further support ONOO
-
-mediated nitration of 
SPARC in vitiligo, as already indicated by the double immuno-fluorescence data. 
Moreover, SPARC is also considerably affected by H2O2-mediated oxidation and 
combined oxidation / nitration by H2O2/ ONOO
-
 on both calcium EF-hands binding 
sites. These effects lead to a major loss of O - donor atoms in both binding sites of 
native SPARC with a likely loss of calcium. Both observations, together with 
significantly up- regulated p53 / p76
MDM2 
/ p21 in the entire epidermal compartment of 
patients with vitiligo, in both lesional and non-lesional skin, suggest SPARC 
inactivation with loss of functionality via ONOO
-
 / H2O2- mediated stress as one general 
event in vitiligo.  
SPARC has been implied in triggering tumour development of melanoma in a p53-
dependent manner (Fenouille et al., 2011a;b). Given, that suppression of SPARC would 
activate p53 / p21 - enhanced cell cycle arrest, leading in turn to inhibition of cell 
proliferation (Fenouille et al., 2011), then it is tempting to propose that these structural 
changes of SPARC, accompanied with its loss of wild type p53 regulation in response 
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to H2O2 / ONOO
-
 in vitiligo, may lead to protection of melanoma development in our 
patients investigated in our study.  
However, our results are in sharp conflict with Fenouille‟s work, who proposed a 
fundamental SPARC / p53 regulation in melanoma (Fenouille et al., 2011 a; b). Clearly 
future work is needed to shed some more light on this scenario. 
 
Is up-regulated VEGF-A expression enhancing SPARC in vitiligo? 
Earlier it was reported that VEGF-A induces SPARC expression in human vascular 
endothelial cells (Kato et al., 2001; Weninger, et al., 1996). Induced SPARC may 
trigger a negative regulatory feedback mechanism via binding to VEGF-A as a 
consequence prevent activation of VEGFR1 (Kupprion et al. 1998; Nozaki et al. 2006). 
In the context of our aim, it is of note that VEGF-A is present in keratinocytes and that 
this expression can be enhanced by NO and H2O2 (Brauchle, et al., 1996; Frank et al., 
1999). Hence, this scenario is a valid condition in vitiligo. We expected up-regulated 
epidermal VEGF-A in this disease. And this was indeed the case, as we found 
significantly higher levels throughout the entire epidermis in lesional and non-lesional 
skin of our patients compared to controls (Figures 57, 59). 
Immuno-fluorescence and Western blot showed undetectable VEGF-A levels in control 
melanocytes (Figures 61, 62), while expression is high in melanocytes of non-lesional 
skin (Figure 60).  
Based on the fact that keratinocytes show significantly increased VEGF-A expression 
during wound healing, e.g.in psoriasis and in response to UV- irradiation (Brown, et al., 
1992; Detmar, et al., 1994; Detmar, et al., 1995; Brauchle, et al., 1996; Weninger , et al., 
1996; Mildner, et al., 1999; Gille, et al., 2000; Lauer, et al., 2000), an important role has 
been proposed for VEGF-A in regulation of vessel function under physiological 
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conditions (Weninger et al., 1996).  In this context, the presence of increased VEGF-A 
positive cells as well as VEGF-A positive vessels were recently described in the centre 
of vitiligo lesions but not in the periphery (Aroni et al., 2010).  
The increased vascularisation was proposed as the end result of active immune 
mechanisms as part of a healing / repair process in vitiligo (Aroni et al., 2010).  
Although these authors expected correlation between VEGF-A-induced vascularisation 
and increased lymphocytes, in the end they failed to prove their concept (Aroni et al., 
2010).  
At the same token we cannot ignore the critical role of VEGF-A in induction of 
angiogenesis in malignant melanoma (Claffey et al., 1996) by stimulating proliferation, 
migration, invasion, anti-apoptotic function and increasing vascular permeability (Alon 
et al., 1995; Dvorak et al., 1995). However, in our vitiligo cases, studied herein, no 
signs of skin cancer has been detected so far, despite of increased VEGF-A expression 
in melanocytes and keratinocytes. These data suggest that VEGF-A could drive benign 
vascularisation in vitiligo.  
Based on our data, it is tempting to speculate that increased SPARC expression /  levels 
in vitiligo serve as “antioxidant” in response to oxidative / nitrative stress after 
induction via VEGF-A. To our knowledge this would be a completely new function for 
SPARC. This assumption is supported by computer simulation, showing that VEGF-A 
is only little affected by H2O2 - mediated oxidation and ONOO
-
 - mediated nitration 
(personal communication with Dr NCJ Gibbons), data not shown. 
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Evidence for H2O2 - and ONOO
- 
- mediated deactivtion of TGF-β1 in 
vitiligo supports p53 dependent p21 induction.  
As a regulatory role for TGF-β1 has been documented in up-regulation of p21 
expression in a p53-independent manner (Rodeck et al., 1994; Krasagakis et al., 1999; 
Rodeck et al., 1999; Hoek et al., 2006) and SPARC induces up-regulation of TGF-β1, 
we finally included evaluation of TGF-β1 in our study.  Our in situ immuno-
fluorescence results show significantly up-regulated TGF-β1 expression in both, 
lesional and non-lesional skin of our patients, with a distinct stronger expression in the 
basal and suprabasal cells (Figures 63, 64). Interestingly, only melanocytes of non-
lesional skin show strong TGF-β1 expression (Figure 65) which is completely absent in 
one detached lesional melanocyte and in healthy controls under in situ and in vitro 
condition (Figures 65, 66). Based on our results that SPARC is significantly up-
regulated, but not functioning after H2O2 – mediated oxidation and ONOO
-
-mediated
 
nitration, it is tempting to conclude that TGF-β1 up-regulation in vitiligo escapes 
regulation by SPARC. Hence, the question to be answered is, whether up-regulation of 
TGF-β1 is under direct control in response to oxidative / nitrative stress. This 
assumption would be supported by increased TGF-β1 in human diploid fibroblasts after 
exposure to UVB via inducing H2O2 (Frippiat et al., 2001; Debacq-Chainiaux et al., 
2005). Given, that TGF-β1 is nitrated as shown by double immuno-fluorescence 
(Figure 68), then one must consider that up-regulation of TGF-β1 is very likely a 
SPARC independent event in vitiligo. As functioning TGF-β1 up-regulates p21 
expression, it is tempting to conclude that the observed up-regulated p21 in vitiligo is a 
consequence of up-regulated p53 and not controlled by TGF-β1. The data from the 
computer simulation support this conclusion (personal discussion with Dr CJ Gibbons).   
194 
 
In summary, confirmation of the previous data, together with our new data presented in 
this thesis, further support a central role for up-regulated functioning wild type p53 as a 
major player in the pathogenesis of vitiligo. One other very important result stems from 
this study.Our data further substantiate that in classical vitiligo the entire epidermal unit 
is part of the disease process  and not only the epidermal melanocyte. 
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Part II 
Comparison of MAL and classical 
vitiligo - a case control study 
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6. Introduction  
6.1 Malignant Melanoma (MM) in association with 
―vitiligo-like‖ leucoderma 
Skin cancer is the most common malignancy in fair skinned people worldwide 
(Breitbart et al., 2006). It can be classified into malignant melanoma (MM) and non-
melanoma skin cancers (NMSC). NMSC involves basal cell carcinoma (BCC), 
squamous cell carcinoma (SCC) and the precursor i.e. actinic keratoses (AC). UVR is 
considered to be the main risk factor for all of them.  These types of skin cancer arise in 
the majority of sun-exposed areas in fair-skinned people. Moreover, the incidence is 
negatively proportioned to skin colour and positively to the amount of exposure to ultra 
violet radiation (Preston and Stern, 1992; Diepgen and Mahler, 2002; Suarez et al., 
2007). Melanoma is a malignant tumor arising from melanocytes. It predominantly 
occurs in skin (95%), but is also found in other parts of the body, where melanocytes are 
present including eye, mucous membranes, gastrointestinal tract, genitourinary tract and 
leptomeninges.(Markovic et al., 2007). Worldwide manifestation of melanoma is 
increasing faster than any other malignancies. It represents less than 5% of all skin 
cancers, but is the cause of approximately all skin cancer‟s deaths (Rigel, 2008). Hence, 
melanoma represents a major clinical problem, as once the disease is spreading beyond 
loco-regional sites, there are currently no curative treatments (Soengas and Lowe, 2003; 
Tsao et al., 2004; Thompson et. al., 2005). New data from the United States documented 
76.000 new cases with melanoma and over 9.000 deaths for the year 2013. The rise of 
incidence was around 6% per annum in the 1970‟s. At the current time this increase is 
rising over 3% per annum (Naveh et al., 2013). 
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Malignant transformation of melanocytes to metastatic melanoma and its escape from 
keratinocyte-controlled regulation takes place via a group of carcinogenic events such 
as mutations in some genes that are involved in the regulation of cell growth, production 
of autocrine growth factors as well as melanocytes adhesion receptors loss (Haass et al., 
2004). This transformation passes five main steps: 
1. Proliferation and spread of cytological normal melanocytes forming a benign nevus 
cell nevus.  
2. These nevi could develop aberrantly forming a dysplastic cell nevus with random 
structural atypia. Dysplastic nevi are considered as premalignant lesions.   
3. Radial growth phase (RGP) in primary melanoma with unlimited hyperplasia may 
develop leading in turn to dermal micro-invasion.  
4. Formation of vertical growth phase (VGP) melanoma. 
5. Those VGP cells may continue in uncontrolled growth, with more invasion 
efficiency and these cells can invade other parts of the body including lung, liver, 
brain and bone via the blood stream. (Figure 69). 
Not all melanomas exhibit these five steps because some RGP or VGP can arise from 
melanocytes directly without the presence of pre-existing nevi (Miller and Mihm, 
2006). Different steps of melanoma development were found to be associated with a 
group of molecular changes leading in turn to unlimited proliferation, invasion and 
metastasis of melanoma cells. Some of these changes are summarised in (Figure 69) 
(Miller and Mihm, 2006). 
198 
 
Epidermis
Dermis
Basal
layer
Upper
layers
BZM
 
 
Figure 69: Proposed molecular alterations associated with the initiation and 
progression of melanoma.  
 
This illustration depicts human melanoma progression. Aberrant proliferation of normal 
melanocytes, presumably in response to UV radiation, results in the formation of benign 
or dysplastic nevi. Radial growth phase (RGP) melanoma exhibits the ability to grow 
intra-epidermal, followed by invasion of the dermis in the vertical growth phase (VGP), 
and culminating with metastasis. Note that only about half of the melanomas are known 
to arise from nevi, and progression can occur without going through all the stages 
depicted. Several melanoma susceptibility genes have been identified in kindred and 
have been validated in mouse models (modified from Zaidi et al., 2008). 
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Over recent decades the post surgical appearance of white patches in patients with 
melanoma has received much attention. This phenomenon is described with various 
names, including vitiligo, melanoma-associated vitiligo, melanoma associated 
hypomelanosis, melanoma associated depigmentation, melanoma associated leucoderma 
(MAL) and vitiligo-like depigmentation (Nordlund et al., 1983; Ram and Shoenfeld, 
2007; Hartmann et al., 2008; Teulings et al., 2015). Even to date, it is obvious that there 
is no common consensus so far, concerning this clinical entity.   
Several types of leukoderma have been described in association with melanoma. 
• Primary melanoma regression is a progressive process, replacing the tumour 
with fibrous stroma within the superficial dermis, although complete regression 
of melanoma is rare (Naveh et al., 2013).  
• Halo nevus (Sutton‘s nevus) presents a white rim around a pigmented nevus. 
It is frequently associated with vitiligo and melanoma (Bolognia 2009; Naveh et 
al., 2013).    
• Melanoma-associated depigmentation (leucoderma) describes a post 
surgical appearance of white patches in sites, distant from the primary tumour, 
arising either spontaneously or following immunological based treatments 
(Naveh et al., 2013; Teulings et al., 2015 ).   
In our study we will designate this special post surgical depigmentation as melanoma 
associated leucoderma (MAL), originating from leucos / white and derma / skin as we 
feel that this is the best description. 
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6.2 Vitiligo and malignant melanoma- Is there a true connection? 
Briefly, vitiligo is a depigmenting skin disorder with varying clinical presentations 
classified to localized (segmental, focal) and generalized (acro-facial, vitiligo vulgaris 
and universal or mixed). The pathogenesis is still not completely understood despite 
many past and recent efforts (Schallreuter, 2014).  Although vitiligo is an old disease, it 
was recently re-classified by the European Task Force group and an international 
consensus group in non-segmental, segmental, mucosal and mixed vitiligo (Taïeb and 
Picardo, 2007; Ezzedine et al., 2012). However, interestingly, melanoma-associated 
leucoderma (MAL) is not included as subtype of vitiligo.  
In 1991 Schallreuter and colleagues proposed an increased risk for development of 
cutaneous melanoma in patients with vitiligo (Schallreuter et al., 1991a). Those data 
were based on a group of 623 patients with melanoma. Eleven of them were developed 
depigmentation more than 2 years prior to diagnosis of the primary tumour (n=11/623).  
A second group of patients (n=11/623) developed depigmentation post surgical excision 
of the primary melanoma. Whether this latter depigmentation (leucoderma) is a classical 
vitiligo or not, is still under debate.  A recent study based on a postal survey included 
2635 patients with non-segmental vitiligo, > 50 years at the time of the study. Fifty % 
eligible questionnaires were returned (n=1307). The time period ranged from 1995-2010. 
Partners of patients served as controls. All skin cancers were validated by a pathology 
report. Multivariate logistic regression models were used to quantify adjusted odds 
ratios (ORs) and 95% confidence intervals (CIs) for associations between vitiligo and 
lifetime prevalence of MM and NMSC. According to this study, patients with vitiligo 
had a 3-fold lower probability of developing melanoma (Teulings et al., 2013). As only 
50% of the questionnaires were returned several possibilities cannot be ruled out. The 
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number of patients, who did not answer the questionnaire, could have had melanoma 
and passed already away. Moreover, the patient age (>50years) would have missed all 
melanomas in younger patients. Hence, more thorough studies are needed to answer the 
question, whether there is indeed a higher risk for patients with classical vitiligo to 
develop melanoma. A study published in 2012, investigating the incidence of melanoma 
from 1970 to 2009 showed an 8-fold increase among young women and 4-fold among 
young men, who developed their melanoma between the age of 18 to 39 years (Reed et 
al., 2012).   
 
6.3 MAL in association with malignant melanoma – Is it a 
good prognostic factor? 
In the context of the clinical outcome of melanoma, MAL has been reported and 
proposed as a favourable prognostic factor for tumour survival in this patient group with 
significantly enhanced 5-year survival rates (Nordlund et al, 1983; Bystryn et al, 1987; 
Quaglino et al, 2010). Development of depigmentation after immunotherapy has been 
correlated with improved survival rates (Rosenberg and White, 1996; Boasberg et al, 
2006; Gogas et al, 2006). As said above, a better overall outcome has been proposed for 
patients with melanoma, who develop vitiligo / depigmentation after excision of the 
tumour or after immunotherapy. A very recent publication systemically evaluated 137 
studies published between 1995 and 2013 on melanoma immunotherapy of stage III and 
stage IV melanoma that reported on autoimmune toxicity and / or vitiligo. 
Methodological quality of each study was based on adapted criteria for systematic 
reviews in prognostic studies. Random-effect models were used to calculate summary 
estimates of the cumulative incidence of vitiligo-like depigmentation across all studies. 
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The prognostic value of this depigmentation on survival outcome was assessed, using 
random-effects Cox regression survival analyses. In 27 studies, reporting individual 
patient data, vitiligo development was significantly associated with both, progression-
free-survival (hazard ratio [HR], 0.51; 95% CI, 0.32 to 0.82; p< .005) and overall 
survival (HR, 0.25; 95% CI, 0.10 to 0.61; p < .003), indicating that these patients have a 
2-4 times lower risk of disease progression and death, respectively, compared to patients 
without development of vitiligo (Teulings et al., 2015). The use of vitiligo and vitiligo-
like depigmentation in this article points once more to the necessity for more 
fundamental knowledge of this tumour associated depigmentation. 
Two important questions came to our mind. Why did these patients develop post -
surgical leucoderma? The other intriguing question to be answered is, whether MAL is 
actually the same entity as classical vitiligo.  
 
6.4 p53 and malignant melanoma 
Inactivation of p53 is considered to be one of cancer characteristics, as 80% of tumours 
have p53 missense mutations and production of aberrant proteins with abnormal 
functions leading to tumour progression and metastasis (Lozano, 2007). In contrast to 
these types of tumours, melanomas mostly hold wild type p53. Mutation of p53 in 
patients with melanoma is ranging from 0 to 30% (Albino et.al., 1994; Papp et al., 1996; 
Zerp et al., 1999; Ragnarsson-Olding et al., 2002; Daniotti et. al., 2004; Houben et al., 
2011). So far all mutations identified, lead to transcriptional inactivity of p53 protein 
(Houben et al., 2011). p53 is predominantly highly expressed with nuclear localization. 
Its expression correlates with tumour progression and invasion. High p53 expression is 
considered as a bad prognostic sign (Yamamoto and Takahashi, 1993; Montano et al., 
1994; Sparrow et al., 1995; Zerp et al., 1999; Rass et al., 2001; Soussi and Beroud, 2001; 
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Soto et al., 2005; Gwosdz et al., 2006; Li et al., 2006). Despite the presence of high  p53 
expression levels  in melanoma, a recent study showed a significant alteration in 
expression of several p53 target genes, involved in apoptosis and cell cycle regulation 
(e.g. p21) (Avery-Kiejda et al., 2011). Moreover, inhibition of p53 in melanoma cell 
lines had limited effect on p53 target gene expression and resulted in decreased 
proliferation of melanoma cells. This result could suggest, that p53 lost the ability to 
regulate its target genes. Rather than acting as a tumour suppressor, it may promote 
melanoma proliferation and progression (Avery-Kiejda et al., 2011). 
 
6.5 p53 / MDM4 interaction in malignant melanoma 
Recently Gembarska and colleagues reported that MDM4 is over-expressed in about 
65% of melanoma (Gembarska et al., 2012). Taking into consideration that p53 
mutations are rare in melanoma, these authors proposed that MDM4 over-expression is 
an important oncogenic event that alters p53-function in a large proportion of patients. 
Moreover, it was suggested that melanocyte MDM4 over-expression coincides with 
NRAS oncoprotein, resulting in turn in a shorter time of melanoma development and 
more aggressive melanoma formation. Hence, it was concluded that targeting the 
MDM4 / p53-interaction should lead to growth inhibition of melanoma.  These data 
demonstrated that high MDM4- expression levels are essential for proliferation of 
melanoma cells in culture, in a p53-independent manner (Gembarska et al., 2012). 
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6.6   p53 / SPARC interaction in malignant melanoma 
In some types of malignancies SPARC exerts tumour suppression function, as it is 
inactivated or expressed in low levels, leading to aggressive and metastatic behaviour 
e.g. in  colorectal cancer (Yang et al., 2007; Cheetham et al., 2008), in pancreatic cancer 
(Puolakkainen et al., 2004) in ovarian cancer (Yiu et al., 2001) and in acute myeloid 
leukemia (DiMartino et al., 2006), while in other types of cancer SPARC seems to have 
a crucial role in promoting tumour progression, as it is expressed in very high levels in 
these tumours e. g. breast cancer (Bellahcene and Castronovo, 1995; Porter et al., 1995; 
Jones et al., 2004; Lien et al., 2007), glioblastomas (Rempel et al., 1998) and melanoma 
(Ledda et al., 1997). 
During progression of malignant melanoma, an alteration in the expression of cell–
matrix and cell–cell communication molecules, including SPARC, was documented 
(Haass et al., 2005b; Miller and Mihm, 2006). It was found that SPARC is strongly 
expressed by advanced primary and metastatic melanomas in both neoplastic cells as 
well as melanoma associated stromal cells with a weaker expression in nevus cells, 
while its expression is absent in normal melanocytes (Ledda et al., 1997; Kato et al., 
2000; Wong and Rustgi, 2013). Fenouille and colleagues reported in 2011 that depletion 
of SPARC in melanoma cells yields activation of p53 and induction of p21, leading in 
turn to G2/M cell cycle arrest and tumour growth inhibition (Fenouille et al., 2011a;b). 
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6.7  SPARC / TGF-β1 / VEGF-A cascade in malignant melanoma 
Increased expression of TGF β 1, β 2 and β 3 proteins has been described in invasive 
primary melanomas as well as in metastatic nodules (Van et al., 1996). Moreover, TGF-
β1 is playing a crucial role in modulating the stroma surrounding melanoma cells 
through paracrine activity (Berking et al., 2001). TGF-β1 increases the expression of 
SPARC protein as well as its mRNA (Nakamura et al., 1996; Damjanovski et al., 1998). 
SPARC also induces the expression and secretion of TGF-β1 suggesting in turn a 
reciprocal regulatory feedback loop between SPARC and TGF-β1 (Bassuk et al., 2000). 
Moreover, TGF- β1 enhances p21 expression through p53-independent mechanism 
(Rodeck et al., 1994; Krasagakis et al., 1999; Rodeck et al., 1999; Hoek et al., 2006). 
VEGF-A is detected in keratinocytes in response to NO and H2O2 (Brauchle, et al., 
1996; Frank et al., 1999). Malignant melanoma cells also express VEGF-A to induce the 
formation of new blood vessels (angiogenesis) (Claffey et al., 1996) via stimulating 
proliferation, migration, invasion, anti-apoptotic function and permeability of vascular 
endothelial cells (Alon et al.,1995; Dvorak et al.,1995). VEGF-A induces the expression 
of SPARC in human vascular endothelial cells (Kato et al., 2001; Weninger, et al., 
1996). This induction of SPARC might be a negative regulatory feedback mechanism as 
SPARC binds VEGF and prevents activation of VEGFR1 (Kupprion et al., 1998; 
Nozaki et al., 2006).  
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7. Aim of the study (part II) 
 
Given, our long standing basic and clinical knowledge in the field of vitiligo, it was 
the aim of this study to use in vivo and in vitro observations for comparison and 
characterisation of melanoma associated leucoderma (MAL) and classical vitiligo.  
For this purpose we decided to use several of those results as applied and shown in 
Part I of this thesis for investigation of MAL, utilising immuno-fluorescence, 
Western blot and in vivo FT-Raman spectroscopy. Considering that patients with 
classical vitiligo do present a partial loss of their inherited protective skin colour, 
but without an increased risk for solar induced skin cancer or increased photo- 
damage in association with up-regulated functioning wild type p53 and DNA-
damage together with an efficient DNA-repair machinery (Schallreuter et al., 2003; 
Salem et al., 2009), two open crucial questions remained to be answered in the case 
of MAL and / or classical vitiligo.  
1. Is development of postsurgical and / or immune-induced leucoderma indeed 
classical vitiligo? 
2. Is development of postsurgical / immune-induced leucoderma a good prognostic 
factor for melanoma survival rates? 
Bearing those questions in mind, we felt, it was only timely to compare those data 
originating from classical vitiligo with post surgical melanoma associated 
leucoderma (synonyms used: vitiligo, vitiligo-like leucoderma).  
As epidermal low or absent epidermal catalase expression is one characteristic 
marker for classical vitiligo, correlating with epidermal accumulation of 10
-3
M 
H2O2 levels, as documented by in vivo FT-Raman spectroscopy, we wished to 
utilise this scenario in our study of MAL. In this context it is of note that a 
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constantly up-regulated functioning p53 in classical vitiligo has been implied as the 
major contributor to DNA-repair and prevention of increased solar induced skin 
cancer. Hence, we decided to follow p53 and p21 together with the MDM2 family 
and regulation by SPARC in MAL (Schallreuter et al., 2003, Salem et al., 2009, 
Schallreuter 2014).  Moreover, as both VEGF A and TGF-β 1 regulate p53 and 
SPARC expression as well as p21 in a p53-independent manner can foster 
hypopigmentation in cultured melanocytes and melanoma cells, we wished to 
include these signals in our study (Martínez-Esparza et al., 1997; Martínez-Esparza 
et al., 2001; Kim et al., 2003).  
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8. Materials and methods 
8.1 Patient history and characteristics of our MAL subject 
The study was in agreement with the local Ethics Committee of the EM Arndt University of 
Greifswald / Germany and with declaration of Helsinki principles. A written consent was 
obtained from the patient. 
The patient developed a cutaneous nodular ulcerated malignant melanoma in a congenital 
naevus at his left upper extremity in 9/2008.  The tumour was excised without lympho 
nodectomy. Histology revealed a predominant epitheliod cell type. Breslow level of 4.75 mm 
and Clark level 4. Absence of microsatellites and tumour infiltrating lymphocytes. No signs for 
perineural and vascular invasion. No tumour spreading until 3/2015.  Development of 
symmetrical depigmentation 6 months post surgery in the face, chest, upper extremities 
including palms and lower extremities. No signs of depigmentation / regression in the 
congenital naevus prior to excision. The clinical examination in 9/2008 showed no halo naevi. 
Wood‟s light examination revealed a weak yellowish fluorescence pointing to oxidised pterins 
as in classical described for classical vitiligo (Schallreuter et a., 1994a). No other immune 
diseases present. Negative family history for vitiligo and melanoma. Otherwise the patient was 
in good general health. Laboratory evaluation at 9/2011 shows low vitamine D levels, low 
vitamine B12 levels, borderline cholesterol elevation, otherwise unremarkable results. 
 
 
 
Figure 70: Facial MAL under WOOD‘s light in a 53 year old patient with 
melanoma (skin phototype III, Fitzpatrick classification) (With kind permission 
from Professor Dr KU Schallreuter). 
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8.2 In vivo Fourier Transform (FT) - Raman spectroscopy  
FT-Raman spectra were acquired using a BRUKER RFS 100/S spectrometer (Bruker, 
Karlsruhe, Germany) with a liquid-nitrogen-cooled Germanium detector. Near-infrared 
excitation was produced by a Nd
3+
:YAG laser operating at 1064 nm. Each spectrum was 
accumulated over 17 min with 1000 scans and a resolution of 4 cm
-1
. Detection of H2O2 
is based on the O=O stretch at 875 cm
-1
. The Met-S=O-stretch was visualised at 1030 
cm
-1
 accordingly. L-tryptophan and its oxidation products 5-OH-tryptophan (930 cm
-1
) 
and N-formyl-kynurenine/kynurenine (1050 cm
-1
) were recently assigned. This 
experiment was done in collaboration with Dr H. Rokos.    
8.3 Full skin biopsies from lesional and non-lesional skin 
After written consent total skin biopsies were taken under local anaesthesia from 
lesional and non-lesional skin of the right volar forearm, when the patient was seeking 
help in the Institute for Pigmentary Disorders in Greifswald / Germany for the rapid loss 
of his facial skin colour. In addition we used 3 healthy controls with skin photo type III 
(Fitzpatrick-classification). Biopsies were taken under the same conditions from 
controls from the volar forearm. 
8.4 Preparation of cryosections  
MAL and control skin biopsies were embedded in optimal cutting temperature 
compound (OCT) (Sakura, RA Lamb, Eastbourne, UK) and placed for about 5 minutes 
in liquid N2 to prevent any post surgical detoriation of the material. Sections were cut 
(3-5 μm) using a Leica CM3050 S cryostat (Leica Microsystems, Milton Keynes, UK) 
and placed onto commercially available  poly-L-lysine coated slides (Sigma, Pool, 
Dorset, UK). The slides were saved at -80°C for future work 
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 8.5 In situ immuno-fluorescence labelling 
Frozen slides were allowed to defrost at RT for 10 minutes followed by dehydration in 1 
x PBS for 5 minutes. Fixation was performed by immersing slides for 6 minutes in ice 
cold- methanol. Then slides were washed in 1 x PBS for 5 minutes, followed by 
blocking with normal donkey serum (10 NDS, Jackson Immunoresearch Laboratories, 
Cambridgeshire, UK) for 90 minutes at RT. Slides were washed once in 1 x PBS for 5 
min followed by another wash once in Tween-20 0.05 for 5 minutes and then twice 
again in 1 x PBS for 5 minutes each. Afterward slides were incubated overnight at 4°C 
with the primary antibodies, diluted in 1 NDS. Thereafter, slides were washed once in 
1 x PBS for 5 minutes, followed by another wash once in Tween-20 0.05 for 5 
minutes and then twice again in 1 x PBS for 5 minutes each. After that, slides were 
incubated for 1 hour at RT with a fluorescent secondary antibody in a dilution of 1:50 in 
1% NDS for 1 hour (donkey anti-rabbit or mouse depending on the primary antibody 
(Jackson Immuno Research Laboratories, Cambridgeshire, UK). Slides were washed 
once in 1 x PBS for 5 minutes, then once in Tween-20 for 5 minutes followed by two 
washes in 1 x PBS for 5 minutes each. Finally, slides were dried and mounted using 
Vectashield Mounting Medium containing 4, 6-diamino-2-phenylindole (DAPI) (Vector 
Laboratories, CA, USA) and covered with a coverslip. Pictures were viewed with a 
Leica DMIRB/E fluorescence microscope (Wetzlar, Germany). Images were captured 
using a Nikon Eclipse 80i microscope with a DS-U101 Nikon camera coupled to a 
Nikon ACT-2U capture program (Nikon, Europe). The antibodies and dilutions used are 
listed in (Table 6). Negative control staining was carried out by omitting the primary 
antibody from the staining procedure and substitution of 1% NDS / PBS.  
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8.6 Double immuno-fluorescence labelling 
 
In situ double immuno-fluorescence was used to detect co-localization of two specific 
proteins within one section. The protocol was similar to the described mono staining 
with some small modifications. After incubating skin sections with the 1
st
 secondary 
antibody and a brief rinse in PBS, sections were blocked with normal donkey serum 
(10 NDS, Jackson Immunoresearch Laboratories, Cambridgeshire, UK) for 90 
minutes at RT. Slides were washed once in 1 x PBS for 5 minutes, followed by two 
washes, once in Tween-20 0.05 for 5 minutes and then twice again in 1 x PBS for 5 
minutes each. Slides were incubated overnight at 4°C with the 2
nd
 primary antibodies, 
diluted in 1 NDS. The rest of the labelling was followed as described in detail.  
ImageJ version 1.37 was utilised (supplied online by NIH at 
http://rsb.info.nih.gov/ij/index.html) to merge FITC- and TRITC- images for evaluation 
of co-localization. The antibodies and dilutions used are listed in (Table 6). 
 
8.7 Quantification of fluorescence intensity 
To quantify the fluorescence, ImageJ version 1.37 was utilised (supplied online by NIH 
at http://rsb.info.nih.gov/ij/index.html). The region to be quantified was highlighted and 
a mean intensity obtained. This was repeated for the rest of the layers. The procedure 
was repeated in at least three epidermal sections of each patient and the mean value was 
obtained and plotted using Microsoft Excel (Microsoft Corporation, USA). Significance 
of data was analysed statistically using two-tailed unpaired t-test. 
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Antibody Dilution Incubation 
time/T 
Source Company Cat. No.  
catalase 1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab16731 
p76
MDM2
 1:20 Overnight/ 
4°C 
Mouse 
monoclonal 
antibody 
Santa cruz 
biotechnology 
sc-965 
MDM4 1:50 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab16058 
 
MDM4-
phospho 
1:50 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab70236 
Nitrotyrosine 1:50 Overnight/ 
4°C 
Mouse 
monoclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab78163 
NKI/beteb 1:50 Overnight/ 
4°C 
Mouse 
monoclonal 
antibody 
Caltag-
Medsystems 
Ltd 
MON7006-1 
p21 1:5 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab7960 
p53 1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab1431 
SPARC 1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab14174 
TGF-β1 1:50 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab66043 
 
VEGF-A 1:100 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab46154 
 
Table 6  
List of primary antibodies and conditions for in situ immuno-fluorescence labelling. 
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8.8 Western blot 
In order to perform Western blotting, the protein samples were first resolved in SDS 
PAGE gel electrophoresis as described before. After activation of polyvinylidene 
difluoride (PVDF) membrane (GE Healthcare, formerly Amersham Biosciences) by 
immersing it in methanol for about 2 minutes, the gel was sandwiched (1 sponge 
(cathode), 1 filter paper, gel, PVDF membrane, 1 filter paper, 1sponge (anode)) and 
placed in the electro blotting chamber filled with transfer buffer pH 8.3 (3g Tris Base, 
14.4g glycine, 0.4g SDS, 1000 ml distilled H2O). The transfer was run at 30 Volts for 
about 3 hours. Afterwards the PVDF membrane was immersed in non-fat milk (5%) 
(2.5g non-fat milk, 50 ml TBS / Tween(8.28g NaCl, 2.42g Tris, 0.47ml Tween 20, 
make volume to 1000ml using distilled water)) for 2 hours at room RT to block 
nonspecific binding sites.  The membrane was incubated overnight at at 4
o
C with 
primary antibody. The antibodies and used dilutions are listed in Table 7. All the 
previous antibodies were diluted in 5% w/v non-fat dry milk powder in TBS / Tween. 
This was followed by 3 washing steps within 30 minutes in TBS / Tween under 
continuous shaking. The membrane was transferred into a plastic dish containing one of 
secondary antibodies (Table 8) which was diluted in 5% w/v non-fat dry milk powder 
in TBS / Tween depending on the host of the primary antibody and incubated for 1 hour 
at RT, followed by wash in TB / Tween. Positive immune-reactivity was detected by the 
enhanced chemiluminescence‟s method (ECL). To do so, the membrane was immersed 
for 4 minutes in equal volumes of enhanced chemiluminescence‟s solution Ι (1 ml of 
250 mM luminol in DMSO, 0.44 ml of 90 mM p-coumaric acid in DMSO, 10 ml of 1 M 
Tris-HCl pH 8.5 in a final volume of 100 ml) (Sigma, Pool, Dorset, UK) and solution Π 
(64 µl of 30% v/v H2O2, 10 ml of Tris-HCl pH 8.5 in a final volume of 100 ml) (Sigma, 
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Pool, Dorset, UK). Positively stained protein bands send a luminescent signal which 
was visualised on a sheet of CL-XPosure Film (Thermo scientific, UK). 
 
Antibody 
 
Dilution 
 
Incubation 
time/T 
 
Source 
 
Company 
 
Cat. No. 
SPARC 1:500 Overnight at 
4
o
C 
Mouse 
monoclonal 
Santa cruz 
biotechnology 
sc-73051 
p53 1:500 Overnight at 
4
o
C 
Rabbit 
polyclonal 
Santa cruz 
biotechnology 
sc-6243 
GAPDH 1:5000 Overnight at 
4
o
C 
Rabbit 
polyclonal 
Abcam 
Cambridge, 
UK 
ab9485 
GAPDH 1:5000 Overnight at 
4
o
C 
mouse 
monoclonal 
Abcam 
Cambridge, 
UK 
ab8245 
p21 1:500 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab7960 
TGFβ1 1:2000 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab66043 
 
MDM2 1:300 Overnight/ 
4°C 
Mouse 
monoclonal 
antibody 
Santa cruz 
biotechnology 
sc-965 
MDM4 1:1000 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab16058 
MDM4-
phospho 
1: Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab70236 
VEGF-A 1:1000 Overnight/ 
4°C 
Rabbit 
polyclonal 
antibody 
Abcam, 
Cambridge, 
UK 
ab46154 
 
Table 7 
 List of primary antibodies used in Western blot in MAL. 
 
215 
 
 
 
Antibody 
 
Dilution 
 
Incubation 
time 
 
Company 
 
Cataloge 
number 
Anti-Mouse IgG Peroxidase 
antibody produced in goat 
 
1:1000 1h/RT Sigma-Aldrich, 
St. Louis, USA 
A2554-1ML 
 
Anti-Rabbit IgG (whole 
molecule)–Peroxidase 
antibody produced in goat 
1:1000 1h/RT 
  
Sigma-Aldrich, 
St. Louis, USA 
A9169-2ML 
 
 
Table 8 
List of Secondary antibodies used in Western blot  
 
8.9  Statistical analysis for Western blot 
The bands were evaluated by utilizing Image J version 1.37 (supplied online by NIH at 
http://rsb.info.nih.gov/ij/index.html). Each band was highlighted and the intensity was 
calculated. Statistical analysis was carried out by Microsoft Excel. The mean of the 
calculated values were plotted in the figures. 
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9. Results 
 
9.1 In vivo FT - Raman analysis identifies the presence of H2O2 -
mediated oxidation in lesional and non-lesional MAL. 
In vivo FT-Raman spectroscopy detects H2O2 levels in the 10
-3
M range in the skin of the 
right volar inner forearm of MAL. This result is not different compared to classical 
vitiligo (Figure 71).   
 
 
 
Figure 71: In vivo FT-Raman spectrum in MAL.  
The spectra, obtained from lesional and non-lesional skin of MAL, provide evidence for 
epidermal accumulation of H2O2 and its oxidation products including 5-OH-tryptophan 
(5-OH-Trp), methionine sulfoxide (Met-S=O) and N-formyl kynurenine / kynurenine 
(NFK/Kyn) at the assigned wave numbers cm
-1
 Schallreuter et al ., 2012a). 
 
 
 
Wave number (cm-1)  
 
H
2
O
2 
     5-OH-Trp          Met-S=O   NFK/Kyn 
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9.2 Evaluation of epidermal catalase, p53 and p21 in MAL  
 
9.2.1 Catalase expression follows a gradient from the basal layer 
to the upper layers and is lower in lesional and non-
lesional skin of MAL compared to control skin. 
 
Nowadays it is a fact that acute vitiligo is characterised by the presence of high 
epidermal H2O2-levels, associated with significantly decreased catalase expression 
throughout the entire epidermal compartment in both, lesional and non-lesional skin 
(Schallreuter et al, 1991, Schallreuter et al., 2008, Salem et al 2009,  Schallreuter, 2014). 
Consequently it was tempting to use this protein as a marker to follow catalase in MAL.  
Our in situ results show a down-regulation of epidermal catalase in lesional (d) and non-
lesional skin of MAL compared to control skin (a). There is one fundamental difference. 
Catalase expression in MAL is much higher in the basal/suprabasal layer compared to 
the upper layers (Figure 72).  
Image analysis of the protein expression confirms a significant decrease in lesional and 
non-lesional skin compared to healthy controls with significantly higher expression in 
basal/suprabasal layers than in the upper layers in MAL (NS p>0.05, ** p>0.01, 
p0.001, mean ± SE) (Figure 73). The results are based on 3 intra- individual 
repeats of immuno-fluorescence labelling.  
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Figure 72: In situ expression of catalase in MAL. 
Immuno-reactivity staining (FITC-labelling, green) shows lower protein expression in 
lesional (d) and non-lesional epidermis (g) compared to control skin (a). Expression 
follows a gradient. Catalase expression is more pronounced in the basal /  suprabasal 
layer of non-lesional (g) and lesional skin (d). N.B. Controls (a) do not show this 
gradient. Scale bar 50µm. Magnification x 400.  
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Figure 73: Image analysis of catalase protein levels in MAL.  
The average fluorescence intensity reveals significant down-regulation of catalase levels 
in lesional (n=21: 3 intra-individual repeats, 7 pictures each) and non-lesional (n=21: 3 
intra-individual repeats, 7 pictures each) epidermis of the patient with MAL compared 
to controls (n=24: 4 individuals, 6 pictures each) There is a significant increase in the 
basal layer of lesional and non-lesional skin. Plots are mean ± SE (NS p>0.05, ** 
p<0.01, p<0.001). 
 
9.2.2 Catalase expression is absent in epidermal melanocytes of MAL 
In situ double immuno-fluorescence labelling with the melanocyte specific marker NKI 
/ beteb1 and catalase, shows no catalase expression in epidermal melanocytes of non-
lesional skin (Figure 74), while the protein is highly expressed in melanocytes of 
healthy controls. 
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Figure 74: Absent catalase expression in epidermal melanocytes of MAL. 
Immuno-reactivity (FITC-labelling, green) shows expression of catalase in MAL and in 
control skin. Melanocytes are detected with TRITC-labelled NKI / beteb1. Overlay with 
catalase shows the presence of the enzyme (yellow) in control skin ((c) / insert), while 
catalase expression is absent in non-lesional skin ((i)/insert). Scale bar 50µm. 
Magnification x 400. 
 
 
Taken together, MAL shows significantly lower epidermal catalase expression with a 
distinct gradient from the basal / suprabasal layers to the upper layers compared to 
control skin. Expression levels are significantly higher in MAL compared to classical 
vitiligo.  
Epidermal melanocytes show no catalase expression in MAL. This finding is not 
different from classical vitiligo.  
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9.2.3 Evaluation of p53 and p21 expression in lesional and non-
lesional skin of MAL 
9.2.3.1 Lower basal/suprabasal p53 expression is accompanied 
with high basal / suprabasal p21 expression in MAL 
 
It has been reported that wild type functioning p53 is highly expressed in melanoma, 
predominantly with nuclear localization (Yamamoto and Takahashi, 1993; Sparrow et 
al., 1995; Zerp et al., 1999; Gwosdz et al., 2006). Expression appears to be increased 
with tumour progression and invasion. Hence, high p53 expression is considered to be a 
poor prognostic sign (Yamamoto and Takahashi, 1993; Montano et al., 1994; Sparrow 
et al., 1995; Zerp et al., 1999; Rass et al., 2001; Soussi and Beroud, 2001; Soto et al., 
2005; Gwosdz et al., 2006; Li et al., 2006). Avery-Kiejda and colleagues reported in 
2011, that despite high p53 expression, target genes, including p21, were severely 
altered. p53 inhibition in melanoma cell lines had no significant effect on its target 
genes. Therefore, it was suggested that p53 in melanoma may have lost its function to 
regulate target genes and rather than acting as a tumour suppressor, it may promote 
melanoma proliferation and progression (Avery-Kiejda et al., 2011).  
Our own in situ data show lower p53 expression in basal / suprabasal layers than in the 
upper epidermal layers in both, lesional (d) and non-lesional skin (g) compared to 
control skin (a) (Figure 75). Image analysis of epidermal p53-expression proves a 
significantly up-regulated protein expression. However, expression is higher in the 
upper epidermis compared to the basal / suprabasal layers. There are no significant 
differences in p53 levels between lesional and non- lesional skin (NS p>0.05, mean ±SE) 
(Figure 76). The data are based on 3 intra -individual staining experiments of the same 
sample.  
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Figure 75: High expression of p53 in epidermis of MAL. 
Immuno-reactivity (FITC-labelling, green) shows high expression of p53 in lesional (d) 
and non-lesional (g) skin of the patient compared to control skin (a). p53 expression 
appears lower in basal / suprabasal layers. p53 is predominantly expressed in the cytosol 
together with little nuclear expression ( inserts f, i:, light blue after overlay with DAPI). 
Scale bar 50µm. Magnification x 400. 
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Figure 76: Significantly increased p53 expression in MAL.  
Image analysis of the average fluorescence intensity shows significantly increased 
levels of p53 in lesional (n=21: 3 intra-individual repeats, 7 pictures each) and non - 
lesional (n=21: 3 intra-individual repeats, 7 pictures each) skin compared to controls 
(n=18: 3 individuals, 6 pictures each) Levels are lower in basal / suprabasal layers than 
in the upper layers of epidermis. There are no significant differences between lesional 
and non - lesional skin. (Plots are mean of 3 different intra individual stainings ± SE) 
( *** p<0.001, * p<0.05, NS p>0.05). 
 
To sum up, p53 shows a reciprocal pattern to catalase expression. Based on our results 
we can conclude that epidermal p53 expression in MAL follows a gradient with lower 
expression in the basal / suprabasal layers, while expression levels are significantly up-
regulated in the upper layers. These results differ from our findings in classical vitiligo, 
where p53 expression is high throughout the entire epidermal compartment. 
 
 
224 
 
9.2.3.2 Weak p53 in situ expression in epidermal melanocytes in 
MAL and healthy controls 
Next we looked at in situ p53-expression of melanocytes using double immuno- 
fluorescence with FITC- labelled p53 and TRITC-labelled NKI / beteb1. The overlay 
showed weak p53-expression in melanocytes in MAL compared to control skin (Figure 
77). This result is different to classical vitiligo where p53 is highly expressed. 
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Figure 77: p53 in MAL is not expressed in melanocytes under in situ conditions. 
Immuno-reactivity (FITC- labelling, green) shows high p53 expression in lesional (d) 
and non- lesional (g) skin of the patient with MAL compared to the control (a). p53 is 
bearly expressed in NKI / beteb1/TRITC labelled melanocytes in MAL and controls (c, 
i, insert).  Scale bar 50µm. Magnification x 400. 
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9.2.3.3 Western blot confirms significantly up-regulated p53 in 
MAL 
 
In order to further substantiate the immuno-fluorescence data, we employed Western 
blot. The results confirm our observed up-regulated in situ p53 expression in both, 
lesional and non-lesional skin of MAL compared to control skin (Figure 78a). Image 
analysis of p53 protein bands in relation to loading control protein (GAPDH) proves 
significantly increased p53 expression in MAL skin compared to skin of healthycontrols 
(Figure 78b). 
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Figure 78: Significantly increased epidermal p53 protein expression in MAL. 
(a) Western blot of p53 protein shows increased levels of its expression in both lesional 
and non-lesional skin of MAL compared to healthy control skin.  Lane 1 protein ladder, 
lane 2 control skin, lanes 3 and 4 lesional and non- lesional skin tissue extracts from  
our  patient with MAL. GAPDH was used as loading control. 
(b) Quantification of p53 bands. Image analysis was performed in relation to loading 
control protein (GAPDH). The result reveals significantly up-regulated expression in 
lesional and non- lesional skin of MAL compared to control skin. Plots are mean ± SE. 
(NS p> 0.05, ** p< 0.01,  p0.001). 
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9.2.3.4 Significantly increased epidermal p21 expression in basal 
/ suprabasal layers of MAL  
 
Next we tested in situ p21- expression in MAL. This protein is strongly expressed in the 
cytosol of the basal / suprabasal cells of lesional and non-lesional skin, while cells in 
upper layers reveal much weaker expression. Overlay with DAPI suggests some nuclear 
expression of p21 (Figure 79).  
Image analysis of p21 confirms significantly up-regulated protein expression in basal / 
suprabasal layers of lesional and non-lesional skin (n=3) (Figure 80). Analysis of the 
upper layers shows significantly higher expression in MAL compared to control skin 
(Figure 80). Data are based on 3 intra-individual staining experiments of the same 
sample.  
To sum up, the result in MAL is very different to classical vitiligo, where p21 is 
expressed throughout the entire epidermis without any significant differences between 
basal and suprabasal layers in lesional and non-lesional skin. The data in MAL suggest 
some nuclear expression of p21.  Moreover, p21 expression in MAL does not follow the 
corresponding p53-expression. In fact, p21 shows a reciprocal expression pattern 
compared to p53 with high expression in basal / suprabasal layers and low expression in 
the upper epidermis. 
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Figure 79: Up-regulated basal / suprabasal p21 expression in MAL.  
 
Immuno-reactivity (FITC-labelling, green) shows p21 expression throughout the entire 
epidermis with stronger expression in the basal / suprabasal layer in lesional (d) and 
non-lesional ( g) skin of MAL. p21 expression is absent in control skin (a).The overlay 
with DAPI suggests p21 expression in the nuclei of the basal layers ( insert f, i light 
blue). Scale bar 50µm. Magnification x 400. 
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Figure 80: Significantly higher p21 expression in MAL.  
Image analysis of the average fluorescence intensity reveals significantly increased p21 
levels in basal / suprabasal layers of lesional (n=21: 3 intra-individual repeats, 7 pictures 
each) and non-lesional (n=21: 3 intra-individual repeats, 7 pictures each)  skin in MAL 
compared to control (n=24: 3 individuals, 8 pictures each). Differences in p21 
expression are not significant between lesional and non-lesional skin (blue columns). 
p21 is also expressed in the upper epidermis, although much weaker compared to the 
basal / suprabasal layers. The difference is still significant between patient and control 
skin (red columns). Plots are the mean ± SE ( p0.001, p0.05, NS p>0.05). 
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9.2.3.5 Western blot analysis confirms significantly increased 
epidermal p21 protein expression in MAL 
 
In order to further substantiate the immuno-fluorescence data, we used again Western 
blot. The results confirm increased p21 expression in lesional and non-lesional skin of 
MAL compared to control skin (Figure 81a). Image analysis of p21 protein bands in 
relation to loading control protein (GAPDH) confirms significantly increased p21 
expression in lesional and non-lesional skin of MAL (Figure 81b).  
 
 
 
 
231 
 
GAPDH
1                 2                3
p21
a
les            nl          con            
%
 o
f 
p
2
1
ex
p
re
ss
io
n
b 
*
*** **
0
0.5
1
1.5
2
2.5
3
control    lesional non-lesional
20 KDa
50 KDa
 
 
Figure 81: Significantly up-regulated p21 expression in skin of MAL. 
(a) Western blot of p21 shows expression of p21protein in lesional and non-lesional 
skin of MAL compared to control skin.  Lane 1 and 2 are lesional and non-lesional skin 
tissue extracts from patient with MAL (respectively), lane 3 control. GAPDH was used 
as loading control.  
(b) Quantification of p21 bands. Image analysis was performed in relation to loading 
control protein GAPDH. The result reveals significantly increased protein expression in 
both, lesional and non- lesional skin of MAL compared to control skin (n=2). Plots are 
mean ± SE. (* p<0.05, ** p<0.01,  p0.001). 
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9.2.3.6  In situ p21 expression in epidermal melanocytes of 
MAL and control skin 
Next, we looked at possible p21 expression in epidermal melanocytes in our patient 
with MAL and in controls.  p21 is weakly expressed in melanocytes of MAL non-
lesional skin, but absent in controls as well as in classic vitiligo ( Figure 82). 
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Figure 82: p21 expression in epidermal melanocytes of MAL and control skin.  
Double immuno-reactivity staining (FITC- labelling, green) in the presence of TRITC / 
NKI / beteb1shows almost absent expression of p21 in melanocytes of MAL. p21 is 
completely absent in melanocytes of  control skin after overlay of both chromophores (c, 
i and insert). Scale bar 50µm. Magnification x 400. 
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9.3 MDM2 and p53 regulation in MAL 
Tumour suppressor gene (TP53) was found to be inactivated in many malignancies but 
rarely in malignant melanoma (Albino et al., 1994; Haluska et al., 1998). MDM2 gene is 
amplified in more than 10% of 8000 human cancers from various sites, including e.g. 
lung and stomach (Toledo and Wahl, 2006). p90
MDM2
 and its homologous MDM4 
proteins may functionally co-operate or work separately in controlling p53 levels and 
activity (Honda et al., 1997; Fang et al., 2000; Pan et al., 2003). Furthermore, another 
member of MDM2 family, i.e. p76
MDM2
, acts positively towards p53 via antagonizing 
the ability of p90
MDM2
 to foster p53 protein degradation through inhibition of p90
MDM2 
binding with p53, but without affecting p90
MDM2
 levels
 
(Perry et al., 2000).  In 2001, 
Polsky and colleagues reported over-expressed MDM2 (p90
MDM2
) protein in non-
invasive melanoma, suggesting its involvement in early malignant transformation of 
melanocytes (Polsky et al., 2001). Moreover, expression of MDM2 (p90
MDM2
)   was 
found to be commonly amplified in invasive as well as metastatic melanoma (Polsky et 
al., 2001). In 2012, Gembarska and colleagues reported that MDM4 is a negative 
regulator of p53. Accordingly, it is over-expressed in about 65% of melanomas. Taking 
into consideration that TP53 mutations are rare in melanomas, these authors proposed 
that MDM4 over-expression is an important oncogenic event, altering p53 function in a 
large proportion of patients (Gembarska et al., 2012).  
 In order to get a better understanding of the reasons behind the reciprocal p53 and p21 
expression in MAL as well as the possibility of p53 inactivation in the epidermis of 
MAL, we looked at p53-regulatory factors, including p76
MDM2
, MDM4 and 
MDM4phospho.  
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9.3.1 High p76
MDM2
 expression in the basal / suprabasal layer of 
lesional MAL 
Our in situ p76
MDM2 
immuno-fluorescence data demonstrated in vitiligo significantly 
higher levels of the p76
MDM
 MDM2 splice variant throughout the epidermis while this 
protein was absent in control skin. In MAL we see a higher expression in the basal / 
suprabasal layer compared to upper layers in lesional skin compared to controls. 
(Figure 83). Image analysis of p76
MDM2
 expression proves significantly higher protein 
expression in lesional epidermis compared to control skin (* p<0.05,  p0.001, 
mean ±SE) (Figure 84). Unfortunately, we have no data on non-lesional skin due to 
shortage of tissue. 
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  Figure 83: Up-regulated basal / suprabasal expression of p76
MDM2
 in lesional 
MAL.  
Immuno-reactivity (TRITC-labelling, red) shows up-regulation in p76
MDM2
 expression 
of lesional (d) skin in MAL. This expression is absent in control skin (skin phototype IІI 
(a)). Expression of the protein is pronounced in the basal / suprabasal layers. Overlay of 
TRITC with DAPI suggests increased expression in the nuclei of epidermal cells with 
more extent in the basal and suprabasal cells identified by purple colour (f) and insert. 
Scale bar 50μm. Magnification  x 400. 
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Figure 84: Significant increase in p76
MDM2 
expression in MAL.  
Image analysis of the average fluorescence intensity shows significantly increased 
levels of p76
MDM2
 in epidermis of lesional skin of MAL (n=21: 3 intra-individual 
repeats, 7 pictures each) compared to healthy control skin (n=24: 3 individual repeats, 8 
pictures each) This expression is significantly higher in basal / suprabasal layers than in 
the upper layers (Plots are mean ± SE) (* p<0.05,  p0.001). 
 
 
9.3.2  Western blot analysis supports up-regulated p76
MDM2
  
The Western blot results show a significant increase in the expression of p76
MDM2
 in 
both lesional and non lesional skin of MAL, while it was almost undetectable in control 
skin (Figure 85). This result is not different from classical vitiligo. 
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Figure 85: Up-regulated p76
MDM2
 expression in MAL.  
(a)Western blot for MDM2 shows an elevation in p76
MDM2
 expression in lesional and 
non-lesional skin of MAL compared to control skin.  Lane 1 protein ladder, Lane 2 
control, Lanes 3-4 lesional and non-lesional skin extracts from MAL. GAPDH was used 
as loading control.  
(b) Quantification of p76
MDM2
 expression. Image analysis of bands was used to 
quantify expression of the protein in lesional and non-lesional skin in relation to its 
expression in control skin. The result reveals significant up-regulated p76
MDM2
 
expression in MAL compared to normal healthy control (NS > 0.05, *** p<0.001). 
238 
 
9.3.3 Significantly increased epidermal MDM4 expression in 
MAL shows a gradient from the basal / suprabasal layer to the 
upper layers 
 
Next, we examined a possible role for MDM4 in controlling p53 in MAL. To do so, 
MDM4 and its phosphorylated protein MDM4phospho were studied in lesional and 
non-lesional skin of our patient with MAL and the results were compared to control skin. 
Our in situ MDM4 immuno-fluorescence staining results show increased MDM4 
expression in both, lesional and non-lesional skin. MDM4 is also expressed in the nuclei 
of basal and suprabasal cells of MAL skin with higher extent in lesional skin (Figure 
86). Image analysis of MDM4 proves significantly up-regulated expression of MDM4 
in the entire epidermis of lesional and non-lesional skin (NS >0.05, ** p<0.01,  
p0.001, mean ±SE) (Figure 87).  
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Figure 86: Increased expression of MDM4 in MAL.  
Immuno-reactivity staining (FITC- labelling, green) shows considerable increase in the 
expression of MDM4 in the epidermis of both lesional (d) and non-lesional (g) skin of 
MAL compared to control with skin phototype ІII (a).N.B. This expression is more 
pronounced in the basal / suprabasal layers. Scale bar 50μm. Magnification  x 400. 
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Figure 87: Significant increase of MDM4 expression in MAL.  
Image analysis of the average fluorescence intensity reveals significantly increased 
MDM4 levels in lesional (n=18: 3 intra-individual repeats, 6 pictures each) and non-
lesional (n=21: 3 intra-individual repeats, 7 pictures each) skin of MAL compared to 
controls (n=24: 3 -individuals, 8 pictures each). Plots are mean ± SE) (*** p<0.001, ** 
p<0.01). 
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9.3.4 Melanocytes of non-lesional skin present MDM4 expression 
We looked at in situ MDM4 expression in epidermal melanocytes in our patient with 
MAL and in controls.  The protein is indeed expressed in MAL as well as in classic 
vitiligo,   but absent in controls (Figure 88).  
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Figure 88: Evidence for MDM4 expression in melanocytes of MAL.  
Immuno- reactivity staining (FITC-labelling, green) shows strong expression of MDM4 
in the epidermis of both lesional (d) and non-lesional (g) skin of MAL compared to 
control skin (phototype IIІ). Melanocytes of non-lesional MAL (i) show MDM4 
expression, which is absent in normal controls (c). Scale bar 50μm. Magnification x 400. 
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9.3.5. Evidence for phosphorylation of MDM4 in MAL 
MDM4 is a negative regulator of p53 (Gembarska et al., 2012). MDM4 looses this 
control based on phosphorylation in response to UVR (Jin et al., 2006). Taking these 
facts into consideration, it was tempting to evaluate the amount of phosphorylated 
MDM4 in MAL. Our results show very high phosphorylation levels of the protein 
throughout the entire epidermis (Figures 89). Image analysis of MDM4phospho proves 
significantly up-regulated expression of the protein in lesional and non-lesional skin 
compared to controls (* p<0.05,  p< 0.01,  p0.001, mean ±SE) (Figure 90). 
Calculation of the MDM4/MDM4phospho ratio reveals complete phosphorylation of 
the protein in the entire epidermis of MAL (Table 9). This result is different to classical 
vitiligo where MDM4 is not completely phosphorylated. 
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Figure 89: Up-regulated expression of MDM4phospho in MAL throughout the 
entire epidermis.  
Immuno-reactivity staining (FITC-labelling, green) shows strong expression of 
MDM4phospho in the entire epidermal compartment of lesional (d) and non-lesional (g) 
skin in MAL compared to control skin (skin phototype ІII) (a). MDM4phospho seems 
to be present in nuclei with more extent in the depigmented skin (insert f, i). Scale bar 
50μm. Magnification x 400. 
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Figure 90: Significantly increased MDM4phospho expression in MAL. 
Image analysis of the average fluorescence intensity shows significantly increased 
levels of MDM4phospho in lesional (n=21: 3 intra-individual repeats, 7 pictures each) 
and non-lesional (n=21: 3 intra-individual repeats, 7 pictures each) skin of MAL 
compared to controls (n=24: 3 individuals, 8 pictures each) (Plots are mean ± SE) (*** 
p<0.001, * p<0.05). 
 
             Protein 
 
Epidermal 
layer 
control lesional 
non-
lesional 
MDM4 basal 10.76 57.27 30.82 
upper 10.42 37.02 29.02 
MDM4phospho basal 18.7 68.99 58.24 
upper 18.7 68.99 58.25 
MDM4phosph/MDM4 basal 1.74 1.20 1.89 
upper 1.79 1.86 2.01 
 
 
Table 9 
 
MDM4phospho-MDM4 immuno-fluorescence ratio in the basal / suprabasal and 
upper layers of MAL. 
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9.3.6 Melanocytes of non-lesional skin do not show MDM4phospho 
expression 
Next we looked at in situ MDM4phospho expression in epidermal melanocytes in our 
patient with MAL and in controls.  The protein is neither really expressed in MAL nor 
in control skin, but it is present in classical vitiligo   (Figure 91). 
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Figure 91: Weak expression of MDM4phospho in melanocytes of MAL.  
Immuno-reactivity staining (FITC-labelling, green) shows high expression of 
MDM4phospho throughout the epidermis of both lesional (d) and non-lesional (g) skin 
of MAL compared to healthy control with skin phototype IIІ. Melanocytes show very 
little MDM4phospho expression in non-lesional (i) and in control skin(c). Scale bar 
50μm. Magnification  x 400. 
246 
 
9.4  Expression of SPARC in lesional and non-lesional skin of 
MAL 
9.4.1 Significant up-regulation in SPARC levels  
 
To the best of our knowledge, the presence of SPARC in the epidermis of patients with 
classical vitiligo has been shown for the first time in the study presented herein (Figures 
43, 45). In 2011, the Fenouille group documented a direct relationship between SPARC 
and the p53 / p21 cascade. They recognised that SPARC inactivates p53 in melanoma, 
with subsequent inhibition of p21 production (Fenouille et al., 2011a;b). Based on these 
data together with our findings, it was tempting to imply a possible role for SPARC to 
explain the different p53 / p21 expression observed in MAL. 
Our in situ results reveal high levels of SPARC throughout the entire lesional and non-
lesional epidermis of our patient with MAL compared to control skin (Figure 92). Here 
it is of note that normal skin shows only background expression. Image analysis of 
SPARC confirms highly significant up-regulated protein expression in lesional and non-
lesional skin compared to control skin (n=4) (Figure 93).  
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Figure 92: High expression of SPARC in MAL.  
Immuno-reactivity staining (FITC-labelling, green) shows increased expression of 
SPARC in lesional (d) and non-lesional (g) skin of MAL compared to control skin (a). 
The nuclear expression seems to be stronger in lesional (insert f) compared to non-
lesional skin. Scale bar 50µm. Magnification x400. 
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Figure 93: Significantly increased SPARC expression in MAL.  
Image analysis of the average fluorescence intensity shows significantly increased 
levels of SPARC in lesional (n=21: 3 intra-individual repeats, 7 pictures each) and non- 
lesional (n=21: 3 intra-individual repeats, 7 pictures each) skin of MAL compared to 
controls (n=32: 4 intra-individual repeats, 8 pictures each). N.B. There are no 
significant differences between lesional and non-lesional skin. (Plots are mean ± SE) 
( p0.001, NS p>0.05). 
 
 
9.4.2 Western blot analysis confirms increased SPARC 
expression in MAL 
In order to quantify protein expression, Western blot analysis was carried out. The 
results show increased SPARC expression in both lesional and non-lesional skin of 
MAL compared to skin of healthy control skin (Figure 94a). Image analysis of SPARC 
protein bands in relation to loading control protein (GAPDH) reveals significantly up-
regulated SPARC expression in the entire skin of MAL (Figure 94b).  
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Figure 94: Significantly up-regulated SPARC levels in skin of MAL. 
(a)Western blot.  SPARC shows an increased expression in lesional and non-lesional 
skin of MAL compared to control skin. Lane1 protein ladder. Lane 2 control. lanes 3-4 
lesional and non-lesional skin extracts from MAL. GAPDH was used as loading control.  
(b) Quantification of SPARC expression. Image analysis of bands was used for 
quantification of protein expression in lesional and non-lesional skin in relation to 
GAPDH. The result reveals significantly up-regulated SPARC expression in lesional 
and non-lesional skin of MAL compared to normal control skin. 
(NS p> 0.05, ** p<0.01, *** p < 0.001). 
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9.4.3 SPARC expression in epidermal melanocytes of MAL 
 
Under in situ conditions melanocytes show the presence of SPARC expression in non-
lesional skin of MAL (insert i), while SPARC is absent in melanocytes of control skin 
(insert c) (Figure 95). 
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Figure 95: Weak in situ expression of SPARC in a dermal melanocyte of MAL.  
Immuno-reactivity staining (FITC-labelling in green) shows high expression of SPARC 
throughout the entire epidermis in lesional (d) and non-lesional (g) skin of MAL 
compared to healthy control skin (a). One TRITC / NKI / beteb1 labelled detached 
dermal melanocyte of non-lesional skin reveals weak expression of SPARC (indicated 
by the orange and yellow fluorescence in the overlay) compared to normal controls 
(only red) (Scale bar 50µm). Magnification x400. 
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9.4.4 SPARC nitration in lesional and non-lesional skin of MAL 
9.4.4.1 5-nitro-tyrosine expression in lesional and non-lesional 
skin  
In classical vitiligo we showed the presence of high epidermal ONOO
- 
levels in lesional 
and non-lesional skin (Salem et al., 2009 and in this thesis). Therefore it seemed 
intriguing to utilise 5-nitro tyrosine to look for possible epidermal ONOO
- 
- expression 
in MAL.  
Our in situ results reveal the presence of nitrated L-tyrosine expression in the skin of 
our MAL patient. This expression is weaker in basal and supra-basal layers than in the 
upper layers (Figure 96). Image analysis of the protein expression reveals significantly 
increased 5-nitro-tyrosine levels in lesional and non- lesional skin of MAL, compared to 
healthy controls (*** p0.001, NS p>0.05, mean ± SE) (Figure 97). 
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Figure 96: High 5- nitro-tyrosine expression indicates ONOO
-
- formation in MAL. 
 
Immuno-fluorescence reactivity of TRITC-labelled 5-nitro-tyrosine shows high 
expression of nitrated tyrosine in lesional (d) and non lesional (g) skin of MAL. 
Importantly, expression seems to follow a gradient with increased expression in the 
upper layers.  Overlay of nitrated tyrosine with DAPI identifies its localization in some 
nuclei of non-lesional skin (purple) (i) compared to contro skin (c) (skin phototype III, 
Fitzpatrick classification). Scale bar 50µm. Magnification x 400. 
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Figure 97: 5-nitro-tyrosine expression in MAL follows a gradient with an increase 
from basal / suprabasal layers to upper layers.  
Image analysis of the average fluorescence intensity shows significantly increased 
levels of ONOO
-
 in lesional (n=28: 4 intra-individual repeats, 7 pictures each) and non-
lesional (n=28: 4 intra-individual repeats, 7 pictures each) skin of MAL. Plots are the 
mean of 4 different intra individual staining ± SE. (*** p0.001, NS p>0.05).  
 
 
 
 
 
 
 
 
 
254 
 
For comparison of nitration levels in MAL, in vitiligo and controls we analysed the ratio 
of 5-nitro-tyrosine in the entire epidermis. Our analysis reveals 0.5 fold higher nitrated 
5-nitro-tyrosine expression in the basal layer of lesional skin of vitiligo compared to 
MAL. Hence,  nitration levels are different between MAL and vitiligo (Table 10). 
Source 
Epidermal 
layers lesional non-lesional 
Vitiligo 
basal 29.35 26.54 
upper 29.35 26.54 
MAL 
basal 18.63 21.00 
upper 
29.97 33.32 
Vitiligo / MAL ratio 
basal 1.58 1.26 
upper 0.98 0.80 
 
Table 10 
 5-nitro-tyrosine ratio in vitiligo  and  MAL patients‘ skin. 
 
9.4.4.2. ONOO
-
 does not affect SPARC in MAL 
In contrast to our previously mentioned data in the vitiligo section of this thesis, double 
immuno-fluorescence staining of FITC-labelled SPARC and TRITC-labelled 5-nitro 
tyrosine in MAL shows only weak nitration of SPARC in nuclei, while nitration is 
almost absent in the cytosol and cell wall (Figure 98). These data suggest that SPARC 
is not nitrated in MAL. This result is different to our observations in vitiligo. Moreover, 
it also may refer to the possible implication of SPARC in p53 inactivation and can 
introduce an explanation for the very different p53 / p21 expression in MAL.    
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Figure 98: Positive nitration of SPARC in the upper epidermis of MAL.  
Immuno-fluorescence reactivity of TRITC-labelled 5-nitro-tyrosine and FITC-labelled 
SPARC represent nitrated SPARC in MAL lesional (f) and non lesional (i) skin. 
Overlay of SPARC and nitrated tyrosine shows positive SPARC nitration in nuclei of 
the upper epidermis of both lesional and non-lesional skin (f, i and inserts) compared to 
healthy controls (c) (skin phototype III, Fitzpatrick classification). Basal and suprabasal 
layers show almost absent nitration. Scale bar 50µm. Magnification x 400. 
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9.5 VEGF-A expression in MAL 
9.5.1 Increased VEGF-A expression in skin of MAL 
It has been shown that VEGF-A expression is enhanced in keratinocytes after H2O2 and 
NO exposure (Brauchle, et al., 1996). At the same token, VEGF-A induces expression 
of SPARC in human vascular endothelial cells (Weninger, et al., 1996; Kato et al., 
2001).  This scenario appealed  to us in the context of our interest. Therefore we decided 
to have a closer look at the expression of VEGF-A in skin of MAL. 
Our in situ results show significantly higher expression of VEGF-A protein in lesional 
(d) and non-lesional (g) epidermis of MAL compared to control skin (a) (Figure 99). 
The data indicate again a gradient with increased expression in the upper layer of the 
skin. Image analysis of VEGF-A proves significantly increased protein expression in 
lesional ( p0.001, mean ± SE) and non-lesional ( p0.01, mean ± SE) epidermis 
compared to controls (Figure 100). 
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Figure 99: Strong expression of VEGF-A in MAL.  
Immuno-reactivity staining (FITC-labelling in green) shows strong VEGF-A expression 
in both lesional (d) and non-lesional (g) skin of MAL compared to healthy control with 
skin phototype ІII (a). In non-lesional skin, SPARC expression appears to be weaker in 
basal / suprabasal layers. Scale bar 50µm. Magnification x 400. 
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Figure 100: Significantly higher VEGF-A expression in MAL.  
Image analysis of the average fluorescence intensity shows significantly increased 
expression of VEGF-A in lesional (n=28: 4 intra-individual repeats, 7 pictures each) and 
non-lesional (n=21: 3 intra-individual repeats, 7 pictures each) skin of MAL compared 
to controls (n=21: 3 individuals, 7 pictures each). Expression is significangtly stronger 
in the upper layer of the epidermis compared to basal / suprabasal layers. (Plots are 
mean ± SE) ( p0.01,  p0.001). 
 
  
 
 
 
 
 
 
 
259 
 
9.5.2 Confirmation of VEGF-A up-regulation in MAL by 
Western blot analysis 
 
To further support our observed increased VEGF-A expression in MAL as possible 
enhancer of SPARC expression, we used Western blot. The results reveal significantly 
higher VEGF-A levels in lesional and non-lesional skin of MAL compared to controls 
(Figure 101a). Image analysis of VEGF-A protein bands in relation to loading control 
protein (GAPDH) confirms significantly increased VEGF-A levels in MAL compared 
to controls (Figure 101b).  
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Figure 101: Significantly increased VEGF-A levels in MAL. 
(a) Western blot shows increased VEGF-A in lesional and non-lesional skin of MAL 
compared to control skin. Lane1 protein ladder. lane 2 control, lanes 3-4 lesional and 
non-lesional skin extracts from MAL. GAPDH was used as loading control. 
(b) Quantification of VEGF-A levels. Image analysis of the bands was used to 
quantify protein expression in lesional and non-lesional skin in relation to its expression 
in control skin. The result confirms increased VEGF-A expression in lesional and non-
lesional skin of MAL compared to control skin (NS p > 0.05, ** p<0.01). 
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9.5.3 In situ VEGF-A expression in epidermal melanocytes  
 
Overlay of FITC-labelled VEGF-A and TRITC-labelled NKI / beteb1 identifies very 
weak VEGF-A expression in melanocytes of non-lesional skin in MAL shows that the 
protein is expressed, while it is absent in the same cells of control skin (Figure 102). 
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Figure 102: VEGF-A expression in epidermal melanocytes of MAL. 
Immuno-reactivity staining (FITC-labelling, green) shows strong expression of VEGF-
A in lesional (d) and non-lesional (g) skin of MAL compared to control skin (skin 
phototype ІII (a). Overlay of NKI / beteb1 positive epidermal melanocytes (TRITC-
labelling) and FITC - labelled VEGF-A yields a weak VEGF-A expression in non-
lesional skin of MAL (insert i), while control melanocytes completely lack expression 
(insert c). Magnification  x 400.  Scale bar 50µm. 
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9.5.4 VEGF-A nitration in MAL 
Next we examined possible nitration of VEGF-A in MAL. The double immuno-
fluorescence results shows almost absent co-localization of FITC- labelled VEGF-A and 
TRITC- labelled 5-nitro-tyrosine in the basal layer of both lesional and non-lesional 
skin of MAL (Figure 103). This result could support a functioning VEGF-A induced 
SPARC cascade in MAL.     
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Figure 103: Evidence for nitration of VEGF-A in MAL. 
Immuno-fluorescence reactivity of TRITC-labelled 5-nitro-tyrosine and FITC-labelled 
VEGF-A in MAL shows strong nitration in the nuclei of non-lesional (insert i, ∆) and 
some weaker expression in lesional epidermis (insert f) skin. Nitration is absent in 
nuclei and cytosol of the basal / suprabasal layer in MAL with some expression in the 
upper layer. Nitration seems stronger throughout the entire epidermis in non-lesional 
skin. Scale bar 50µm. Magnification x 400. The original experiment included analyses 
in control skin.  
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9.6 Evaluation of epidermal TGF-β1 expression in MAL 
9.6.1 TGF-β1 expression corresponds to p21 expression in MAL 
 
Given, that SPARC is functioning in MAL then p53 could be target to inactivation by 
this protein. This assumption is supported by the p21 expression in the upper epidermal 
compartment which was significantly higher compared to control skin, but lower 
compared to classical vitiligo. However, our MAL data demonstrated very strong p21 
expression in the basal / suprabasal layer, while in classial vitiligo p21 is expressed 
throughout the epidermis. Here the question is, whether this p21 expression could be 
originating from p53-independent regulation.  In this context it was known that TGF-β1 
stimulates p21-
 
production through a p53-independent mechanism (Rodeck et al., 1994; 
Krasagakis et al., 1999; Rodeck et al., 1999; Hoek et al., 2006). Our immuno- 
fluorescence show strong TGF-β1 expression in the basal / suprabasal layers in lesional 
and non-lesional epidermis of MAL compared to control skin) (Figure 104). Overlay 
with DAPI suggests the presence of TGF-β1 in some, but not all nuclei (Figure 104 (f, 
i)). Image analysis of TGF-β1 confirms significantly increased protein expression in the 
basal / suprabasal layers of lesional and non-lesional skin compared to controls. The 
data are based on 3 intra-individual stainings of the same sample. Plots are mean ± SE. 
(*** p0.001, NS p>0.05) (Figure 105). TGF-β1 expression is completely absent in the 
upper epidermal layers of non-lesional skin. The predominant location of TGF-β1 in the 
basal layer corresponds with our in situ results from p21 expression in the same patient, 
involving two layers of the basal /suprabasal cells in lesional skin, while non-lesional 
and control skin only  show expression in the basal  layer (Figure 104).  
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Figure 104: Increased cytosolic TGF-β1 expression in the basal / suprabasal layers 
of MAL.  
FITC-labelling (green) of TGF-β1 expression reveals strong cytosolic expression in 
lesional (d) and non-lesional (g) skin of MAL compared to healthy controls (a). Overlay 
with DAPI suggests the presence of TGF-β1 in some nuclei of the basal layer in lesional 
and non-lesional skin (light blue). N.B. Expression of TGF-β1 extends to the suprabasal 
layers in lesional skin, while it is restricted to the basal layer in non- lesional and control 
skin. In MAL this result corresponds to the same distribution as p21, catalase, p76
MDM2
, 
and MDM4 which all show reciprocal pattern compared to p53, VEGF-A and 
expression of ONOO
-
. Scale bar 50µm. Magnification x400. 
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Figure 105: Significantly higher TGF-β1 expression in the basal / suprabasal layers 
of MAL.  
Image analysis of the average fluorescence intensity yields significantly increased TGF-
β1 levels in the basal/suprabasal layers of the epidermis in lesional (n=21: 3 intra-
individual repeats, 7 pictures each) and non-lesional (n=21: 3 intra-individual repeats, 7 
pictures each) skin of MAL compared to controls (n=24: 3 individuals, 8 pictures each). 
Expression is not significantly different between upper epidermis of non-lesional and 
control skin. Plots are the mean of 3 different intra-individual stainings ± SE. (*** 
p0.001, NS p>0.05). 
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9.6.2 TGF-β1 is not expressed in epidermal melanocytes of MAL 
 
Next, we looked, whether TGF-β1 is present in epidermal melanocytes. To address this 
question, we used double immuno-fluorescence with FITC-labelled TGF-β1 and 
TRITC-labelled NKI / beteb1. The in situ result showed no TGF-β1 expression in 
melanocytes in control and non-lesional epidermis of MAL (Figure 106).  
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Figure 106: Absence of TGF-β1 expression in epidermal melanocytes of MAL. 
Immuno-reactivity staining (FITC-labelling, green) shows high expression of TGF-β1 
in lesional (d) and non-lesional (g) skin of MAL compared to healthy control (a). In this 
case our NKI / beteb1 labelled melanocytes are detached. Overlay of both 
chromophores show no sign for the presence of TGF-β1 in melanocytes. Scale bar 
50µm. Magnification x400. 
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9.6.3 Western blot confirms significantly increased TGF-β1 
expression in both lesional and non-lesional skin of MAL 
 
In order to quantify protein expression, Western blot analysis was carried out. The 
results confirm increased TGF-β1 expression in both lesional and non-lesional skin of 
MAL compared to skin of healthy controls (Figure 107a). Image analysis of TGF-β1 
protein bands in relation to loading control protein (GAPDH) reveals significantly 
increased TGF-β1 expression in lesional and non-lesional skin of MAL (Figure 107b).  
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Figure 107: Significantly increased TGF-β1 expression in skin of MAL. 
(a) Western blot of TGF-β1 shows expression of TGF-β1 protein in lesional and non-
lesional skin of MAL compared to control skin.  Lane 1 and 2 are lesional and non -
lesional skin tissue extracts from the patient with MAL (respectively), lane 3 control. 
GAPDH was used as loading control. 
(b) Quantification of the TGF-β1 bands. Image analysis was performed in relation to 
loading control protein (GAPDH). The result reveals significantly increased expression 
lesional and non- lesional skin of patients with MAL compared to normal controls (n=2). 
(Plots are mean ± SE) ( *p>0.05,   p0.001). 
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9.6.4 TGF-β1 is weakly nitrated in non-lesional MAL  
We then asked the question, whether ONOO
-
 nitrates TGF-β1 in the epidermal 
compartment of MAL. The results show that TGF-β1 is weakly nitrated in non-lesional 
skin (Figure 108) but not in lesional and control skin. Based on these results, it is 
tempting to conclude that p21 expression in MAL is regulated by TGF-β1 in a p53 
independent manner.  This result is very different from classical vitiligo, where we 
found strong evidence for nitration of TGF-β1 in the basal / suprabasal layer in this 
entity.   
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Figure 108: Weak nitration of TGF-β1 in non-lesional MAL. 
 Double immuno-fluorescence reactivity of TRITC-labelled 5-nitro-tyrosine and FITC-labelled 
TGF-β1 shows weak nitrated TGF-β1 in MAL in non-lesional skin corresponding to the 
presence of ONOO
-
 in these layers. NB. There is no evidence for nitration of TGFβ1 in control 
skin. Scale bar 50µm. Magnification x 400. 
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10. Discussion 
 
Malignant melanoma (MM) is associated with different forms of hypopigmentation 
which may either appear as regression in primary or metastatic melanoma, halo nevi 
around pre-existing melanocytic nevi, or melanoma associated leucoderma at sites 
distant from the primary tumour (Ortonne et al., 1978; Schallreuter et al., 1991a; 
Aisenbrey et al., 2003). In the literature this depigmentation has been documented with 
various names, including vitiligo.  We here assigned the name melanoma associated 
leucoderma (MAL), as this term covers a precise clinical description of this postsurgical 
and / or immune induced depigmentation in association with malignant melanoma.  
The aim of this thesis was, to find out, whether melanoma associated leucoderma (MAL) 
is a distinct clinical entity compared to classical vitiligo.  
The development of “vitiligo” in melanoma patients is a well known. Still it presents a 
puzzling and poorly understood phenomenon. In this context it is important to recognize 
that melanoma is a cutaneous malignancy originating from a proliferation of atypical 
melanocytes, while classical vitiligo is characterised by hypopigmented / depigmented 
skin lesions with a loss of functional epidermal melanocytes (Schallreuter et al. 2008a, 
Tobin et al., 2000; Schallreuter, 2014; Quaglino et al., 2010). 
In 1991, Schallreuter and colleagues studied this hypopigmentation phenomenon in 623 
patients with cutaneous melanoma. Eleven cases had classical vitiligo at least 2 years 
before diagnosis of melanoma (n=11), while others (n=11) developed melanoma 
associated depigmentation after surgery of their primary and / or metastatic melanoma 
(Schallreuter et al., 1991a). In a prospective cohort study from a single institution 
vitiligo was documented  in 83 of 2954 melanoma patients, yielding in turn a 
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cumulative incidence of 2.8% compared to 3.7% in the  Hamburg study and data from 
4.1% according to Bystryn and colleagues (Bystrin et al.,1987; Schallreuter et al 1991; 
Quaglino et al., 2010). In the Italian study the incidence of “vitiligo” was before 0.6% 
and after melanoma 2.2%. Hence, these numbers are similar to normal subjects 
considering a worldwide prevalence ranging between 0.5-1.5% (Krüger et al., 2012).  
Quaglino and co-workers strongly argued that “melanoma-associated vitiligo” is a 
distinct clinical entity, separate from vitiligo vulgaris. Moreover, in their study showed 
a significantly higher percentage of autoimmune diseases in the “vitiligo” patients and 
melanoma (7 of 83) compared to melanoma patients without vitiligo (80 of 2871) (p = 
0.004). Therefore these authors suggested a distinct “vitiligo” for a subgroup of patients 
with a high prevalence of immune-mediated diseases in association with a favourable 
tumour prognosis (Quaglino et al., 2010). One aim of this thesis was to characterize and 
compare MAL with classical vitiligo. For this purpose we studied epidermal catalase 
expression, as this protein is one reliable and established biomarker for H2O2-mediated 
stress in vitiligo (Schallreuter, 2014). In addition, we used a panel of epidermal proteins 
around the regulation of p53, including p21, p76 
MDM2
, MDM4, MDM4phospho, 
SPARC, VEGF-A, TGF-β1. Moreover, we included evaluation on nitration via ONOO- 
levels, as this radical is
 
an additional biomarker for oxidative / nitrative stress in 
classical vitiligo (Schallreuter et al 2003; Salem et al., 2009).
 
  
Presence of epidermal H2O2 and some oxidation products in MAL  
Our first approach was in vivo evaluation of epidermal H2O2 levels with MAL using in 
vivo FT-Raman spectroscopy. To the best of our knowledge, our results identified for 
the first time the presence of H2O2 accumulation in MAL together with some oxidation 
products, including 5-OH-tryptophane, methionine sulfoxide and formyl kynurenine / 
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kynurenine in MAL (Figure 71) (Rokos et al., 2004, Schallreuter et al., 2012a). Based 
on this result we can conclude that classical vitiligo and MAL show the same results for 
epidermal oxidative stress.  
Despite confirmation of H2O2 accumulation and oxidation of some assigned amino 
acids, epidermal catalase expression was still present, but lower in lesional and non-
lesional skin of MAL compared to control skin. Moreover, protein expression followed 
a gradient with significantly higher levels in the basal / suprabasal layers than in the 
upper layers (Figure 72). These findings differ from classical vitiligo, where catalase 
expression is lacking this gradient and expression is significantly lower or even absent 
(Figure 17) (Schallreuter etal., 1991; Salem et al., 2009, Schallreuter, 2014). 
Interestingly, our data are in agreement with a previous study, which documented 
decreased epidermal catalase expression in normal skin of patients with melanoma 
(Sander et al., 2003).    
Here it is noteworthy that catalase is highly expressed in epidermal melanocytes in 
healthy control skin, while the enzyme is absent in non-lesional melanocytes of MAL 
and in non-lesional classical vitiligo (Figures 17, 74). This result is supported with data 
from Maresca and colleagues, who observed in melanocytes a correlation between 
catalase levels and melanogenesis (Maresca et al. 2007).  
Given, that ONOO
-
 levels are significantly increased in both lesional and non-lesional 
skin of patients with classical vitiligo (Salem et al., 2009 and here in this thesis), we 
wanted to know, whether this free radical could be a player in MAL. Our immuno-
fluorescence labelling of 5-nitro-tyrosine, as the foot print of ONOO
-
, shows 
significantly higher expression in the upper epidermal layers of MAL with almost 
absent expression in the basal / suprabasal layers (Figure 96). This result is very 
different compared to classical vitiligo, where the distribution of 5-nitro-tyrosine 
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indicates nitration throughout the entire epidermal compartment of lesional and non-
lesional skin (Figure 50). 
 In order to compare nitration levels between vitiligo and MAL, ratios of ONOO
-
expression throughout the epidermis were calculated. This analysis revealed higher 
nitration levels in the basal / suprabasal layers of classical vitiligo compared to MAL 
(Table 6).   
Source 
Epidermal 
layers lesional non-lesional 
Vitiligo 
basal 29.35 26.54 
upper 29.35 26.54 
MAL 
basal 18.63 21.00 
upper 
29.97 33.32 
Vitiligo / MAL ratio 
basal 1.58 1.26 
upper 0.98 0.80 
 
Table 10 
Comparison of epidermal ONOO
-
 - levels in classical vitiligo and MAL (shown 
earlier). 
 
To sum up, our immuno-fluorescence data show in MAL considerable epidermal 
oxidative / nitrative stress expression.  Importantly, levels seem to be higher in the 
upper (differentiating) part of the epidermis, while the basal / suprabasal cells, forming 
the proliferation zone, are more protected against oxidative / nitrative intervention. In 
vivo FT-Raman results are not different between classical vitiligo and MAL. However, 
as catalase expression is present in MAL, it was tempting to invoke a more efficient 
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turnover of H2O2 with less ONOO
-
 formation. In this context it is of interest that the 
epidermal proliferation zone is better prortected compared to the differentiation zone in 
the same compartment. 
 
Detection of a distinct p53 / p21 cascade in MAL  
After confirmation of up-regulated functioning epidermal wild type p53 levels in part I 
of this thesis (Schallreuter et al., 2003; Salem et al., 2009), together with the distinct 
different catalase expression patterns in classical vitiligo and MAL, we compared the 
p53 cascade in lesional and non-lesional skin of both. In MAL we found significantly 
up-regulated p53 levels in the upper epidermis with lower expression in the basal / 
suprabasal layers (Figures 78, 81). These low p53 levels in basal keratinocytes were 
also present in melanocytes of non-lesional skin with almost absent p53 expression. Our 
in situ results of p21 expression in MAL revealed a reciprocal pattern compared to p53 
expression. Expression levels of p53 and p21 are differing significantly from classical 
vitiligo, where both are increased throughout the entire epidermis (Figures 82, 84, 85). 
Under in situ conditions melanocytes show weak p53 and p21 expression in non-
lesional skin of MAL.  This result is different to classical vitiligo, as those melanocytes 
express high p53 and p21 levels in non-lesional skin (Figures 23, 27, 77, 82). 
High p53 levels have been reported in melanoma (Yamamoto and Takahashi, 1993; 
Montano et al., 1994; Sparrow et al., 1995; Zerp et al., 1999; Rass et al., 2001; Soussi 
and Beroud, 2001; Soto et al., 2005; Gwosdz et al., 2006; Li et al., 2006). Our own data 
show significantly up-regulated p53 in the upper layers of MAL skin, regardless of 
lesional or non-lesional origin. Here it is tempting to propose, that the entire skin of 
patients with MAL may be regulated by a reciprocal presence of p53 and / or p21 
interaction in the epidermis.  Our MAL data are supporting the suggestion by Avery-
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Kiejda and colleagues, who proposed loss in control of p53 target genes, including p21 
in melanoma (Avery-Kiejda et al., 2011).  
This reciprocal p53 / p21 expression pattern raises some questions. 
One major question seems to be, whether up-regulated p53 is functional in MAL. 
The presence of higher p21 expression in the upper layers of MAL skin may suggest a 
functional p53 for induction of p21 expression in the differentiation zone of the 
epidermis (Figures 75, 78),  This assumption would be supported via the presence of 
H2O2 / ONOO
-
 leading to enhancement of p53-DNA - binding capacity (Salem et al., 
2009). The next question is: How is the scenario in the basal / suprabasal layers where 
proliferation is taking place? 
 
Could the presence of p76
MDM2 
explain p53 accumulation in MAL? 
As said above, the MDM2 family plays an important role in p53 regulation (Haupt et al., 
1997; Honda and Yasuda, 2000; Kubbutat et al., 1997; Oliner et al., 1993; Perry et al., 
2000; Giglio et al., 2010). Briefly, p76
MDM2
 has a positive regulatory function towards 
p53 via antagonising p53-p90
MDM2
 binding, preventing in turn p53 ubiquitination (Perry 
et al., 2000; Giglio et al., 2010). In addition, p76
MDM2 
binds to p53 mRNA and promotes 
translation (Naski et al., 2009).  
 In this context it is of interest that significantly up-regulated epidermal p76
MDM2 
splice 
variant has been documented in classical vitiligo (Salem et al., 2009). This result was 
confirmed in this thesis / partI.  Therefore our next interest was, getting a closer look 
into p53 degradation. 
Our immuno-fluorescence and Western blot data showed up-regulated p76
MDM2
 in 
lesional skin of MAL with high levels in the basal proliferation zone and significantly 
less expression in the upper differentiation layers of the epidermis.  Hence, p76
MDM2
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expression correlates with a reciprocal p53 expression (Figure 83). These data could 
point to a lack of functioning p76
MDM2 
in control of p53 degradation in the proliferation 
zone of MAL. Moreover, here it becomes of interest that the p53 gradient in MAL 
correlates with a reciprocal pattern of catalase and p21 expression.  With other words, 
the proliferation zone is more efficient in H2O2-reduction due to significantly up-
regulated catalase, while H2O2 levels may be higher in the upper layers, as catalase 
expression is significantly lower in this upper differentiation zone. This assumption 
would be supported by the fact, that H2O2 induces p53 (Vile, 1997; Xie et al., 1999). 
Importantly, our MAL results point to a distinct difference to our classical vitiligo data 
(Salem et al., 2009 and in part I of this thesis), where distribution of p53 and p76
MDM2
 
protein expression spans the entire epidermis without showing significant differences in 
expression levels between any layers. 
 
MDM4 in MAL is phosphorylated and therefore may not be involved in 
p53 regulation 
MDM4 is exercising controversial roles in control of p53.  Some studies support a 
positive regulatory role for MDM4 towards p53 through antagonising p53 / p90
MDM2 
binding
 
(Sharp et al., 1999; Jackson and Berberich, 2000; Stad et al., 2000). Other 
authors suggested cooperation of p90
MDM2
 and MDM4 after heterodimerization, 
influencing in turn p53 levels and function (Kawai et al., 2007). 
Our in situ immuno-fluorescence results show significantly higher MDM4 expression in 
lesional and non-lesional skin of MAL with more pronounced expression in the basal / 
suprabasal layers than in the upper layers (Figure 86). Taking into consideration the 
positive role of MDM4 towards p53 levels, we would rather have expected high p53 
levels in the basal / suprabasal layers and not in the upper layers.  However, our p53 
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data showed a reciprocal expression gradient in MAL. Hence, a positive influence of 
MDM4 expression on p53 should be absent.  Bearing in mind the negative action of 
MDM4, our results rather imply MDM4 in control of p53 in MAL. These data are 
supported by a proposed inactivation of MDM4 in response to phosphorylation (Jin et 
al., 2006). Importantly, this action can cause retention of the protein in the cytoplasm 
away from p90
MDM
. Our immuno-fluorescence labelling exhibited a high degree of 
MDM4-phosphorylation throughout the entire epidermis (Figure 89). Calculation of 
MDM4phospho / MDM4 ratio in control skin in addition to lesional and non-lesional 
skin of MAL revealed total phosphorylation of the protein in MAL (Table9). This result 
favours exclusion of MDM4 in control of p53 ubiqitination in MAL, while in classical 
vitiligo we showed partial phosphorylation of MDM4 (Table5). 
Our overall data of MDM4 in MAL are different from our classical vitiligo results, 
suggesting impaired MDM4 function by the action of p76
MDM2
 which may prevent 
heterodimerization of MDM4 with p90
MDM2
 and consequently ubiquitination of p53. 
Another mechanism could be activation of p53 via inhibiting the binding of MDM4 and 
/ or p90
MDM2
 to p53. Moreover, this result could point to the probability that another yet 
unknown protein may be in control of this different p53 expression in MAL.  
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             Protein 
 
Epidermal 
layer 
control lesional 
non-
lesional 
MDM4 basal 10.76 57.27 30.82 
upper 10.42 37.02 29.02 
MDM4phospho basal 18.7 68.99 58.24 
upper 18.7 68.99 58.25 
MDM4phosph/MDM4 basal 1.74 1.20 1.89 
upper 1.79 1.86 2.01 
 
Table 9 
 
MDM4phospho-MDM4 immuno-fluorescence ratio in the basal / suprabasal and 
upper layer of MAL. 
 
SPARC nitration - can it explain the different p53 expression pattern 
between vitiligo and MAL? 
 
In order to shed more light on the reason behind our observed p53 expression gradient 
in MAL and based on data of Fenouille and colleagues, who reported a negative role of 
SPARC over-expression towards p53 levels and activity (Fenouille et al., 2011a;b), it 
was tempting to study the expression of this protein in our case of MAL. Similar to our 
classical vitiligo results presented in part I of this thesis, the epidermis of MAL holds 
significant up-regulated SPARC expression based on immuno-fluorescence and 
Western blot techniques (Figures 92, 94).  The expression is distributed throughout the 
entire epidermis.  These results together with our catalase data may refer to direct up-
regulation of SPARC in MAL via increased H2O2 levels in the epidermis. A second 
possibility could be based on H2O2 mediated increase of SPARC levels via VEGF-A. 
This idea is supported by documented VEGF-A increase in response to H2O2 (Brauchle, 
et al., 1996). A possible role for VEGF-A in regulation of SPARC stems from the 
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observation that this protein is enhancing SPARC expression in human vascular 
endothelial cells (Kato et al., 2001; Weninger, et al., 1996). 
The up-regulated SPARC throughout the entire epidermis of MAL in association with 
low p53 expression in the basal / suprabasal layers raised the question about possible 
inactivation of SPARC in the upper layers of the epidermis. As we showed the presence 
of ONOO
-
 in MAL, following a gradient from basal / suprabasal layers to the upper 
epidermis, we considered the possibility of SPARC inactivation by ONOO
- 
mediated 
nitration as observed in the case of classical vitiligo. Our data showed almost absence of 
SPARC nitration in basal / suprabasal layers in lesional skin with very weak nitration in 
the same layers of non-lesional skin in MAL (Figure 98). Interestingly, nitrated SPARC 
is present in nuclei of the upper layers of both lesional and non-lesional skin (Figure 
98). These data support our observed, low p53 expression in basal / suprabasal layers as 
well as its high levels in the upper layers of MAL skin.  
Based on these data, it is tempting to suggest that SPARC protein is inactivated in the 
upper layers of MAL epidermis. This scenario would be the same as in classical vitiligo 
and it is very likely caused by ROS / RNS-mediated stress. However, in the basal / 
suprabasal layers of MAL the situation is not the same. It appears completely different 
from classical vitiligo. Here SPARC is not nitrated in association with low p53. This 
result may suggest that SPARC is still functioning, fostering in turn p53 inactivation / 
degradation. 
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Could increased VEGF-A support up-regulated SPARC protein 
expression in MAL?  
VEGF-A is expressed in both lesional and non-lesional skin of MAL (Figures 99, 104). 
The result shows less expression in the basal / suprabasal layers compared to the upper 
part of the epidermis. In order to investigate a possible role in control of SPARC up-
regulation via VEGF-A in the presence of H2O2 / ONOO
-
 in the upper layers of MAL, 
we used VEGF-A co-localization with 5-nitro-tyrosine. Our data showed very little co-
localization in both lesional and non lesional skin (Figure 103). These data could 
support a possible role of VEGF-A induction of SPARC as reported in human vascular 
endothelial cells (Kato et al., 2001; Weninger, et al., 1996).         
 In this context it is of interest that up-regulated VEGF-A in melanoma coincides with 
induction of new blood vessel formation (Brauchle, et al., 1996; Claffey et al., 1996; 
Graells et al., 2004; Srivastava et al., 2003). Our data on up-regulated VEGF-A 
expression in lesional and non-lesional skin of MAL may refer to the possibility that 
VEGF-A levels increase at the entire integument of patients with melanoma and not 
only in loco of the tumour. 
 
Can TGF-β1 explain p53-independent expression of p21 in MAL?  
To get a better understanding of the reasons behind our observed reciprocal pattern in 
p53 / p21 expression in MAL, it was tempting to study the expression of TGF-β1.  In 
this context it is of note that this protein can enhance p21 in a p53 independent manner 
(Datto et al., 1995; Li et al., 1995; Kim et al., 2006). Our immuno-fluorescence and 
Western blot results showed significantly up-regulated TGF-β1 in the basal / suprabasal 
layers in lesional and non-lesional skin of MAL, while expression was much lower in 
the upper epidermis.  The result was congruent with p21 protein expression (Figures 
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104, 107). These overall data may suggest the capability of TGF-β1 in compensating for 
active p53 shortage and / or inactivity in the basal / suprabasal layers. The increase in 
TGF-β1 expression in basal / suprabasal layers could be due to the up-regulation of 
functional and non-nitrated SPARC. This mechanism has been shown in rat mesangial 
cells in vitro and in vivo, where TGF-β1 increased in response to elevation of SPARC 
levels (Bassuk et al., 2000). TGF-β1 is not nitrated in the basal / suprabasal layers of 
MAL, while the upper layers seem to be nitrated (Figure 108). These results favour 
TGF-β1-triggered p21 expression in the basal / suprabasal layers in MAL rather than 
p53 induced p21 expression as observed in classical vitiligo. It also points out to another 
difference between MAL and classical vitiligo. In this context, our data in classical 
vitiligo revealed totally non-functional nitrated TGF-β1 in both lesional and non-
lesional skin. This is very different in MAL.  
These overall data in MAL may propose a a link between H2O2 / ONOO
-
 and 
depigmentation via inducing VEGF-A / SPARC / TGF-β1 cascade but this hypothesis 
need more investigations as well as samples to be proved ( Figure 109).  Our prospects 
are based on the facts that TGF-β1 is known as a promoter for hypopigmentation. It 
affects melanogenic proteins negatively as it is able to degrade or inactivate the 
tyrosinase enzyme. Moreover, it also down-regulates the production of MITF, TRP-1 
and TRP-2 leading to disturbances in melanosomal maturation and inhibition of 
melanogenesis resulting in hypopigmentation (Martínez-Esparza et al., 1997; Martínez-
Esparza et al., 2001; Kim et al., 2003). 
Taken together, based on our data, we can conclude that MAL is a distinct different 
entity compared to classical vitiligo. The drawback of this work is that we only had one 
case four extensive study of MAL.  However, as we found so many differences 
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compared to classical vitiligo, we still feel that this work is valid and provides a major 
contribution to the understanding of this peculiar depigmentation.  
As MAL has been implicated in better prognosis of melanoma survival, it is noteworthy 
that our study patient presented at time of first diagnosis in 8/2008 an ulcerated nodule 
in a superficial spreading melanoma, arising in a congenital naevus.  The histology 
confirmed a Clark level IV and a Breslow thickness of 4.67 mm.  Importantly, the 
patient did not undergo lymphnodectomy.  He developed the first signs of 
depigmentation in 2009. Until 4/2015 he has not developed any signs of metatstases. 
Importantly, our patient had no other immune diseases. Therefore we cannot connect his 
individual survival time to the proposed better overall outcome for this distinct patient 
group as suggested by Quaglino and colleagues (Quaglino et al., 2010). In order to 
validate the influence of immune diseases in the context of our investigation, more 
patients are needed with characterised MAL. 
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Figure 109: Hypothetical pathway involved in depigmentation in MAL.  
A scheme summarising the possible role of H2O2 / ONOO
- 
in promoting melanoma 
associated leucoderma (MAL) via induction of TGF-β1 expression; the 
hypopigmentaion promoter.   
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11. Conclusion 
 
Based on recent data and our novel results, we can conclude that the 
entire epidermal homeostasis in vitiligo is affected in the disease process. 
(PART I). 
 
1. Based on recent data together with our novel data presented herein, we can 
extend strong evidence that the entire epidermal compartment, regardless , 
whether it is depigmented (lesional)  or normal pigmented  (non-lesional) is 
part of the depigmentation process in vitiligo. We can conclude that all 
epidermal keratinocytes spanning from proliferation up to differentiation, are 
active players in the disease process.  Hence, this disease does not only include 
absence of functioning melanocytes. Vitiligo is a disease affecting the entire 
epidermal unit.  
2. We have confirmed the presence of oxidative and nitrative stress overload 
affecting the entire epidermis. Whether this is the cause or consequence of the 
disease, still needs to be shown. However, to date epidermal H2O2   accumulation 
together with its consequences is a fact in the pathogenesis of vitiligo.  
3. Although patients with vitiligo lack partially protection against UVR due to 
absence of melanin in their depigmented skin, in addition to massive ROS / 
RNS-mediated oxidative / nitrative stress in their entire epidermal compartment, 
they do not present a significant elevated risk for development of non-melanoma 
skin cancer (NMSC) and photo-damage despite signs for increased DNA-
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damage in the skin and plasma(Calanchini-Postizzi and Frenk, 1987; 
Schallreuter et al 2002; Salem eta., 2009; Teulings et al., 2013)  
Our data confirmed previous results from our group (Salem et al 2009). The 
novel data in part I of this thesis further support the overriding role of up-
regulated wild type functioning p53 in the disease process. This assumption is 
supported by our novel data on MDM4, MDM4phospho, SPARC, TGFβ1 and 
VEGF-A expression in the epidermis of these patients. 
This constant up-regulation of p53 could be based on the induction and up-
regulation of p76
MDM2
 and MDM4/MDM4phospho interaction in the entire 
epidermal compartment of these patients. This assumption is supported by the 
presence of p76
MDM2 
splice variant which is completely absent in healthy skin. 
4. Furthermore, as our results indicate the presence of up-regulated, but nitrated 
SPARC, we would like to suggest a novel function for this regulatory protein as 
possible radical scavenger in classical vitiligo based on oxidation and nitration 
of the protein structure. This assumption is fostered by Computer Simulation. 
From all results obtained, we would like to conclude that up-regulation of 
epidermal SPARC in classical vitiligo is directly under control by H2O2 which 
includes induction through this ROS and scavenging of ROS and RNS.  This 
assumption is supported by prevented induction of SPARC through VEGF-A 
and TGFβ1, as both proteins are also affected by nitration, leading in turn to 
non-functional signalling with regards to SPARC regulation. 
To sum up, our novel data further substantiate our original proposed idea, how patients 
with vitiligo are protected by a constantly up-regulated functioning   p53 /p21 cascade 
against development of non-melanoma skin cancer and photo-damage despite absence 
of inherited pigment and the presence of DNA-damage.  Moreover, our data suggest 
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that up-regulated SPARC functions as radical scavenger in classical vitiligo. This is a 
completely new idea.   
 
MAL is a distinct entity compared to classical vitiligo despite the 
presence of epidermal oxidative / nitrative stress (PART II) 
The aim of part II in this thesis was, to find out, whether melanoma associated 
leucoderma (MAL) is a distinct clinical entity compared to classical vitiligo. There are 
many reports in the literature, but at the present time, there is no common consent on 
this phenomenon. To approach our aim of answering the raised question, whether MAL 
is classical vitiligo or not, we compared both leucodermas with the same methodology 
under the same conditions..  
1. Upon Wood‟s light examination we see a weak fluorescence of the white lesion 
in MAL, pointing to the presence of oxidised pterins. A yellowish fluorescence 
is the clinical hallmark for correct diagnosis of classical vitiligo (Schallreuter et 
al., 1994a).  
2. In MAL the entire epidermis holds H2O2 and ONOO
-
 accumulation proven by in 
vivo FT-Raman spectroscopy and by immuno-fluorescence. This result is the 
same as in classical vitiligo.   
3. Based on our immuno-fluorescence data, we can conclude that MAL involves 
the entire epidermal compartment which is the same in classical vitiligo.  
 
Immuno- labelled expression patterns point to fundamental differences between MAL 
and classical vitiligo, utilising the same protein panel including catalase, ONOO
-
, p53, 
p21, p76
MDM2
, MDM4, MDM4phospho, SPARC, VEGF-A and TGF-β1. 
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In vitiligo we always observed distribution of our protein in question throughout the 
entire epidermis except TGFβ1 expression.  
In MAL we observed in most of the proteins a significant gradient from the basal / 
suprabasal to the upper layer, with higher expression in the basal / suprabasal layers, 
and low expression in the upper layer or in the reciprocal way. Figures 110a, b, c 
summarise these results, supporting a very different scenario compared to classical 
vitiligo.  
 
Figure 110a:  Absence of all our proteins in question in healthy control 
epidermis but catalase is present in keratinocytes and melanocytes.  
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Figure 110b:  Distribution of the proteins in question in MAL non-lesional 
epidermis. 
The scheme depicts the distribution of the protein in the basal / supra basal layers (BL) 
and in the upper layers (UL) in the epidermis as described in detail in the result section.  
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Figure 110c:  Distribution of the proteins in question in MAL lesional epidermis. 
The scheme depicts the distribution of the protein in the basal / supra basal layers (BL) 
and in the upper layers (UL) in the epidermis as described in detail in the result section.  
Looking at the effect of ONOO
-
-mediated nitration of SPARC and TGFβ1 we can see 
that in classical vitiligo SPARC is heavily nitrated throughout the entire epidermis 
which is very different in MAL. In lesional MAL SPARC is not nitrated in the basal 
layer with little nitration of nuclei in the upper layer. In non-lesional MAL nitrated 
SPARC is expressed in the nuclei of the upper layer. In the case of TGFβ1we see strong 
nitration in the upper layer with almost absence in the basal layer in lesional and non-
lesional skin.   
Based on our results it is tempting to conclude that in MAL t H2O2 / ONOO- 
accumulation ispresent but it seems to be better controlled by an effective functioning 
catalase. Whether other antioxidant systems including thioredoxin reductase, GPx and 
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glutathione reductase as well as methionine sulfoxide reductases A&B are affected in 
MAL needs to be shown. 
 
The development of postsurgical depigmentation in melanoma patients is well known. 
Still this phenomenon is puzzling and poorly understood. In this context it is important 
to recognize that melanoma is a cutaneous malignancy originating from a proliferation 
of atypical melanocytes, while vitiligo is characterised by hypopigmented / 
depigmented skin lesions with a loss of functional epidermal melanocytes and 
aberrant funcyionality of keratinocytes (Schallreuter et al. 2008a, Tobin et al., 2000; 
Schallreuter, 2014; Quaglino et al., 2010; Lotti et al 2008a; b).  
Based on our data we can suggest that MAL and classical vitiligo are two different 
entities.  
Whether co-existence of MAL and classical vitiligo in patients with cutaneous 
melanoma could be important for tumour survival rates needs investigation of more 
patients. However, in this context it is interesting that our patient with MAL until 3 / 
2015 had no signs of tumour progression over a period of almost 7 years since his 
primary surgery. Here it is also interesting that he has no other immune diseases. As the 
presence of those have been attributed to a favourable outcome, it seems that at least in 
our patient there is no connection (Quaglino et al., 2010).  
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12. Future work 
 
Data presented in this thesis revealed that MAL is a distinct entity compared to classical 
vitiligo. The following future work may be helpful to further substantiate the differences 
between these two depigmentation disorders. 
 Comparison of p76MDM2 and p90MDM2 expression in MAL. 
 Identification of p76MDM2/p90MDM2- in situ levels in melanocytes of MAL non-
lesional skin. 
 As nitration is present in MAL, studying nitration of p21, p53, p76MDM2, 
p90
MDM2
, MDM4/MDM4phospho should be involved.  
 Degree of melanocyte detachment in MAL compared to classical vitiligo should 
be an interesting topic to follow in more detail. 
 Shedding more light on the possible role of TGF-β1 in promoting 
hypopigmentation in MAL via studying its negative effect on the expression of 
melanogenic proteins such as MITF, TRP-1 and TRP-2. 
 Most importantly, more samples of MAL patient samples are mandatory to 
confirm our findings. 
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